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Summary. 
Class I phosphoinositide (PI) 3-kinases exert profound effects on cell growth, division, 
motility and metabolism via their primary lipid product phosphatidylinositol 3,4,5-
trisphosphate (PtdIns(3,4,5)P3) and a metabolite of this, phosphatidylinositol 3,4-
bisphosphate (PtdIns(3,4)P2). Many effector proteins for PtdIns(3,4,5)P3 are well 
recognised but by contrast, few molecular targets for PtdIns(3,4)P2 have been identified. 
This study describes a screen to identify PI 3-kinase-responsive proteins that is selective 
particularly for these. The approach features a unique three-tier affinity approach and 
incorporates a primary recruitment of target proteins to membranes of intact cells, 
selectively enriched in PtdIns(3,4)P2. In addition, this screen utilises stable isotope 
labelling with amino acids in cell culture (SILAC) to differentially label cells stimulated 
in the absence and presence of the PI 3-kinase inhibitor wortmannin. The integration of 
these techniques provides a ratio-metric readout, allowing authentically 3-
phosphoinositide (3-PI) responsive components to be distinguished from the co-purifying 
background proteins. The identification of tandem pleckstrin homology domain 
containing protein-1 (TAPP-1) and protein kinase B (PKB) among a multitude of proteins 
expressing known lipid binding domains (LBDs) demonstrates the utility of this strategy. 
Analysis of other similarly, isotopically enriched candidate 3-PI interacting proteins 
yielded two novel lipid binding proteins, PARIS-1 (prostate antigen recognised and 
identified by SEREX 1) and IQGAP1 (IQ motif containing GAP1). The concentration 
dependent interaction of PARIS-1 and IQGAP1 with PtdIns(3,4,5)P3 was confirmed by an 
in vitro, SPR based assay. Intriguingly, IQGAP1, a potential tumour promoter, lacks a 
currently established LBD and may therefore exemplify an entirely novel 3-PI selective 
binding domain. 
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1. Introduction. 
This thesis will describe the optimisation and implementation of a screen for potential 
molecular targets for a class of intracellular lipid signals known to execute vital roles in 
important cellular processes. The controlled synthesis and degradation of such lipid 
signals are vital for normal cell function but equally aberrations in either their metabolism 
or the proteins which respond to them are implicated in a variety of disease states from 
diabetes to cancer. 
 
1.1  Cell Signalling. 
Cells within all tissues need to communicate in order to regulate cell activity and 
elicit a concerted response, such as senescence or growth. Cell communication 
encompasses a wide range of events but essentially can be divided into three types; 
autocrine, paracrine and endocrine. Autocrine and paracrine signalling is undertaken by 
all cells and operates over short distances, whereas endocrine signalling is undertaken by 
more specialist cell types over larger distances. The term cell signalling broadly describes 
the many facets involved in translating the received communication, from transferring the 
signal across the outer plasma membrane to eliciting a measured and co-ordinated 
response. 
 
1.1.1 Cell Membranes. 
All cell membranes consist of lipids which have amphipathic properties, 
possessing both a hydrophilic headgroup and hydrophobic tail(s), the latter consisting of 
saturated and/or unsaturated hydrocarbons. These lipids consists of phospholipids 
(glycerophopholipids and sphingomyelin), which are a major component but also of 
cholesterol and glycolipids. The fluidity, thickness and function of a membrane vary 
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according to the lipid constituents. However, it is the inherent amphipathic characteristics 
of lipids which orientate them into a bilayer, resulting in a highly hydrophobic internal 
region between the internal and external lipid monolayers or leaflets. This provides a 
barrier, preventing the movement of molecules, very often retaining them against their 
concentration gradient, as with stores of energy and components for growth. Whilst this 
compartmentalisation is crucial, it poses a problem in transferring signals from one cell to 
another or across internal compartments and requires additional signalling machinery – 
membrane receptors. 
 
1.1.2 Receptors. 
Cell surface receptors provide a mechanism by which to transduce across 
membranes signals provided by non-cell penetrant or polar ligands such as growth factors 
and neurotransmitters. Notable exceptions to this requirement are provided by steroid 
hormones and nitric oxide which are small and hydrophobic enough to readily cross 
membranes and exert their effects directly. However, receptors transduce non-permeable 
signals by undergoing a chemical or conformational change on the intracellular face of the 
bilayer following extracellular ligand binding. The cell surface receptors can be divided 
into three classes based on their mechanism of action, ion-channel-linked receptors, G-
protein coupled receptors and enzyme-linked receptors. 
 
Ion-channel-linked receptors or ionotrophic receptors are transmembrane proteins 
which upon ligand binding undergo a conformational change, allowing the passage of 
ions, such as Na+, K+ and Cl-, through an internal pore. An example of such an 
ionotrophic receptor is provided by the nicotinic acetycholine receptor in neurones which, 
following activation by acetycholine, allows passage of Na+/K+ ions down their 
 23
concentration gradients. The effect is to depolarise the electrical potential maintained 
courtesy of the Na+-K+ pump (intracellularly relatively negative, as three Na+ ions are 
actively pumped out for every two K+ ions pumped in) and initiate an action potential 
down the axon. 
 
G-protein coupled receptors (GPCRs) are the largest family of receptors and are 
responsible for regulating a wide variety of processes including olfaction, sight, 
inflammation, neurotransmission, secretion, contraction, and electrochemical impulses 
from the nervous system. Indeed approximately 40% of all prescription pharmaceuticals 
target GPCRs [1]. Characteristically, GPCRs are serpentine proteins which cross the 
membrane seven times. Each of these transmembrane regions orientates itself to form a 
ring structure, creating a pore for ligand binding. Upon ligand binding, the GPCR 
undergoes a conformational change on the intracellular face of the membrane. This in 
turn, induces a change in the conformation of an internal membrane-bound transducer; a 
heterotrimeric GTP-binding protein (G-protein). There are several types of heterotrimeric 
G-proteins including, Gs, Gi and Gq, each of which is linked to a signalling outcome. The 
G-protein is comprised of three subunits, α, β and γ, of which the α-subunit exchanges 
guanosine diphosphate (GDP) for guanosine triphosphate (GTP) upon GPCR activation. 
Once GTP is bound the G-protein undergoes a further conformational change and 
separates into two components, the GTP bound α-subunit and a βγ complex, both of 
which are now capable of interacting with and activating/inhibiting effector proteins. 
 
Enzyme-linked receptors, typically have only one transmembrane region and their 
cytosolic tail is either intrinsically capable of enzyme activity or associates directly with 
an effector possessing enzyme activity. Although most possess only a single 
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transmembrane pass, many require dimerisation either to facilitate ligand binding and/or 
to achieve activation following ligand binding. The most abundant enzyme-linked 
receptor class are the receptor tyrosine kinases (RTKs), activated by many growth factors 
and hormones including epidermal growth factor (EGF), platelet-derived growth factor 
(PDGF) and insulin. Following ligand binding and dimerisation, these receptors undergo 
trans-autophosphorylation, transferring a phosphate group from adenosine triphosphate 
(ATP) to a specific tyrosine residue(s) within cytoplasmic tail of the opposing RTK 
dimer. Phosphorylation of these tyrosine residues, if within the kinase region, increases 
the enzyme activity towards effector substrates. If the tyrosine phosphorylation is outside 
the kinase region, it usually creates a unique sequence of additional residues surrounding 
the phosphorylated tyrosine, known as a consensus sequence. The phosphotyrosine 
residue then usually represents a docking site within the appropriate consensus sequence, 
providing a target for the binding, recruitment or activation of specific effector proteins 
via modules or domains which recognise such sequences, often with high affinity 
(introduced in 1.4). 
 
1.1.3 Second Messengers. 
Second messengers are molecular intermediaries responsible for transferring the 
signalling output of ligand bound cell surface receptors to the intracellular environment. 
The concept of second messengers was first introduced by Earl Sutherland in 1958 
following his studies on cyclic adenosine monophosphate (cAMP) [2]. He observed that, 
whilst adrenaline resulted in liver cells converting glycogen to glucose, this could not be 
achieved without the second messenger cAMP. 
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1.2 Phosphatidylinositol (PtdIns). 
Prior to Earl Sutherland’s seminal paper on cAMP [2], Mabel and Lowell Hokin 
reported an agonist-stimulated phosphatidylinositol (PtdIns) turnover [3]. Inositol lipids 
had already been observed within mycobacterium [4] and this was followed by similar 
observations of inositol phospholipids within animals and plants [5-8]. Several groups, 
notably C. Ballou, R. Dawson and D.M. Brown contributed to establishing the D-1 
positional substitution of the myo-inositol ring to phosphatidic acid [9-11]. Later, the 
same groups, following up on Jordi Folch’s observation of a polyphosphoinositide [6], 
determined that mono-, bis-, and tris- phosphate components of myo-inositol could be 
isolated [5,12-22]. Finally, these inositol derivatives from PtdIns, PtdIns4P and 
PtdIns(4,5)P2 were suggested to be interconvertable by 
phosphorylation/dephosphorylation following studies measuring the radiolabelled 
incorporation of phosphate, myo-inositol and glycerol into tissue slices [13,14]. The 
structure of phosphoinositides (PIs) is shown in Figure 1 and highlighted are the positions 
at which the molecule is capable of modification by a variety of enzymes.  
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Figure 1.1  The structure of inositol phospholipids. 
 
 
 
The inositol head-group, which can be reversibly phosphorylated on the 3-, 4- and 
5- positions of the inositol ring by a variety of enzymes, is attached to 
diacylglycerol (typically stearyl/arachidonyl) via a phosphodiester bond. The stearic 
acid (sn-1 position of the glycerol moiety) and arachidonic acid (sn-2 position of the 
glycerol) are highly hydrophobic and consequently are inserted in the inner leaflet 
of the membrane, presenting the water-soluble inositol head-group to the cytosol. 
Figure adapted from [23]. 
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1.2.1 The Abundance and Occurrence of Phosphoinositides (PIs). 
Phospholipid components of cell membranes can be divided into two types, acidic 
phospholipids and non-acidic phospholipids. These two types can be subdivided, with 
non-acidic phospholipids including phosphatidylethanolamine (PtdEth), 
phosphatidylcholine (PtdCho) and sphingomyelin. Acidic phospholipids consist of three 
major types, phosphatidylserine (PtdSer), phosphatidic acid (PtdOH) and PI (PtdIns and 
its polyphosphate derivates). To put the abundance of these phospholipids in perspective, 
PtdSer is the most abundant of the acidic phospholipids followed by PtdOH and PI – 
which comprises ~1-5% of total cellular lipids [24,25]. The acidic phospholipids have 
several overlapping roles in signalling including; (i) facilitating binding to second 
messengers, seen with PtdSer/PtdOH and electrostatic interactions with FYVE (Fab1p, 
YOTB, Vac1 and EEA1) domains (see Chapter 5) [26]; (ii) acting as substrates in the 
production of second messengers, such as with PtdIns(4,5)P2 and phospholipase-C (PLC) 
mediated synthesis of Ins(1,4,5)P3 and diacylglycerol (DAG) [27]; and (iii) are second 
messengers themselves, such as PtdIns(3,4,5)P3 and PtdIns(3,4)P2 [28,29]. PIs in 
particular, play a crucial role in cell signalling, are generated by de-novo synthesis or 
recycling from other PI  species and differ only in the chemical moiety (head-group) 
attached via the sn-3 carbon of diacylglycerol.  
 
This interconversion of PI species is achieved by a considerable network of PI 
kinases and phosphatases. The concerted actions of these enzymes can result in the 
production of seven polyphosphoinositide derivatives, as reflected in Figure 1.2, but each 
with much lower abundance than PtdIns. Of the seven naturally occurring derivatives, 
PtdIns4P and PtdIns(4,5)P2 are the most abundant with PtdIns(4,5)P2 accounting for about 
5% of the total PI [24,25]. The concentrations of PtdIns4P and PtdIns(4,5)P2 are 
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maintained by appropriate kinases and phosphatases such as the PtdIns 4-kinase and the 
PtdIns4P 5-kinase respectively. However, despite such apparent scarcity, PtdIns and its 
metabolites have a disproportionately important role in cell signalling, with PtdIns(4,5)P2 
particularly important as a substrate for two separate “arms” of the PI signalling pathway. 
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Figure 1.2  The phosphoinositide cycle. 
 
 
The synthesis and degradation of PIs is maintained by the constitutive or regulated 
activity of a number of lipid kinases and phosphatases. Key examples of the 3- and 4- 
phosphatases (Pase) as well as the substrate selectivities of the PI 3-kinase enzymes 
(PI3K) will be introduced individually in Chapter 1.3. Also indicated is the PLC mediated 
hydrolysis of PtdIns(4,5)P2 into Ins(1,4,5)P3 and DAG. Figure adapted from [30]. 
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1.2.2 PtdIns(4,5)P2 and PLC. 
 The first of these “arms” of the PI pathway was uncovered when a causal link 
between PI turnover and Ca2+ signalling was suggested by R. Michell [31]. The precise 
nature of the role that PI metabolites play in this context was subsequently shown by M. 
Berridge and colleagues [32]. Thus, Berridge et al. demonstrated that activation of 
receptors coupled to PI-PLC results in the hydrolysis of PtdIns(4,5)P2, generating two 
second messengers, Ins(1,4,5)P3 and DAG [27]. The soluble Ins(1,4,5)P3 is able to freely 
diffuse through the cytosol and activates release of Ca2+ from intracellular stores via a 
specific Ins(1,4,5)P3 receptor. Changes in intracellular Ca2+ levels then trigger many 
downstream responses, regulating a wide range of cellular processes including 
fertilisation, muscle contraction and cell motility [33]. Subsequently, numerous kinases 
and phosphatases are capable of metabolising Ins(1,4,5)P3, its metabolites serving both to 
terminate Ca2+ signalling or perhaps, generate additional signalling molecules [i.e. 
Ins(1,3,4,5)P4 production by Ins(1,4,5)P3 3-kinase] and allow the recycling of inositol and 
PtdOH (derived from DAG) back to PtdIns [34-36]. 
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1.3 The Enzymes responsible for 3-PI metabolism. 
 A second “arm” of the PI signalling pathway was to be discovered upon the 
observation of an enzyme capable of phosphorylating PI species at the D3 position of the 
inositol ring (PI 3-kinases) [37]. Two key PI metabolites phosphorylated on the D3 
position include PtdIns(3,4,5)P3 and PtdIns(3,4)P2, both of which are approximately 1000 
fold less abundant than PtdIns(4,5)P2 [24,25] but are crucial second messengers required 
for normal cell function [38]. The enzymes responsible for their synthesis and degradation 
following PI 3-kinase activation determine the prevailing output of 3-PI signalling events 
and these are detailed within the signalling pathway illustrated in Figure 1.3. The capacity 
of these 3-PI metabolising enzymes to generate rapidly one lipid species either at expense 
of, or alongside another, is highlighted by the extremes of lipid concentrations achieved 
by specific stimuli such as growth factors, insulin or invasive pathogens [39-41]. 
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Figure 1.3  The class IA PI 3-kinase signalling pathway. 
 
 
Following activation of class IA PI 3-kinases, downstream of activated RTKs (Chapter 1.1.2), the coordinated actions of lipid 
phosphatases such as PTEN, SHIP2 (5-phosphatases) and the 4-phosphatases can control the prevailing outcome of the 3-PI 
second messengers generated; either PtdIns(3,4)P2 and/or PtdIns(3,4,5)P3, and recruit effector proteins accordingly. 
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1.3.1 PI 3-Kinases. 
PI 3-kinases (the most intensively studied PI kinase) were first observed 
unknowingly in 1984 as a minor inositol lipid kinase activity associated with the 
immunoprecipitated oncogene product Src [42]. They were reported shortly 
afterwards in 1985 associated with the Polyoma Middle T antigen and Abl [43], 
and later in activated growth factor receptor complexes such as those stimulated 
by PDGF [44] and CSF-1 [45]. Their novel ability to phosphorylate the D-3 
position on the inositol ring was reported in 1988 [37] and dramatic and transient 
rises in PtdIns(3,4,5)P3 as a response to physiological stimuli were observed in 
1989 [39]. PI 3-kinases have since been shown to be integral to many 
physiological functions such as cell growth, proliferation, survival, intracellular 
trafficking, differentiation [46-50], migration [51], secretion [52], axonal guidance 
[53] and apoptosis [54], as well as the dysfunction of these processes implicated in 
diseases such as cancer and diabetes [55-57].  
 
Eight different PI 3-kinase isoforms have now been identified and these are 
divided into three classes (class I [subclasses IA and IB], II and III). The three 
classes of PI 3-kinase are differentiated and defined by their structure and 
substrate specificity [47,50]. Although Class I PI 3-kinases are capable of 
phosphorylating the D3 position of all PIs in vitro, they are the only isoforms 
demonstrated to use PtdIns(4,5)P2 in vivo to produce PtdIns(3,4,5)P3. The subclass 
IA enzymes are activated/recruited by receptor and non-receptor tyrosine kinases 
and are dimers consisting of a p50α/55α/p55γ/p85α/p85β regulatory domain and a 
p110α/β/δ catalytic subunit [38]. The subclass IB comprise of only one member 
which is activated/recruited by GPCRs, predominantly via the βγ subunit of the 
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Gi–coupled GPCRs [58,59] and is a dimer consisting of the p110γ catalytic 
subunit and either a p101 or p84 regulatory subunit. 
 
   The class II PI 3-kinases, unlike either the class I or III enzymes, are 
monomeric, possessing no regulatory domain, although the catalytic core of each 
class II enzyme shares structural homology with the class I proteins [50]. The 
class II enzymes consist of three isoforms, PI3KC2α, PI3KC2β and PI3KC2γ. 
Originally it was proposed that the class II enzyme activity might phosphorylate 
PtdIns4P to produce PtdIns(3,4)P2 in vivo as it does in vitro. Whilst this 
mechanism of PtdIns(3,4)P2 production cannot be ruled out, it is now widely 
accepted that this lipid is predominantly synthesised by the action of 5-
phosphatases on PtdIns(3,4,5)P3. It is now well documented that Class II PI 3-
kinases similar to class III, produce PtdIns3P in vivo, but act predominantly at the 
plasma membrane rather than other intracellular endosomal membranes [51].  
 
Class III PI 3-kinase is the human orthologue of the only representative of 
PI 3-kinases in Saccharomyces cerivisiae (Vps34) and was first reported in 1995 
[60]. The class III enzyme has a regulatory binding domain of 150kDa and is only 
capable of phosphorylating PtdIns so can be more accurately described as a PtdIns 
3-kinase. Class III enzymes are predominantly involved in endosome fusion and 
intracellular trafficking and as such are located mainly on intracellular membranes 
[50,61]. 
 
Two inhibitors in particular have been widely used to determine the 
biological functions of PI 3-kinases, namely wortmannin and LY294002 [23]. 
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Wortmannin, a cell permeable, fungal metabolite, was originally isolated from 
Penicillium wortmannii [62] and reported to inhibit phagocytocis induced 
respiratory burst [63]. It was later shown to be a potent competitor of ATP, 
binding to and irreversibly inhibiting PI 3-kinases with a low nM IC50 [64]. Also 
LY294002, a reversible, ATP-competitive inhibitor, selective for PI 3-kinases was 
synthesized from the flavenoid quercetin [65] and has an IC50 in the µM range. 
Much early work in elucidating the roles of PI 3-kinases in cell signalling was 
made possible by the use of these inhibitors. 
 
1.3.2 Phosphatase and Tensin Homolog Deleted on Chromosome 
Ten (PTEN). 
The removal of PtdIns(3,4,5)P3 generated by class I PI 3-kinases is 
necessarily tightly regulated. Loss of this control either through excessive 
synthesis or lack of catabolism often results in cell transformation (uncontrolled 
cell growth and/or proliferation) [66]. One of the key phosphatases required for 
the removal of PtdIns(3,4,5)P3 concentrations is PTEN, a 3-phosphatase which 
acts directly to oppose the activity of class I PI 3-kinases by returning 
PtdIns(3,4,5)P3 to PtdIns(4,5)P2 [67]. The role of PTEN as a tumour suppressor is 
well established, due in part to its constitutive activity and the lack of redundancy 
offered by other 3-phosphatases. 
 
PTEN belongs to a family of protein tyrosine phosphatase (PTP)-like 
enzymes whose characteristic active site depends on a critical, cysteine-containing 
sequence of amino acids [68]. This active site is highly sensitive to oxidation and 
mechanisms of PTEN regulation whereby reactive oxygen species (ROS), 
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liberated as a consequence of RTK activation, inhibit PTEN activity are beginning 
to be understood [69]. Despite the significance of PTEN in normal cells, it is 
absent in the 1321N1 astrocytoma cell line employed for this study, so these cells 
are heavily dependent on the metabolism of PtdIns(3,4,5)P3 to PtdIns(3,4)P2 via 
the 5-phosphatases Src Homology 2 domain containing Inositol polyphosphate 5-
phosphatase 2 (SHIP2). 
 
1.3.3 Src Homology 2 domain containing Inositol polyphosphate 
5-phosphatase 2 (SHIP2). 
An alternative means of metabolism of PtdIns(3,4,5)P3 is via the 5-
phosphatases. These enzymes remove the 5-phosphate group from PtdIns(3,4,5)P3, 
generating PtdIns(3,4)P2 which is widely considered as a second messenger in its 
own right [38]. Although several 5-phosphatases are thought to contribute to the 
metabolism of PtdIns(3,4,5)P3, including SKIP (skeletal muscle and kidney 
enriched inositol 5-phosphatase) and PIPP (proline rich inositol polyphosphate 5-
phosphatase) [70-74], SHIP1 and SHIP2 are thought to be the prominent 5-
phosphatases involved in the production of PtdIns(3,4)P2. The two enzymes do 
however differ in both structure and expression. SHIP1 contains an N-terminal 
SH2 domain, two NPXY motifs and a C-terminal proline rich region and its 
expression is limited mainly to haemopoeitic cells. SHIP2 only contains a single 
NPXY motif, a SH2 domain and C-terminal proline rich and sterile alpha motif 
(SAM) domains which mediate protein-protein interactions [73,75,76]. SHIP2 is 
ubiquitous in its expression but is particularly highly expressed in cells which lack 
SHIP1 (liver, heart, muscle, brain and adipocytes) [70]. 
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1.3.4 4-phosphatases. 
The degradation of PtdIns(3,4)P2 [generated as a consequence of 5-
phosphatase activity on PtdIns(3,4,5)P3] is controlled by the 4-phosphatases which 
exist as two main isoforms; type I and type II, sharing a 37% amino acid identity. 
Similar to PTEN, they are members of the PTP family, containing a catalytic 
cysteine motif which is sensitive to oxidation [77-79], a key feature which is 
exploited within this study. The type I (INPP4A) and II (INPP4B) 4-phosphatases 
differ in their levels of expression and tissue distribution and both can exist as two 
splice variants, α and β. The C-terminal region of the α isoforms is hydrophilic 
while the β isoforms have a hydrophobic tail which may contain a transmembrane 
sequence [80]. The literature reports that both type I and type II isoforms show 
strong preference for metabolising PtdIns(3,4)P2 to PtdIns3P in vitro [77,78,81]. 
However, the enzymes preference for PtdIns(3,4)P2 over the water soluble 
Ins(1,3,4)P3 and Ins(3,4)P2 generated during the re-cycling of Ins(1,4,5)P3 to 
inositol [82], is not supported by any cellular observations. It has been suggested 
that the 4-phosphatases exist not only to remove PtdIns(3,4)P2 but also contribute 
to the functional pools of PtdIns3P [79]. The cellular location of these pools of 
PtdIns3P at either the endosomal or plasma membranes is however, not clear. 
 
1.4 PtdIns(3,4,5)P3/PtdIns(3,4)P2 as Second Messengers. 
 The enzymes which contribute to the synthesis and degradation of 
PtdIns(3,4,5)P3/PtdIns(3,4)P2 from PtdIns(4,5)P2 have been introduced. In contrast 
to the PLC/PtdIns(4,5)P2 “arm” of the PI signalling pathway, the PI 3-kinase-
dependent “arm” is capable of directly recruiting and/or activating a wide variety 
of effectors [38]. In fact, this feature is unique amongst second messenger 
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systems, including cAMP and Ins(1,4,5)P3 which tend to target a limited number 
or solitary, immediate effectors such as; protein kinase A (PKA), cAMP-regulated 
ion channels and exchange protein directly activated by cAMP (Epac) or the 
Ins(1,4,5)P3 receptor respectively, which then regulates multiple downstream 
events. The wide variety of effectors capable of responding directly to 
PtdIns(3,4,5)P3 and/or PtdIns(3,4)P2 do so through protein modules or domains 
which are capable of selectively recognising these lipid products. The concept of 
modular domains will be introduced later.  
 
The list of effector proteins capable of interacting with PtdIns(3,4,5)P3 
and/or PtdIns(3,4)P2 include Grp-1 [83], Btk [84], protein kinase B (PKB)/Akt 
[29,85], PDK1 [86,87], DAPP-1 [88], SWAP-70 [89], GAP1 [90], DOCK180 
[91], ARNO [92,93], cytohesin-1 [94], centaurin-α [95,96], Gab1 [97], ARAP3 
[98], lamellipodin [99], ARAP1 [100,101] and TAPP-1 [102]. Currently TAPP-1 
is the only protein established to show selective binding for PtdIns(3,4)P2, with the 
remainder reported as either selective PtdIns(3,4,5)P3 binding proteins or showing 
dual specificity to PtdIns(3,4,5)P3/ PtdIns(3,4)P2. Each of the above effectors, 
recruited and/or activated by PtdIns(3,4,5)P3/PtdIns(3,4)P2 have been shown or 
assumed, to serve different or overlapping cellular processes and their functions 
range from scaffolding proteins to small G-protein regulators and protein kinases. 
 
The best known and most widely studied of these is PKB/Akt, its mode of 
recruitment and activation following PtdIns(3,4,5)P3 synthesis defining a 
paradigm for a wider class of PtdIns(3,4,5)P3 binding proteins. PKB is a 
serine/threonine kinase and is one of the most influential protein kinases in human 
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physiology [103,104]. Following activation of class I PI 3-kinases and the 
production of PtdIns(3,4,5)P3, PKB recruitment to the plasma membrane is 
mediated via a selective interaction of PtdIns(3,4,5)P3 with the PH domain of PKB 
[29,85]. The activities of two other serine/threonine (S/T) kinases (PDK1 and 
mTORC2) are then responsible for modulating the activity of PKB by 
phosphorylating it at T308 and S473 respectively [103,105,106]. Once activated 
PKB is, in turn, capable of phosphorylating its many substrates. Its varied 
substrates are responsible for mediating a wide range of cellular processes, 
critically including cell survival by inhibition of apoptosis or cell death. However, 
aberrations in the mechanism of PKB activity or the processes which regulate it, 
resulting in overactive or constitutive activation of PKB, are intrinsically linked to 
disease states such as diabetes and cancer, and as such, it is an example of an 
oncogene.  
 
PKB has, however, also been shown to demonstrate the facility to bind 
PtdIns(3,4)P2 [107,108]. However, the widely recognised activation of PKB under 
conditions of elevated PtdIns(3,4,5)P3 concentrations, achieved either following 
receptor activation or by mutations in PtdIns(3,4,5)P3 metabolising enzymes, has 
questioned the significance of its PtdIns(3,4)P2 binding capability. Furthermore, 
due to the importance of the tumour suppressor PTEN in metabolising 
PtdIns(3,4,5)P3 and of course the primary consequence of PI 3-kinase activation 
being PtdIns(3,4,5)P3, perhaps it is of little surprise that much attention has been 
directed towards PtdIns(3,4,5)P3 and its effectors.  
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1.5 Protein Domains. 
Protein domains are structurally conserved modules, very often displayed by 
multiple proteins and are often characterised by a three dimensional structure or 
scaffold. Many different proteins domains exist for the selective recognition of 
key molecular targets or ligands which include complementary protein/peptide 
modules or motifs as well as phospholipids, most pertinently 3-PI. The concept of 
protein domains was introduced courtesy of the first observed oncogene – that of 
the viral Rous Sarcoma gene (Src) [109,110]- and now nearly all proteins have 
been shown to present at least one functional module or domain. Some examples 
of widely expressed domains crucial in cell signal propagation and their ligands 
include, SH2 (phospho-Y), SH3 (P-rich peptides), FYVE (PtdIns3P), PH 
(predominantly 3-PIs), PX (predominantly PtdIns3P), IQ (calmodulin), PDZ 
(predominantly peptides), CH (actin), WW (P-rich peptides), 14-3-3 (phospho-S) 
and UIM (ubiquitin) [111-114].  The SH2 and PH domains are introduced below 
as exemplary domains, however, the structure and ligand specificity of the 
established lipid binding domains (LBDs), PH, PX and FYVE are addressed more 
thoroughly in Chapter 5. 
 
1.5.1 The Src Homology 2 Domain (SH2). 
The Src homology 2 (SH2) domain fulfils a prominent role within cellular 
signalling and is present within many proteins and comprises approximately 100 
amino acids [114]. SH2 domains employ a characteristic structure of a β-sheet 
with two α-helices either side. They have been observed in proteins with wide 
ranging functions from adaptors, kinases, phosphatases to cytoskeletal regulators 
[115]. The SH2 domain characteristically bind phosphorylated tyrosine residues 
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but shows varying preference towards the adjacent amino acids (~5 residues C-
terminal to the phospho-tyrosine), providing a mechanism for differential 
selectivity [115]. An example of a functional ligand or consensus sequence for the 
SH2 domain is provided by the RTK autophosphorylation sites, as previously 
introduced. The recruitment to autophosphorylated RTKs of the parent protein by 
its SH2 domain can provide a mechanism by which to consequently activate the 
recruited proteins and to build signalling complexes at sites of receptor activation. 
SH2 domains are found within 110 human proteins (SMART database Aug. 2010 
[116,117]) and a relevant example is the prominent 5-phosphatase SHIP2, whose 
name is derived from its SH2 domain. Indeed SHIP2’s SH2 domain may provide a 
mechanism for its membrane recruitment following RTK activation. 
 
1.5.2 The Pleckstrin Homology Domain (PH). 
 PH domains were first observed in pleckstrin (Pleckstrin Homology) and 
later the PH domain of PLCδ1 was the first motif to show specific recognition of a 
phosphoinositide [118], although at least ten more domains have subsequently 
been identified which are capable of lipid binding [25,119,120]. PH domains are 
~125 amino acids in length and they characteristically have little sequence 
similarity between one example and another but possess a highly conserved 
secondary structure. This structure is often referred to as a β-barrel (Figure 5.1) 
and creates a pocket for ligand binding, which with subtle variation can change its 
selectivity between different PIs [25,119,120]. PH domain containing proteins are 
integral components of a multitude of effectors and are capable of recognising 
several PIs. The function of these PH domain containing proteins include kinases, 
small G-protein regulating proteins (guanosine nucleotide exchange factors 
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[GEFs], GTP-ase activating proteins [GAPs]) and phospholipases to name but a 
few [38,120]. Furthermore, parent protein recruitment to cell membranes via these 
domains has been shown to mediate a wide range of processes such as growth, 
survival, membrane trafficking and cytoskeletal dynamics [25,121-123]. Examples 
of some of the better characterised and widely known PH domain proteins include 
PLC-δ which shows selectivity for  PtdIns(4,5)P2, Btk and Grp-1 which show 
selectivity for PtdIns(3,4,5)P3, PDK1 and PKB which show dual selectivity for 
PtdIns(3,4,5)P3 and PtdIns(3,4)P2 and TAPP-1 which shows selectivity for 
PtdIns(3,4)P2. 
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1.6 The Aims of this Study. 
 In contrast to PtdIns(3,4,5)P3, few selective binding proteins for PtdIns(3,4)P2 
have been identified. This study aims to address this lack of currently established 
PtdIns(3,4)P2 binding proteins by optimising a screen to isolate novel 3-PI effectors, 
and specifically those for PtdIns(3,4)P2. It is intended that uncovering PtdIns(3,4)P2 
specific effector proteins will allow conclusions to be drawn on the role of 
PtdIns(3,4)P2 as an independent second messenger. The described screen utilises a 
unique pharmacological approach to manipulate the actions of 3-PI metabolising 
enzymes; dramatically increasing the cellular concentrations of Ptdins(3,4)P2. 
Subsequently, those proteins which are recruited to these membranes are recovered, 
and their identities determined by mass spectrometry. Positive candidates are cloned 
and expressed and their lipid binding characteristics are determined by in vitro assays. 
The results of this study advance the understanding of the PI 3-kinase-dependent 
signalling network. 
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2. Materials and Methods 
2.1 Materials 
1321N1 astrocytoma cells and HeLa cells were from the European 
Collection of Cell Cultures. Foetal bovine serum (FBS) and dialysed FBS were a 
reserve order from Gibco. Antibodies against SHIP2, TAPP-1, as described 
previously [124], and PARIS-1 (raised in sheep against an N-terminal sequence 
[amino acid residues 17-29]) were obtained from the Division of Signal 
Transduction Therapy (DSTT), University of Dundee. GST-tagged PH domains of 
Grp-1, TAPP-1, lamellipodin, PKB and PLC-δ were also obtained from the DSTT. 
Potassium bisperoxo(1,10-phenanthroline)oxovanadate (V) (bpV[phen]) was from 
Merck, PDGF and EGF were from Sigma. Neutravidin beads were from Pierce 
and VectaSpin spin-filters were from Whatman. All synthetic lipids and inositol 
derivatives were from Cell Signals (Lexington, KY, USA). Ultrapure water for 
mass spectrometer sample preparation, used where indicated, was from J.T. Baker 
and Trypsin Gold was from Promega. Heavy isotope substituted (13C) amino acids 
were from C.K. Gas Products (Cambridge U.K) and normal or “light” amino acids 
were from Sigma. Testis, brain and liver cDNA libraries were Matchmaker GAL4 
Two-Hybrid Systems obtained from Clontech. KOD Hot Start polymerase and 
TOPO II blunt vector were from Roche and Invitrogen respectively. All expressed 
sequence tag (EST) and cDNA plasmids were from I.M.A.G.E. consortium 
(Cambridge U.K.) and primers were from MWG Eurofins. Streptavidin-dextrose 
(SA) sensor chips for surface plasmon resonance together with Q-Sepharose and 
S-Sepharose fast flow chromatography media were obtained from G.E.Healthcare, 
as were polyvinylidine fluoride (PVDF) and nitrocellulose supported Hybond-C 
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Extra membranes. Fatty acid free BSA was from Sigma. SDS polyacrylamide gels 
were from Invitrogen. 
 
2.2 Methods. 
2.2.1 Cell Culture. 
1321N1 astrocytoma cells from European Collection of Cell Cultures were 
maintained in Dulbecco’s Modified Eagles Medium (DMEM) supplemented with 
5% (v/v) FBS. Cells were routinely seeded at ~20,000 cells/cm2 in a 75cm2 flask 
and allowed to achieve confluence (~250,000-300,000 cells/cm2) at 37°C in a 5% 
(v/v) CO2 atmosphere prior to tryptic digestion with Tryple Express (Gibco) and 
re-plating approximately once a week or as required. Where necessary HeLa cells 
were maintained identically except FBS was supplemented to 10% (v/v). 
 
Stable Isotope Labelling with Amino acids in Cell Culture (SILAC) 
medium comprised DMEM which lacked arginine (R), lysine (K) and methionine. 
Medium was freshly supplemented with 0.2mM methionine, additional glutamine 
(2mM), 5% (v/v) dialysed FBS and penicillin/streptomycin (Gibco - 100units/ml 
penicillin [1 unit = potency in 0.6µg of supplier’s standard] and 100µg/ml 
streptomycin). Medium was then differentiated by addition of “heavy” amino 
acids (0.4mM arginine 6 [R6], 0.8mM lysine 6 [K6]) or equivalent concentrations 
of “light” amino acids (R0, K0). Cells were initially seeded at 20,000 cells/cm2 
and allowed at least seven cell doublings, splitting where necessary, in their 
respective medium prior to preparation of lysates. All dishes received a medium 
change with appropriate DMEM 18 hrs before stimulation. 
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2.2.2 Preparation of Cell Extracts. 
2.2.2.1 Crude Cell Fractionation. 
The preparation of crude cytosolic (liberated by digitonin 
permeabilisation) and subsequent membrane fractions (Triton X-100 [TX-100] 
soluble material) for the purpose of tracking the re-localisation of cellular 
components in response to stimuli was achieved from individual wells of cells up 
to multiple 15cm dishes (10-176cm2), depending on the experimental requirement. 
Confluent 1321N1 cells were washed twice in 2-10ml of serum-free DMEM 
(maintained in 5% (v/v) CO2 atmosphere) or modified Krebs-Henseleit buffer 
(25mM Hepes pH 7.6, 118.4mM NaCl, 1.3mM CaCl2, 1.2mM MgSO4, 4.7mM 
KCl, 1.2mM KH2PO4, 11.6mM D(+) glucose) (subsequently maintained without 
additional CO2) and allowed to equilibrate in a similar volume of the same 
medium at 37°C for 60 min. Where required, inhibitor or vehicle alone was added 
for the final portion of this time. Cells were then incubated in the presence or 
absence of PI 3-kinase stimuli as indicated to promote the translocation of 3-PI 
effector proteins to the cell membranes. The plates were then transferred onto ice 
and the medium was aspirated rapidly and replaced, between 1-4 times 
consecutively, with 2-10ml of ice-cold, digitonin permeabilisation buffer (25mM 
Hepes, pH 7.2, 100μg/ml digitonin, 75mM NaCl, 50mM NaF, 100μM EDTA, 
100μM EGTA supplemented freshly with 0.1% (v/v) 2-mercaptoethanol, 100μM 
phenylmethylsulfonyl fluoride (PMSF) 100μM benzamidine and 1mM sodium 
vanadate) and the cells maintained on a rocking platform at 4°C for 10 min before 
collection of the resulting supernatant as the soluble protein (cytosol) fraction. The 
remaining adherent layer of insoluble cell debris was washed briefly with 
permeabilisation buffer to remove any residual, soluble material prior to recovery 
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of the membrane fraction by scraping in 1-4ml of ice-cold lysis buffer buffer 
(50mM Tris, pH 7.5, 50mM NaF, 1mM EDTA, 1mM EGTA, 5mM sodium 
pyrophosphate, 10mM glycerol 2-phosphate, 0.5% (w/v) TX-100, supplemented 
freshly with 0.1% (v/v) 2-mercaptoethanol, 100μM PMSF, 100μM benzamidine 
and 1mM sodium vanadate). These fractions were centrifuged at 10,000g for 10 
min at 4°C prior to discarding the insoluble pellet and snap freezing the 
supernatant in N2 and storage at -80° for later analysis by SDS-PAGE. 
 
2.2.2.2 Triton X-100 Cell Lysates. 
Cell lysates for preliminary experiments to optimise Neutravidin-biotin 
PtdIns(3,4)P2 depletion of TAPP-1 (indicated where relevant) were generated 
similarly, although the digitonin solution was omitted and samples simply scraped 
into lysis buffer after the 60 min equilibration and subsequent treatment/inhibition 
period(s) as required. 
 
2.2.2.3 Selective Elution from Membranes. 
Proteins recruited to membranes enriched in PtdIns(3,4)P2 as a 
consequence of bpV(phen) treatment could be recovered selectively by elution of 
digitonin permeabilised cells with Ins(1,3,4)P3 washes. Sample preparation was as 
detailed for crude cell fractionation with the incorporation of an additional 
selective elution step prior to final TX-100 recovery of the insoluble fraction. 
Experimental scale was varied (typically 1-10ml of permeabilisation and elution 
buffer required for dishes ranging between 6-15cm respectively) according to 
requirement. Proteins bound to 3-PI as a consequence of elevated PtdIns(3,4)P2 
concentrations were recovered selectively from permeabilised cells by washing in 
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the appropriate volume of buffer A (10mM Hepes, pH 7.2, 100μM EDTA, 100μM 
EGTA supplemented freshly with 0.1% (v/v) 2-mercaptoethanol, 100μM PMSF, 
100μM benzamidine and 1mM sodium vanadate) supplemented with or without 
100μM Ins(1,3,4)P3 or Ins(1,4,5)P3 for 10-60 mins at 4°C. The eluted proteins 
were then analysed by SDS-PAGE. 
 
2.2.3 Affinity and Ion Exchange Chromatography. 
Inositol phosphate specific membrane eluates or for the purposes of 
optimisation, triton extracts, were purified further by affinity chromatography 
using Neutravidin beads pre-coupled to biotinylated PtdIns(3,4)P2 (120-240nmol 
lipid/1ml packed matrix) for a minimum of 30 mins at 4°C in either lysis buffer or 
buffer. Extracts were pre-cleared with Neutravidin beads alone for a minimum of 
30 mins at 4°C except in the case of SILAC experiments. Samples were then 
incubated with Neutravidin-biotin PtdIns(3,4)P2 complex for 60 mins at 4°C. The 
recovery of target proteins from the Neutravidin-biotin PtdIns(3,4)P2 complex was 
achieved by collection in 10μm polypropylene filter tubes (VectaSpin Micro, 
Whatman) coupled to an aspirator manifold modified via a 2ml syringe to support 
the filter tube. Each sample was washed through rapidly with 2-10 bead volumes 
of either ice cold lysis buffer or buffer A, according to experimental format, with 
eluate discarded to waste. Final sample recovery was achieved by elution with one 
bead volume of buffer B (2.2% (w/v) sodium dodecyl sulphate (SDS) in 70mM 
Tris pH 6.8) at 70°C. For larger scale experiments, notably SILAC, buffer B was 
diluted (by a maximum of 4 fold) to allow for subsequent vacuum concentration 
by a similar factor. Alternatively, where TX-100 extracts were used for 
experimental optimisation, Neutravidin-biotin PtdIns(3,4)P2 complexes were 
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washed by a brief centrifugation step in an appropriate volume of lysis buffer 
which was discarded prior to direct suspension of the beads into SDS-sample 
buffer. 
 
Where indicated, but routinely for SILAC experiments, final sample 
complexity was reduced by application of ion exchange chromatography prior to 
affinity chromatography with the Neutravidin-biotin PtdIns(3,4)P2 complex. 
Single or multiple steps of ion-exchange chromatography consisted of loading 
samples onto Q-sepharose and S-sepharose columns (anion and cation exchangers 
respectively) and eluting with 150-600mM NaCl. Additionally, where indicated 
the column flow-through was also recovered for analysis. Elution volumes of 
NaCl were limited to 2-5 column bed volumes (0.3-0.5ml) to minimise the amount 
of biotinylated lipid required to achieve optimum concentration at the subsequent 
step. Although primarily ensuring a reduction of sample complexity, 
chromatographic fractionation in this manner also limited the carry-over of 
Ins(1,3,4)P3. 
 
2.2.4 SDS-PAGE. 
Each cell extract for analysis was either supplemented with the appropriate 
volume of NuPAGE 4xLDS (lithium dodecyl sulphate) sample buffer (Invitrogen) 
and 14.5mM 2-mercaptoethanol or the remaining constituents were added 
separately where SDS had been included during sample preparation, ensuring that 
final concentrations in each instance were 62.5mM Tris pH 6.8, 0.01% (w/v) 
bromophenol blue, 10% (v/v) glycerol and SDS to a maximum of 5% (v/v). 
Alternatively, notably for SILAC experiments, prior to the addition of sample 
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buffer constituents, samples were first reduced (using 10mM dithiothreitol at 70oC 
for 5 min) and alkylated (using 50mM iodoacetamide at room temperature for 30 
min). Samples (~25μg for routine analysis and 25-100μg for samples intended for 
analysis by mass spectrometry) were loaded on Novex, pre-cast, bis-tris gels, 
typically 4-12% (w/v) and were run according to the manufacturer’s instructions. 
Exceptionally, SILAC samples were developed to only 1/3-1/2 the gel length, 
~25-35 mins at 150V. Developed gels were then stained immediately with 
Colloidal Coomassie (Invitrogen) or Silver Snap (Pierce) according to the 
respective manufacturer’s protocol. Alternatively, gels were processed further by 
Western blotting. 
 
2.2.5 Western Blotting. 
PVDF membrane, pre-wetted in methanol and allowed to equilibrate for 10 
mins in transfer buffer (Invitrogen) and 15% (v/v) methanol was assembled into a 
cassette and transferred using the Bio-Rad mini Trans-Blot PROTEAN wet 
transfer system. Transfer was achieved, typically with a ~60cm2 membrane, either 
at 60V for 2.5 hrs or at 16V overnight. The membranes were then blocked for 30 
mins in Tris-buffered saline with Tween-20 (TBST) (50mM Tris pH 7.6, 150mM 
NaCl, 0.1% [v/v] Tween-20) supplemented routinely with 5% (w/v) Marvel or 
alternatively with 3% (v/v) BSA for anti-phospho blots. Following blocking, 
membranes were incubated with primary antibody (typically 0.1-1μg/ml) for 1 hr 
at RT or overnight at 4°C in appropriate TBST blocking buffer supplemented with 
0.05% (w/v) NaN3 as a preservative. Several subsequent rounds of washes in 
TBST, typically 3 x 10 mins preceded incubation for 1 hr at RT with appropriate 
horseradish peroxidase-coupled secondary antibody (0.1μg/ml) in appropriate 
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TBST blocking buffer. Following an additional cycle of washes in TBST (3 x 10 
mins), protein-antibody complexes were visualised by exposure to Immobilon 
Western ECL (Millipore) chemiluminescent substrate and the output recorded on a 
CCD camera under conditions of linear light accumulation. Images were 
quantified using AIDA (Advanced Image Data Analysis) software. 
 
2.2.6 Agarose Gel Electrophoresis. 
For the purposes of gel purification or qualitative analysis of fragment size, 
DNA samples were supplemented with DNA sample buffer (0.25% (v/v) xylene 
cyanol FF, 0.25% (v/v) bromophenol blue, 50% (v/v) glycerol, 1X TAE [40mM 
Tris-HCl pH 7.6 with acetic acid, 1mM EDTA]) and stored at 4°C. Separation of 
DNA fragments was achieved on a 1% (w/v) agarose gel (1g agrose/100ml TAE 
per gel required), prepared by heating until the agarose dissolved and then 
supplemented freshly with 0.02% (v/v) SYBR safe DNA gel stain (Invitrogen) 
before allowing to cool and pouring into a gel platform prior to solidifying. 
Following cooling to room temperature, the agarose gel was submerged in 1X 
TAE buffer and 10-20μl of sample was loaded accordingly into each well. Gels 
were developed for 1 hr at 140V prior to exposure on a CCD camera to visualise 
the bands and quantitation, where required, was by AIDA. Subsequent DNA 
purification from gel slices was carried out using QIAquick Gel Extraction Kits 
(Qiagen) according to the manufacturer’s instructions. 
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2.2.7 Primer Design. 
Primer design was achieved using pDRAW (AcaClone software) ensuring 
the selection of appropriate vectors and strategy based on the presence/absence of 
restriction sites within the cDNA of interest. Having selected suitable sequences 
(~15-35 nucleotides) from within the cDNA both 5’-3’ and 3’-5’, this was checked 
using NetPrimer (Premier Biosoft International) to ensure the absence of any 
significant primer dimers, hairpins and cross dimers. An approximate score of 
between 0-100 is provided on this basis, and no primer was selected that fell 
below a score of 65. All oligonucleotides (including sequencing primers) were 
ordered from MWG Eurofins (sequence submitted on the basis of 5’-3’ regardless 
of sense/antisense), using either their HPSF (high purity salt free) standard 
unmodified oligonucleotide service or the unmodified oligonucleotide à la carte 
service for those where incorporation of additional restriction sites was required 
due to cloning strategy. The primers used are listed in Table 2.1. 
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Table 2.1  Primer Sequences. 
Construct Sense (5'-3') Anti (5'-3') 
PDIA5 GCTGCTGGGATGGCGC CTGAGGCAGGAATTATAACTCTTCC 
CIQGAP 
718-1657 GTCTATGTCGACCTATGCAGCTTTCTCGGGAGG TATGCGGCCGCTTACTTCCCGTAGAACTTTTTGTTGAG 
NIQGAP 
1-721 GTCTATGTCGACCCATGTCCGCCGCAGAC GGATCTCCTCCCGAGAAAGC 
CLIC1 TCAACGGATCCAAGCTTATGGCTGAAGAACAACCG AGATGAGATCTGCGGCCGCTTATTTGAGGGCCTTTGC 
RACK1 TCTTGGTCGACGGATCCATGACTGAGCAGATGACC AGTACGGGCCCGCGGCCGCCTAGCGTGTGCCAATGGT 
VCL GTCCAGTCGACGGATCCATGCCAGTGTTTCATACGCGC CTACTGTCGACGCGGCCGCCTACTGGTACCAGGGAGTC 
PKM2 TCAACGGATCCAAGCTTATGTCGAAGCCCCATAGTGA AACCAAGATCTGCGGCCGCTCACGGCACAGGAACAACA 
ANKFY1 ACATGTCTGTGCCAGATGAGAAG CTAAGAAACCCCACCCAGAGTC 
YES1 GTCTATGTCGACATGGGCTGCATTAAAAGTAAAG GCTGCGGCCGCTTATAAATTTTCTCCTGGCTGG 
SOLO C-
term GTCTATGTCGACCTATGCCTGGGGACACCTTG GCTGCGGCCGCTCACAGAGGCGTGGTGGG 
CRTAP TCTATGTCGACATGGAGCCGGGGCGC GCTGCGGCCGCCTAGCTGGTCTCCTCCAGTTCCA 
OSBPL11 TGGACTTTGGCGTTAAGATGC GTGTCACTCTGCTGGTTGTGTTG 
FOXK2  CTGGATCCATGGCGGCGGCCG CTGTCGACCTAGTTCTGGACACCCTTTTCCC 
PICALM CAGAGATGTCCGGCCAGAG CCATCAAGTTACATAAACTGTATCTGTG 
PFN ATGGCCGGGTGGAACG GTCAGTACTGGGAACGCCG 
PXK ATGGCCTTCATGGAGAAGC CCTCAGATCAATGGTGGGAC 
SPARC GCACCATGAGGGCCTGG GGAGTGGATTTAGATCACAAGATCC 
FERMT2 ATGGCTCTGGACGGGATA  TTCACACCCAACCACTGG 
EPSIN1 ATGGGTGATCAGAGCTGG  CCCTTCCTCCTATAA 
KDELC2 GACCATGCGCCGCCTC GACTCAAAGTTCTTCTCTTGAAGGC 
FKBP9  CTCGCCGCCCCGATG  TGCCAGGTTTAGAGTTCATCGTG 
EIF4E  ATGGCGACTGTCGAACCG  GAAGGTGTCTTCTTAAACAACAAACC 
SERPINH1 GCCATGCGCTCCCTCC GGCCCTATAACTCGTCTCGC 
ANXA6 ACTCAGTCGACGGAGACCATGGCCAAACC CGGAGACCATGGCCAAACC 
SWAP70 GCCATGGGGAGCTTGAAGG GCAAGCTCAGTCACTCCGTGG 
PARIS-1-
Short PH 
GTCCCTCCGCAGATCTCCGGCTGGCAGCGATGGA 
GGGCG CAGCCCGCCGTGACCTCCTGCCA 
PARIS-1-
Long PH  
GTCCCTCCGCAGATCTCCGGCTGGCAGCGATGGA 
GGGCG GCCTTGCAGCCCTAACCTGCCCTTC 
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2.2.8 Polymerase Chain Reactions (PCRs). 
All PCR reactions were carried out using a PTC-200 Peltier Thermal 
Cycler and KOD Hot Start DNA Polymerase (Calbiochem) with all reactions 
initially attempted using 100-500ng template DNA from human brain, liver and 
testis cDNA libraries. If PCR from the libraries failed, cDNAs or ESTs obtained 
from the I.M.A.G.E. consortium were used as an alternative, and template DNA in 
these PCR reactions was reduced to 10ng. As standard, primer concentrations 
were 300nM although this was decreased incrementally to a minimum of 50nM in 
conjunction with increasing template, where necessary. All reactions were carried 
out according to the manufacturer’s instructions, and additionally both with and 
without 1% (v/v) DMSO. PCR cycling conditions were as described in the 
manufacturer’s instructions for KOD Hot Start DNA Polymerase. Briefly, these 
were: 1. Activate; 95°C for 2 min, 2. Denature; 95°C for 20 sec, 3. Anneal; Primer 
Tm°C (as provided by NetPrimer analysis) for 10 sec, 4. Extension; 70°C ~20 
sec/kb target DNA, with steps 2-4 repeated for 30-35 cycles. 
 
2.2.9 Sub-Cloning and Transformations. 
Following agarose gel purification, the PCR products were ligated either 
directly into pGex-6P-x (where x = 1, 2 or 3) or, more commonly, intermediately 
into pCR-Blunt II TOPO prior to insertion into pGex-6P-x. The Zero Blunt TOPO 
PCR Cloning Kit (Invitrogen) was used according to the manufacturer’s 
instructions. Briefly, approximately 2μl of PCR product was incubated for 10 min 
at room temperature with 1μl of pCR-Blunt II TOPO in the presence of 200mM 
NaCl and 10mM MgSO4 made up to a total volume of 6μl with PCR grade water. 
The resulting ligation product was added, with gentle mixing, to a freshly thawed 
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(on ice) aliquot of chemically competent TOP10 E.Coli and allowed to rest on ice 
for 30 mins. The TOP10 cells were then heat shocked at 40°C for 30 secs and then 
transferred immediately back on to ice. To this, 200μl of SOC (2% [w/v] 
Tryptone, 0.5% [w/v] yeast extract, 10mM NaCl, 2.5mM KCl, 10mM MgCl2, 
10mM MgSO4, 20mM glucose) medium at room temperature was added and the 
samples transferred to a shaker for gentle horizontal agitation at 37°C for 1 hr 
before plating on LB (Luria Bertani) plates containing 50µg/ml kanamycin and 
incubating at 37°C for 16+ hrs. Eight colonies were selected, cultured for 12 hrs at 
37°C in 5ml LB freshly supplemented with 100μM kanamycin and the DNA was 
isolated. Following qualitative confirmation of the insert size by restriction digest 
and agarose gel analysis, the insert was sequenced with either M13 forward and 
reverse primers or with appropriately designed sequencing primers. Upon 
sequence confirmation both target vector (pGex-6P-x) and PCR product were 
digested with appropriate restriction enzymes and compatible buffer (Roche), 
typically for 1-2 hrs at 37°C. The target vector was then subsequently treated with 
shrimp alkaline phosphatase (Roche) according to the manufacturer’s instructions 
for 30 mins at 37°C in order to ensure that vector alone could not re-ligate. 
Following an agarose gel purification to eliminate undesirable DNA fragments, 
the cDNA and vector were ligated overnight at room temperature using T4 DNA 
ligase (Roche), typically in the following insert : vector ratios, 0:1, 1:1 and 1:3. 
The ligation mix was added to an aliquot of chemically competent BL21 E.Coli 
and cells transformed as described previously for TOP10s with the exception that 
resulting bacterial S.O.C. cultures were plated on 50µg/ml ampicillin LB plates. 
The resulting colonies were cultured for 12 hrs at 37°C in 5ml of LB 
supplemented freshly with 100μM ampicillin. An aliquot (100μl) of these cultures 
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was adjusted to 20% (v/v) with respect to glycerol and stored at -80°C as a starter 
culture for larger scale protein expression, following DNA purification and 
qualitative confirmation of insert size by agarose gel analysis of restriction digest. 
 
2.2.10 Protein Expression. 
The pGex-6P-x constructs incorporating sequence verified inserts were 
expressed by seeding 100ml of ampicillin supplemented (100μM) LB broth with 
transformed BL21 E.coli starter cultures generated as described in 2.2.9. Cultures 
were grown overnight at 37°C prior to dilution of the initial culture to 500ml with 
appropriate medium. Protein expression was promoted by addition of isopropyl β-
D-thiogalactoside (IPTG) at 50-400µM for 1-16 hrs at 30°C or 37°C as indicated. 
After centrifugation at 4000g for 10 min, cell pellets were lysed by a single round 
of freeze-thawing in 25ml of ice-cold lysis buffer as previously described followed 
by sonication. Samples were centrifuged at 6000g and 4°C for 30 mins and the 
supernatant loaded onto a 1ml glutathione-sepharose column pre-equlibrated with 
lysis buffer and maintained at 4°C. The column was washed with 10ml buffer C 
(50mM Tris/HCl, pH 7.2) supplemented with 500mM NaCl and then with a 
further 10ml of buffer C supplemented with 150mM NaCl. The protein was eluted 
with 5ml buffer C supplemented with 150mM NaCl and 15mM glutathione. The 
eluate was dialysed against 5 litres of buffer B supplemented with 150mM NaCl, 
1mM dithriothreitol and 20% (v/v) glycerol in a Slide-A-Lyser cassette (Pierce) 
for 12 hrs prior to aliquotting, snap freezing in liquid nitrogen and storage at -
80°C. 
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2.2.11 Protein Lipid Overlay Assay. 
All lipids were purchased in a lyophilised state and as the free acids of 
their dipalmitoyl forms: PtdIns, PtdIns3P, PtdIns4P, PtdIns5P, PtdIns(3,4)P2, 
PtdIns(4,5)P2, PtdIns(3,4,5)P3 and were reconstituted into 1mM stocks in 1 : 2 : 
0.8 by volume of chloroform : methanol : water. Stock lipid solutions were 
immediately stored at -80°C and for a maximum of 2 weeks preventing 
diminished protein binding capacity owing to the acid labile nature of phosphate 
bonds around the inositol ring. These stock solutions were then serially diluted so 
as to ensure that 1μl spotted onto Hybond-C extra membrane resulted in amounts 
ranging from 1-500pmol. After allowing 30 mins at room temperature to dry, the 
membranes were then blocked at room temperature for 1 hr with TBST 
supplemented freshly with 3% (w/v) fatty acid free BSA (Sigma). Following 
blocking, the membranes were incubated overnight at 4°C with 0.2µg/ml of the 
GST-fusion proteins of interest presented in the previously described blocking 
buffer. The membranes were then washed 10 x 5 mins in TBST prior to, and after 
the addition of the primary anti-GST antibody at 0.5μg/ml for 1 hr at room 
temperature. The secondary HRP-conjugated antibody, at 0.1μg/ml, was incubated 
for 1 hr at room temperature before washing the membrane as previously. Finally, 
the membrane was exposed to Immobilon Western ECL (Millipore) 
chemiluminescent substrate and the output recorded by a CCD camera under 
conditions of linear light accumulation as for Western blotting. 
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2.2.12 Surface Plasmon Resonance (SPR). 
Lyophilised, dioctanoyl, biotinylated PtdIns(4,5)P2, PtdIns(3,4)P2 and 
PtdIns(3,4,5)P3 were reconstituted to 10mM in 10mM Hepes pH 7.2 and stored at 
-20°C. As required, lipids were diluted to their working concentration of 100μM 
in SPR buffer (100mM Hepes pH 7.2, 100μM EGTA and 100μM EDTA). 
Streptavidin (SA) chips were loaded into a Biacore 3000 and all four flow cells 
were flushed through with SPR buffer prior to independent loading of each flow 
cell with a distict lipid (including a blank, control lane). Lipids were loaded at a 
flow rate of 5μl/min until response units (RU) of approximately 400-600 were 
achieved above with the control baseline. SPR buffer was then supplemented with 
0.2mg/ml fatty acid free BSA and allowed to flow over each of the four lanes at 
100μl/min for a minimum of 15 mins in an attempt to block non-specific binding 
to the chip surface. When present, 0.2mg/ml BSA was maintained throughout all 
subsequent steps. Test proteins were then diluted to working concentrations in the 
BSA containing SPR buffer. Proteins were presented to the lipid surface in 
increasing concentrations (ranging ~1-1000nM), usually including at least one 
duplicate and analysed with a flow rate of 100μl/min. Protein injection and 
dissociation times were set arbitrarily at first (1-3 min and 1-5 min respectively) 
with subsequent runs advised by initial data. Owing to diminishing responses over 
time, presumably either because of hydrolysis of the lipid or increasing non-
specific binding to the dextran matrix the lipid-bound chips were used for no more 
than 12 hrs and limited to a maximum of 4-5 test proteins (each run with 5-6 
concentrations). Where off-rates were sufficiently low to require regeneration, this 
was achieved (maximum twice per chip) with 30sec pulses of 5mM NaOH 
followed by appropriate washing buffer until a stable baseline signal was attained. 
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2.2.13 Preparation of Mass Spectrometry (MS) Samples. 
Samples requiring MS analysis were first reduced by supplementing with 
10mM DTT and incubated for 5 mins at 70°C. Alkylation was then carried out by 
adding 50mM iodoacetamide and incubating in the dark, at room temperature for 
30 mins. The remaining constituents of sample buffer were then added. The three 
samples were then run out partially, on a pre-cast, bis-tris Novex gels (as 
previously described). After staining with collioidal coomassie, subsequent steps 
were carried out in a laminar flow hood, wherever possible. Each sample lane was 
then cut into 8-10 slices and these then diced to approximately 1mm3 pieces. Gel 
pieces were then transferred to lowbind Eppendorf tubes, washed with; ultrapure 
water, 50mM ammonium bicarbonate and 50% (v/v) acetonitrile / 25mM 
ammonium bicarbonate, using 0.5ml of each reagent and allowing 10 min at RT 
on a shaking platform per step. The gel pieces were then treated with 0.3ml 
acetonitrile for 10-15 min at room temperature before removing the solvent to 
waste and drying in a vacuum concentrator. The gel pieces were then swolled in 
50mM ammonium bicarbonate containing 5µg/ml trypsin gold (Promega), in 
sufficient volume to cover the gel pieces, for 30 mins at 30°C on a shaker. After 
30 mins additional ultrapure water was added, as required, in order to maintain the 
sample volume. The gel pieces were then incubated overnight at 30°C with gentle 
agitation. One volume of acetonitrile was then added to the digests which were 
shaken for 10-15 min before collecting the supernatant in newly labelled low bind 
Eppendorfs and evaporating to dryness in a vacuum concentrator. Meanwhile, the 
gel pieces were re-extracted with 100µl acetonitrile / 2.5% (v/v) formic acid, 
shaking for a minimum of 10 mins at RT. The resulting supernatant (100µl 
acetonitrile / 2.5% (v/v) formic acid) was collected and combined with the now 
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dried, first extract, and re-dried in a vacuum concentrator. Samples were stored at 
-20°C and immediately prior to MS run, reconstituted to 1% formic acid. 
 
2.2.14 Stable Isotope Labelling by Amino Acids in Cell Culture 
(SILAC) Analysis. 
Following re-constitution, samples prepared previously for MS were 
centrifuged at 13,000g to remove any debris and then analysed on an LTQ-
Orbitrap XL mass spectrometer system (Thermo Scientific) coupled to a U3000 
nano-LC system (Dionex). The samples were loaded at 20µl/min onto an LC-
Packings PepMap C18 trap column (0.3 x 5mm) equilibrated in 2% (v/v) 
acetonitrile and 0.1% (v/v) formic acid then washed for a further 3 min following 
sample load. The trap column was then switched in-line with an LC-Packings 
PepMap C18 column (0.075 x 150mm) equilibrated similarly. The peptides were 
separated by a 100 min discontinuous gradient from 2% to 45% (v/v) acetonitrile 
in 0.1% (v/v) formic acid  (2-45% acetonitrile over 65 min) at a flow rate of 
300nl/min. The HPLC was interfaced to the mass spectrometer with an FS360-50-
15-N-20 PicoTip (New Objectives) fitted to a nanospray interface (Proxeon) with 
a voltage of 1.1kV applied to the liquid junction. The Orbitrap XL was set to 
analyse the survey scans at 60,000 resolution with the top five ions in each duty 
cycle selected for MS/MS in the LTQ linear ion trap. The Raw files were 
processed with MaxQuant (Version 1.0.13.13) as described previously [125,126]. 
Peak lists generated by Quant.exe were searched against the International Protein 
Index human database version 3.37 run on an in-house server using the Mascot 
search engine v.2.2 (Matrix Science). Peptide tolerance was set to 7 ppm and 
0.5Da allowing a maximum of three missed cleavages with trypsin. 
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Carboxyamido-methylation of cysteine was set as a fixed modification, oxidation 
and acetylation of methionine as variable modifications and heavy SILAC labels 
were (13C)6 arginine (R) and (13C)6 lysine (K). 
 
Identification was performed using MaxQuant with protein ratios compiled from 
the contribution of individual peptide ratios, with a false discovery rate of 1%. Site 
quantification was by least modified peptides allowing variable modifications, 
requiring at least one unique peptide of minimum 6 amino acids in length for 
positive identification. However, analysis did allow contribution from razor 
peptides, with retention of low scoring version of peptides and filter labelled 
amino acids options deselected. 
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Chapter 3. 
 
 
 
 
 
 Development of a Screen for Novel PtdIns(3,4)P2 Binding Proteins. 
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3.1 Introduction. 
  In the previous introductory Chapter the concept of lipids and particularly 
phosphatidylinositol as second messengers was introduced. This concept is 
developed further in the current Chapter which focuses on the development of a 
protocol to isolate and enrich novel interacting partners of the little studied second 
messenger, PtdIns(3,4)P2. 
 
3.1.1 PtdIns(3,4)P2 as a Potential Second Messenger. 
  Following the identification of 3-phosphoinositides as minor components of 
cellular membranes, a period of intense interest focussed on PtdIns(3,4,5)P3 due to 
its emerging role as a second messenger within diverse cellular processes [39,46-
57]. Moreover, the recognition of PTEN as a tumour suppressor further 
highlighted the significance of aberrant PtdIns(3,4,5)P3 regulation in disease states 
such as diabetes and cancer [127-129]. Subsequently, it was shown that class IA 
PI 3-kinase stimulation commonly causes an acute temporal elevation of 
PtdIns(3,4,5)P3 concentrations synthesised from PtdIns(4,5)P2 followed by a lag 
and more sustained (up to 60 min) [130-132] accumulation of PtdIns(3,4)P2, 
although surprisingly few studies have measured the lipids directly. This model of 
synthesis coupled to the significance of PTEN largely consigned PtdIns(3,4)P2 and 
the 5-phosphatases, to a role as a degradation product and a redundant mechanism 
for the removal of excess PtdIns(3,4,5)P3 respectively. Alternative mechanisms 
were presented for the regulated and independent synthesis of PtdIns(3,4)P2 via a 
PtdIns3P 4-kinase, or by PI 3-kinase activity towards PtdIns4P [130-132] (later 
suggested to be class II PI 3-kinases as a consequence of in vitro assays [51]), but 
these views were not widely accepted.  
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  Interest in the role of PtdIns(3,4)P2 as a second messenger was, however, 
renewed with the proposal that PKB and PDK1 were able to bind PtdIns(3,4)P2 
[86,133,134]. Mounting evidence which now implicates PtdIns(3,4)P2 as a 
potentially important signal includes; PtdIns(3,4)P2 requirement for complete PKB 
activation [135]; the identification of a small group of established PtdIns(3,4)P2 
binding molecules (dual adaptor of phosphotyrosine and 3-phosphoinositides 
[DAPP1], TAPP1 and lamellipodin) [99,124,136-140]; the suppression of growth 
in megakaryocytes and fibroblasts by attenuation of PtdIns(3,4)P2 accumulation; 
the PtdIns(3,4)P2–dependent regulation of cell growth downstream of the GATA-1 
transcription factor [141] and a potential role for the 4-phosphatases as tumour 
suppressors [142]. Furthermore, a mutation in type I 4-phosphatase has been 
reported in mice, leading to the weeble phenotype, which is manifest in neuronal 
loss [79,143]. Although this phenotype is still viable it underlines the significance 
of PtdIns(3,4)P2 synthesis and is not incompatible with the notion that it may act 
as a second messenger within its own right.  Recent data supporting this 
conclusion shows the type I 4-phosphatase (INPP4A) acting as a suppressor of 
glutamate excitotoxicity in the CNS of mice and that targeted disruption of the 
INPP4A gene results in neurodegeneration in the striatum [144]. Despite these 
data, little work has been done to reveal the downstream effectors of 
PtdIns(3,4)P2. Given the large number of known PtdIns(3,4,5)P3 binding partners 
including PKB/Akt, PDK1, Bruton's tyrosine kinase (Btk), dual adapter for 
phosphotyrosine and 3-phosphoinositides (DAPP-1), centaurin-α, Gab1, growth 
factor receptor bound protein 2-associated protein 1 (GAP1), switch-associated 
protein 70 (SWAP-70) and general receptor of phosphoinositides 1/cytohesin-3 
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(Grp-1) [89,95,105,138,145-153] it seems unlikely that the above list of 
PtdIns(3,4)P2 binder partners represents the complete repertoire. Thus, the 
predominant aim of this study was to expand the current list of known 
PtdIns(3,4)P2 interacting proteins. 
 
3.1.2 The Determination of Conditions to Drive the Selective 
Accumulation of PtdIns(3,4)P2 in Cell Membranes. 
  In order to investigate the possibility of novel PtdIns(3,4)P2 binding proteins 
this study took advantage of the pharmacological inhibition of PTPs (protein 
tyrosine phosphatases). The PTP family are phosphatases whose activities are 
characteristically dependent on a reactive cysteine residue. These enzymes are 
generally constitutively active but capable of inhibition by oxidation of the 
cysteine residue, notably via endogenously generated ROS (reactive oxygen 
species) [154,155]. ROS are commonly produced by the membrane bound enzyme 
complex NADPH oxidase (nicotinamide adenine dinucleotide phosphate-oxidase), 
crucial in the immune system’s respiratory burst. They are however, also produced 
following growth factor mediated stimulation of RTK allowing the initiation of 
intracellular redox sensitive signalling cascades [155,156]. 
 
  Vanadate analogues, similar to ROS, can also act as potent PTP inhibitors by 
their action on the PTP family of enzymes [157]. Two related phosphatases 
include the lipid metabolising enzymes PTEN and the 4-phosphatases described in 
Chapter 1, which possess the characteristic reactive cysteine residues [69,158-
160]. Thus, vanadate analogues can be used to manipulate cellular 3-
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phosphoinositide levels, via their ability to inhibit the action of PTEN and 4-
phosphatases on PtdIns(3,4,5)P3 and PtdIns(3,4)P2 respectively [41,132]. 
 
  Existing data from the laboratory, shown in Table 3.1, demonstrate the 
effects of sodium vanadate and the cell permeable vanadate analogue, potassium 
bisperoxo[1,10-phenanthroline]oxovanadate [V] (bpV[phen]) on cellular PI 
concentrations within PTEN null 1321N1 astrocytoma cells [41]. Despite subtle 
differences in the output of several PI species both reagents cause a dramatic 
change in the levels of PtdIns(3,4)P2 with the coincident loss of PtdIns(4,5)P2 
suggesting that the 2500-5000 fold increase in the former is primarily at the 
expense of the latter. Subsequent work detailed the mechanism by which the role 
of bpV(phen) as a generic PTP inhibitor has a threefold effect on the P I3-kinase 
signalling pathway [41]. Firstly class IA PI 3-kinases become constitutively active 
as a consequence of inhibition of the PTPs which regulate the activity of RTKs. 
Indeed, following bpV(phen) treatment, the PI 3-kinase activity associated with 
anti-phosphotyrosine immunoprecipitates can be seen to increase substantially.  
Secondly, the activity of the 4-phosphatases which metabolise PtdIns(3,4)P2 is 
inhibited and thirdly, the specific activity of SHIP2 is increased. 
 
  The extent to which the specific activity of SHIP2 can be increased is 
underlined by the constitutive activation of class IA PI 3-kinases which occurs 
with little or no observed increase in the concentration of PtdIns(3,4,5)P3. This 
presents a convincing argument that the capacity for activation of the 5-
phosphatases, specifically SHIP2, is equal to or greater than that of the class IA PI 
3-kinases. Indeed, bpV(phen) is able to ablate the platelet derived growth factor 
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(PDGF) dependent accumulation of PtdIns(3,4,5)P3 when given concomitantly 
[41]. 
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Table 3.1 The effects of vanadate analogues on cellular PI 
concentrations. 
 
 
 
Lipid  Stimulus 
Control Sodium Vanadate (1mM) bpV(phen) (0.1mM) 
 
(% Total PI) (Fold control) (Fold control) 
PtdIns 80.615 + 1.556 0.89 + 0.01 0.95 + 0.03 
PtdIns3P 0.425 + 0.039 1.73 + 0.01 3.95 + 1.86 
PtdIns4/5P* 7.511 + 0.586 2.30 + 0.26 0.77 + 0.06 
PtdIns(3,5)P2 0.022 + 0.003 1.96 + 0.22 8.63 + 4.77 
PtdIns(3,4)P2 0.004 + 0.001 13.68 + 4.59 5164.00 + 2243 
PtdIns(4,5)P2 11.407 + 1.026 1.09 + 0.02 0.27 + 0.11 
PtdInsP3 0.011 + 0.001 1.15 + 0.015 2.17 + 1.25 
 
 
 
1321N1 astrocytoma cells were pre-labelled with [3H] inositol and incubated for 
30mins with and without 1mM sodium vanadate or 100μM bpV(phen) prior to 
0.5M TCA extraction. Each PI species as a proportion of total [3H]PI is 
represented by control, with values equating to means ± S.E.M. of ten 
experiments. The fold change following treatment with either sodium vanadate 
and bpV(phen) treatment is shown and is representatitive of at least 3 
experiments. Data reproduced from [41] and experiments carried out by I. Batty. 
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3.1.3 The Phosphorylation of SHIP2 Increases its 5-Phosphatase 
Activity. 
  The mechanism in which SHIP2, a prominent 5-phosphatase, is capable of 
mediating such acute changes in PtdIns(3,4,5)P3 concentrations following 
pharmacological inhibition of PTPs was recently investigated. SHIP2 had 
previously been reported to possess basal levels of activity, with regulation 
principally determined by its localisation as either cytosolic or at the cell 
periphery, a mode of action similar to PTEN. Several studies underlined that 
SHIP2 activity was unaffected by phosphorylation following treatment with a 
variety of stimuli such as PDGF, epidermal growth factor (EGF), nerve growth 
factor (NGF) and insulin-like growth factor (IGF) [161-165]. This conclusion was 
widely disseminated in the literature as a consequence of subsequent review 
articles [166,167]. 
 
  However, in order to explain the observed disparity between the 
PtdIns(3,4,5)P3 concentrations following treatment with PDGF alone or with 
PDGF together with bpV(phen), the activity of the 5-phosphatases must possess a 
capacity for increased activation, an effect unlikely simply due to membrane 
recruitment alone. In contrast to the prevailing view in the literature, Batty et al. 
demonstrated that the specific activity of SHIP2 can be increased 8-10 fold with 
EGF or bpV(phen) treatment, an effect which is mediated by tyrosine 
phosphorylation [41,168]. Thus, SHIP2 immunoprecipitates from bpV(phen) or 
EGF treated samples showed an increase in activity of SHIP2 towards 
Ins(1,3,4,5)P4, the water-soluble inositol headgroup of PtdIns(3,4,5)P3, in 
conjunction with tyrosine phosphorylation. Moreover, the increased activity and 
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phosphorylation of these immunoprecipitates could be eliminated by incubation 
with the tyrosine phosphatase SHP1. These estimates of 8-10 fold increases in 
specific activity were later confirmed by intracellular assays measuring the rate of 
PtdIns(3,4,5)P3 hydrolysis in PTEN null 1321N1 cells following treatment with 
and without sodium vanadate [41].  
   
  This capacity for the activity of SHIP2 to be regulated, and under certain 
conditions be coupled to the activity of class IA PI 3-kinases and the inhibition of 
the 4-phosphatases, presents a mechanism to effectively switch the signalling 
output of class IA PI 3-kinases from PtdIns(3,4,5)P3 to PtdIns(3,4)P2. The 
existence of such a route of synthesis provides strong evidence that PtdIns(3,4)P2 
is not merely a breakdown product of PtdIns(3,4,5)P3 but that their cellular 
concentrations can be independently controlled. 
 
3.1.4 TAPP-1/2: The definitive PtdIns(3,4)P2 Binding Proteins. 
  Of all the evidence introduced in 3.1.1 and the capacity for an increase in the 
specific activity of SHIP2, discussed previously, arguably the most convincing 
indication that PtdIns(3,4)P2 can elicit a response independently of PtdIns(3,4,5)P3 
was provided by the identification of TAPP-1 and TAPP-2 [102,169]. TAPP-1/2 
were identified by homology using a bioinformatics approach based on the 
observation that six conserved residues within the N-terminal region of PH 
domains, called the PPBM (putative PtdIns(3,4,5)P3 binding motif) appear to 
confer high affinity PtdIns(3,4,5)P3 binding [102]. However, the subsequent 
discovery of the novel selectivity and high affinity of TAPP-1/2 for PtdIns(3,4)P2 
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questions the reliance on such bioinformatics tools for assigning lipid selectivity, 
an issue addressed in Chapter 5. 
 
  Although the function of TAPP1/2 is still unclear, it is likely a scaffold 
protein and has been postulated to be responsible for shuttling the multi-PDZ 
domain protein MUPP1 and the protein tyrosine phosphatase PTPL1 to the plasma 
membrane following PtdIns(3,4,)P2 synthesis [124,170]. The fact that TAPP-1 is 
highly conserved between humans and mice [169] suggests it has a critical, but as 
yet not fully understood role, a conclusion further supported by the presence of an 
additional, conserved, N-terminal PH domain with, to date, no reported lipid 
binding affinity. Regardless, the reported selectivity of the C-terminal TAPP-1 PH 
domain has led to its widespread use as a marker for PtdIns(3,4)P2 in 
immunohistological and in vitro assays [171,172], and in this study provides a 
model protein by which to track and optimise the isolation of similarly recruited 
binding proteins. 
 
3.1.5 Other Proposed PtdIns(3,4)P2 Binding Proteins. 
  In addition to TAPP-1/2 several proteins have been reported to present 
affinity for PtdIns(3,4)P2, although none seem to show similar levels of selectivity 
or affinity to those demonstrated by TAPP-1/2. The potential candidates identified 
include, but are not limited to; PKB, PDK1, DAPP-1, SWAP-70, lamellipodin, 
peroxiredoxin 1 (PRDX-1), vinculin and Igrm-1 
[88,89,98,104,131,135,138,145,173-176]. With the exception of PKB and PDK1, 
which have been studied more thoroughly, the majority of these proposed binding 
proteins have had their affinity and/or selectivity for 3-PIs assumed via affinity 
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precipitation from cell extracts or estimated based on their observed binding in 
protein lipid overlay assays. In cases of identification from affinity precipitations, 
samples are often complex protein mixtures, containing both specific and non-
specific proteins and significance may be erroneously attached to proteins purely 
on the basis of possessing an established LBD. Moreover, protein lipid overlay 
assays, more commonly known as fat blots, have significant caveats but their 
advantages and disadvantages in contributing understanding to lipid selectivity 
will be discussed in Chapter 5. 
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3.2 Results. 
3.2.1 The Physiological Recruitment of TAPP-1. 
  It is widely accepted that signalling downstream of class IA PI 3-kinases is 
mediated by PtdIns(3,4,5)P3 and PtdIns(3,4)P2 [177,178]. Whilst much research 
has been focussed on PtdIns(3,4,5)P3 and its effectors, little effort has been 
directed towards PtdIns(3,4)P2. By optimising a screen for the selective 
recruitment and subsequent isolation of the model PtdIns(3,4)P2 binding protein, 
TAPP-1, it was intended that similarly recruited, potentially novel PtdIns(3,4)P2 
proteins could be identified.  
 
  In order to achieve this recruitment of novel binding proteins, the previously 
observed phenomenon of dramatically elevated PtdIns(3,4)P2 concentrations in 
response to treatment with the cell permeable vanadate analogue bpV(phen) 
(Table 3.1) would be exploited [41]. However, having established a mechanism 
for the recruitment of potential binding proteins, the techniques for subsequent 
isolation were considered. 
 
  To make this isolation of TAPP-1 and novel PtdIns(3,4)P2 proteins applicable 
for maximal recovery and to allow subsequent identification of these proteins, any 
approach would require rapid and selective fractionation of the cell. To achieve 
rapid cell lysis and to allow free cytosolic proteins to be removed/eliminated from 
subsequent processing, this study utilises digitonin permeabilisation which has 
several advantages over other possible approaches.  Fixation approaches, whilst 
allowing instantaneous cross linking of cell proteins and maximising the yield of 
even low affinity binding proteins at the membrane, are incompatible with 
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identification of novel candidates, particularly via mass spectrometry. Crude, 
whole-cell fractionation with detergents such as Triton X-100 (TX-100) would 
liberate intracellular proteases destabilising potential interactions as well as 
complicating the final sample with proteins from multiple cell compartments. This 
is a feature shared, although to a more limited extent, with homogenising or 
osmotically lysing the cells, approaches which in our hands were also commonly 
incomplete (data not shown and I. Batty, unpublished data). 
 
  Digitonin however, is a detergent which selectively targets cholesterol, which 
is present at high concentrations in the plasma membrane but essentially absent in 
other membranes [179-182]. The pores generated by digitonin, achieved in a 
method similar to that of the innate immune response of compliment to non-self 
cells and bacterial pore forming complex streptolysin-O, would allow rapid, in situ 
permeabilisation of cells without disrupting cell compartmentalisation and 
crucially without liberating intracellular stores of proteases. 
 
  The use of digitonin to achieve this goal was tested experimentally and 
within 2 mins, following permeabilisation with digitonin, cytosolic proteins such 
as SHIP2, TAPP-1, PKB, and GAPDH amongst others (data not shown), could be 
detected by immunoblotting the soluble eluate of unstimulated 1321N1 cells. The 
presence of SHIP2 in the cytosolic extract confirmed that pore size was not 
prohibitive to elution of proteins ≤150kDa in size. Indeed, later experiments to 
more comprehensively characterise the protein constituents of this eluate, would 
result in identification of proteins upwards of 300kDa.   
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  Figure 3.1 shows the results of an experiment using 1321N1 astrocytoma 
cells, treated as indicated before transferring the culture dishes to ice and 
permeabilising with digitonin, retaining the eluate. Finally, residual membrane 
fractions were recovered by TX-100. This allowed crude fractionation into 
cytosolic and membrane (membrane, membrane bound and residual proteins) 
fractions. The majority (~90%) of cellular TAPP-1 was isolated in the cytosolic 
fraction of control cell populations. The residual, apparently membrane bound 
fraction of TAPP-1 perhaps represented a proportion trapped in either un-
permeabilised cells, within internal cellular compartments or bound to the 
cytoskeleton, as this value was not diminished by prior treatment with the generic 
PI 3-kinase inhibitor wortmannin (data not shown). This localisation of TAPP-1 
was reversed with bpV(phen) treatment, and to a more limited degree with PDGF 
treatment, with the majority of TAPP-1 bound to cell membranes, an effect which 
can be, for TAPP-1 at least, maintained for ≥60 mins. The small proportion of 
TAPP-1 recruited to cell membranes upon PDGF treatment corroborates previous 
data showing limited accumulation of PtdIns(3,4)P2 following PDGF treatment in 
1321N1 cells [41]. Bearing in mind the phenomena of downstream signal 
amplification; this noticeable recruitment of TAPP-1 to cell membranes achieved 
by PDGF treatment may be sufficient to maximally activate a downstream effector 
whose activity is directly or indirectly regulated by TAPP-1. It may therefore be 
possible that the supramaximal concentrations of PtdIns(3,4)P2 achieved by 
bpV(phen) treatment are not necessarily required to elicit a physiological 
response.  
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Figure 3.1  TAPP-1 recruitment to cell membranes. 
 
 
 
 1321N1 cells were pre-treated with vehicle alone (0.1% [v/v] DMSO) or 
vehicle plus 1μM wortmannin (indicated by W) for 30 mins prior to 
incubation as control (CON) or stimulated; PDGF (5min, 50ng/ml) or 
bpV(phen) (30min, 100μM). Cells were then permeabilised by digitonin, 
yielding a soluble, cytosolic fraction (open bars) and residual membrane 
fractions (closed bars) and these were immunoblotted for TAPP-1. The data 
are presented as the proportion of total TAPP-1 proteins associated with each 
fraction (representative immunoblot shown in lower panels). Results are 
mean ± the range of duplicates, and represent similar data obtained on three 
further occasions. 
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  This recruitment of TAPP-1 to cell membranes, seen in Figure 3.1 for 
bpV(phen) and PDGF treatment, was shown to be PI 3-kinase dependent by its 
complete inhibition with wortmannin. Although, unusually high concentrations of 
wortmannin were used in these instances (1µM), this is a necessity in order to 
overcome the ~2500 fold increase in cellular PtdIns(3,4)P2 concentrations (Table 
3.1) achieved by bpV(phen) treatment (assuming an IC50 for class IA PI 3-kinases 
of 10nM, 1µM should achieve ~99% inhibition).  Most importantly, however, 
these results highlight the potential of this approach to locate TAPP-1 and other 
similarly recruited 3-phosphoinositide (3-PI) binding proteins to cellular 
membranes. 
 
3.2.2 The Isomer Selective Elution of TAPP-1. 
  The above experiments effectively utilised cellular membranes enriched with 
PtdIns(3,4)P2 after stimulation with bpV(phen) as an affinity matrix to recruit 
TAPP-1 and other 3-PI responsive proteins. These cells were then permeabilised 
with digitonin which released, conservatively, 90% of unbound cytosolic proteins 
(Figure 3.1). Subsequent, consecutive washes of these permeabilised cells further 
diminished the unbound cytosolic contaminants with little effect on the TAPP-1 
recruited to membranes. The possibility of selectively recovering these recruited 
proteins with a competing concentration of the water soluble head-group of 
PtdIns(3,4)P2, Ins(1,3,4)P3, was investigated. If successful this would provide a 
second tier of affinity purification and do so without damaging currently 
uncompromised cellular membranes. 
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  Figure 3.2A demonstrates that following stimulated recruitment TAPP-1 is 
retained on PtdIns(3,4)P2 enriched cellular membranes for prolonged periods 
despite repeated washing. Thus, after 60 mins and several washes, TAPP-1 and 
presumably similar PtdIns(3,4)P2 binding proteins, remained tightly membrane 
associated. In stark contrast to this, TAPP-1 could be readily eluted from 
PtdIns(3,4)P2 enriched cellular membranes by supplementing the washing buffer 
with Ins(1,3,4)P3. The concentrations of the eluting Ins(1,3,4)P3 were selected 
based on the following estimates of lipid levels within 1321N1 astrocytoma cells. 
Under resting conditions PtdIns concentrations in these cells have been measured 
at ~10nmol/mg of total cell protein and PtdIns(4,5)P2 represents ~5% of this value. 
Consequently, under conditions of bpV(phen) treatment where approximately half 
of the cellular PtdIns(4,5)P2 is fluxed via PtdIns(3,4,5)P3 (no change) in ~30 mins 
and accumulates as PtdIns(3,4)P2, the latter lipid is present at concentrations of 
~250pmol/mg [183]. 
 
  Figure 3.2A and the associated quantitation in Figure 3.2B illustrates the 
optimisation of this Ins(1,3,4)P3-dependent elution by the incremental sampling of 
60 min washes supplemented with varying, competing concentrations of 
Ins(1,3,4)P3. Accordingly, TAPP-1 was recovered from the PtdIns(3,4)P2 enriched 
membranes in a time- and Ins(1,3,4)P3 concentration-dependent manner, 
corresponding with diminished recovery of TAPP-1 in the associated membrane 
fractions. The maximal elution of TAPP-1 shown in Figure 3.2, of approximately 
50-60% is recovered with 100µM Ins(1,3,4)P3, representing a molar excess over 
cellular PtdIns(3,4)P2 in the region of 100-1000 fold. Similar results, although not 
shown, were obtained by eluting with short chain (dibutyryl) PtdIns(3,4)P2. 
 80
 
 
 
 
 
 
 
 
Figure 3.2 The concentration dependent elution of TAPP-1 with 
Ins(1,3,4)P3.  
(A) Following treatment with 100μM bpV(phen) for 30mins, 1321N1 cells were 
permeabilised with digitonin to remove unbound cytosolic proteins. The 
remaining residual membrane fraction was incubated for 60mins at 4°C in the 
absence (0μM) or presence of increasing concentrations of Ins(1,3,4)P3 as 
indicated. The eluate was sampled at intervals, as indicated, and the resulting 
samples immunoblotted for TAPP-1 (upper band). (B) The quantification of 
samples blotted in A as a percentage of total TAPP-1 recruited to membranes 
following bpV(phen) treatment. Closed circles (●) indicate 0μM; open circles (○), 
1μM; closed triangles (▲), 10μM and open triangles (Δ) 100μM Ins(1,3,4)P3. 
Similar data was obtained on two further occasions. 
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Figure 3.2A 
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Figure 3.2B 
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  Figure 3.3 addresses the isomer selectivity of the elution of TAPP-1 from 
PtdIns(3,4)P2 enriched membranes. Digitonin permeabilised 1321N1 cells, pre-
treated with bpV(phen), were washed with buffer supplemented with identical 
concentrations of Ins(1,3,4)P3 or Ins(1,4,5)P3 (the inositol head-group of 
PtdIns(4,5)P2), before analysing the distribution of TAPP-1 as above. As shown 
previously, washing of PtdIns(3,4)P2 enriched membranes in buffer alone resulted 
in little elution of TAPP-1 over 60 mins. However, supplementing the wash buffer 
with 100µM Ins(1,3,4)P3 resulted in recovery of 50-60% of total TAPP-1. In 
contrast, supplementing the wash buffer with 100µM Ins(1,4,5)P3 resulted in little 
or no elution of TAPP-1 from cellular membranes - comparable to that seen for 
buffer alone. These data demonstrate that TAPP-1 can be selectively eluted with 
Ins(1,3,4)P3 and suggests that its association with membranes is directed by 
features compatible with the known selectivity of its C-terminal PH domain. 
 
  Having established that TAPP-1 can be recruited to PtdIns(3,4)P2 enriched 
membranes and that it can be selectively eluted, the utility of a two step affinity 
purification to reveal novel candidate proteins was investigated. Figure 3.4 
illustrates the protein content associated with samples obtained over the course of 
such a two step affinity purification. Following bpV(phen) stimulation, 1321N1 
cells were permeabilised by consecutive digitonin washes to remove unbound 
cytosolic proteins. Permeabilised cells were then eluted with wash buffer 
supplemented with or without Ins(1,3,4)P3 and finally, residual membrane bound 
fractions were recovered with TX-100 buffer. A proportion of each of the 
digitonin washes, the Ins(1,3,4)P3 eluate and the residual membrane fractions were 
retained for analysis of protein content, as revealed by the silver staining of SDS-
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PAGE gels. Sequential washes with digitonin (D1-D4), as expected, showed a 
coordinate loss in the protein content with the final wash essentially devoid of 
protein despite silver stain sensitivity to sub-nano gram amounts [184,185]. 
Analysis of the protein content from the subsequent elution buffer [+/-100µM 
Ins(1,3,4)P3] revealed a number of candidate bands which were eluted in a 
Ins(1,3,4)P3 dependent manner from membranes enriched in PtdIns(3,4)P2. 
Examples of these enriched candidate bands are highlighted within Figure 3.4 as 
bands A-G. 
 
  Following isolation of candidate bands which were selectively eluted in a 
fashion similar to TAPP-1, such as those labelled A-G in Figure 3.4, attempts to 
determine their identities were made by mass spectrometry (MS). Identification 
was, however, confounded by two factors. Firstly, the dilute (low protein) nature 
of the Ins(1,3,4)P3 eluate, regardless of the level of enrichment of candidate bands, 
made processing of sufficient quantities for MS identities problematic. Secondly, 
the inconsistent nature of observed bands coupled to the variable pattern of 
background proteins folied attempts to pool multiple gel bands from repeated 
experiments. However, the application of this two step affinity approach clearly 
provides a means by which numerous candidate PtdIns(3,4)P2 interacting proteins 
can be enriched and isolated within a fraction of considerably less complexity than 
cytosolic extracts. 
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Figure 3.3  The isomer selective InsP3 elution of TAPP-1 from 
membranes.  
 (A) Following TAPP-1 recruitment to membranes with bpV(phen) (100μM, 
30mins) treatment and subsequent permeabilisation/washing by digitonin, the 
residual membrane bound fraction was eluted for 60min at 4°C in the absence 
(NONE) or presence of 100μM InsP3 (either Ins(1,3,4)P3 or Ins(1,4,5)P3). The 
resulting eluate (C) and the recovered membrane fraction (M) was then 
immunoblotted for TAPP-1 protein. (B) Quantitation of A. The wash step, 
following cytosolic removal, supplemented with or without IP3 (Ins(1,3,4)P3 or 
Ins(1,4,5)P3 as indicated) is represented by open bars and the residual 
membrane bound fraction by closed bars. TAPP-1 values are a percentage of 
total TAPP-1 recruited to membranes following bpV(phen) treatment. The 
results are representative of data obtained on three further instances with 
respect to Ins(1,3,4)P3 and one further instance with respect to Ins(1,4,5)P3. 
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Figure 3.3A 
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Figure 3.3B 
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Figure 3.4  The Ins(1,3,4)P3-dependent elution of multiple 
membrane recruited proteins. 
 
 
 
 1321N1 astrocytoma cells were stimulated with bpV(phen) and 
permeabilised with digitonin to allow removal of unbound cytosolic proteins 
(D1). Consecutive 2min washes in digitonin buffer were also sampled (D2-D4) 
recording the efficiency of cytosolic elution. Prior to recovery of the 
membrane fraction (M) by LDS, residual membrane and membrane bound 
proteins were exposed to a 60min wash with and without 100μM Ins(1,3,4)P3 
(W+ and W- respectively) with right hand panels representing an 
enlargement of the silver stain gel. Bands labelled A-G are notably enriched 
or present as a consequence of Ins(1,3,4)P3 elution. Data representative of at 
least 8 further experiments. 
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3.2.3 The Affinity Purification of TAPP-1. 
  The existing two step affinity purification recruits, to a physiological 
membrane in a PI 3-kinase dependent manner, proteins capable of binding 
PtdIns(3,4)P2. Additionally, the protocol uses an Ins(1,3,4)P3 elution step, 
providing the second tier of affinity purification whilst maintaining the integrity of 
internal organelles. It is evident from Figures 3.1 - 3.4 that this approach is 
capable of isolating and enriching TAPP-1 and equally, numerous similarly 
responsive candidate protein bands. Despite this enrichment of candidate proteins, 
their identification by MS was thwarted by a combination of low protein 
concentration and carry over of contaminating background proteins (Figure 3.4). 
 
  To overcome these issues, the efficacy and utility of a third affinity 
purification step which made use of an immobilised short chain lipid was tested. 
Previous studies have often used a similar approach successfully, albeit in 
isolation [89,98,174,186,187]. The advantages of incorporating this immobilised 
lipid approach would include a further reduction of non-specific proteins via a 
third purification step and additionally, allow dilute protein samples to be 
concentrated into a small volume by affinity association to an immobilised lipid 
matrix.  
 
  The components selected for the lipid matrix were short chain PtdIns(3,4)P2 
with an attached biotin moiety and Neutravidin (an agarose matrix coupled to a 
streptavidin derivative). The very high affinity interaction between biotin and 
avidin (Kd ~10-15 M) would provide the flexibility for increased incubation times 
and where necessary extensive washing without loss of the lipid from the matrix. 
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Neutravidin resin was selected as the matrix in favour of other avidin derivatives 
due to the reported characteristic of low non-specific binding [188], a crucial 
factor when considering the mass spectrometry issues encountered previously. The 
capacity of the Neutravidin for biotinylated-PtdIns(3,4)P2 was assumed to be 
~200nmol/ml resin, on the basis of the manufacturer’s provided values of between 
≥120nmol biotinylated BSA/ml resin and ≥205nmol biotinylated p-NPE/ml resin 
(molecular weights of 66.43KDa and 365.4 respectively). In order to determine 
the optimum conditions for affinity capture of TAPP-1, tests were carried out on 
TX-100 extracts of digitonin permeabilised cells prior to integration with the 
existing two tier affinity purification.   
 
  Figure 3.5 details the optimisation of TAPP-1 depletion using a Neutravidin 
biotinylated-PtdIns(3,4)P2 complex. Following treatment with bpV(phen), 1321N1 
cells were permeabilised and washed in digitonin as described above and the 
membrane bound fraction recovered by TX-100 extraction. Samples were then 
incubated with Neutravidin coupled to varying amounts of biotinylated-
PtdIns(3,4)P2. The TAPP-1 recovery, as a consequence of SDS elution of the 
lipid-matrix and in some instances its depletion from the supernatant, was 
subsequently measured by immunoblotting. Figure 3.5A shows the recovery of 
TAPP-1 into SDS eluates from the lipid-matrix and its correlated loss from the 
supernatant of samples following incubation with identical volumes of 
Neutravidin (50μl) and increasing amounts of biotinylated-PtdIns(3,4)P2 (where 
10nmol, based on the above estimation on the capacity of the Neutravidin, is a 
saturating amount). Maximal TAPP-1 depletion from the supernatant is shown to 
be achieved by ~5nmol biotinylated-PtdIns(3,4)P2 over a pre-determined 60 mins 
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time period. Thus, the binding capacity of the lipid-matrix is not a factor limiting 
the efficiency of TAPP-1 recovery. 
 
  The small fraction of TAPP-1 recovered by non-lipid coupled Neutravidin 
beads (~5%) was unaffected by pre-blocking the avidin binding sites with biotin, 
or the matrix with BSA or lysozyme, prior to lysate depletion and increased 
proportionally with bead volume (data not shown). This suggests that this minority 
is trapped within the matrix and is not binding specifically to either the avidin 
component or the agarose cage. Also tested was the use of alternative buffer 
conditions and detergents such as cholate, CHAPS and NP-40 with each showing 
similar TAPP-1 depletion/recovery (data not shown). 
 
  Figure 3.5B illustrates the influence of both Neutravidin-lipid mass and 
concentration on the efficiency of TAPP-1 precipitation. TX-100 extracts from 
1321N1 cells, of equal protein content, were generated as described above and 
incubated with varying volumes of Neutravidin, each saturated with lipid (10-
25nmol). A range of lipid concentrations (2μM-50μM) was achieved by diluting 
samples prior to incubation, with additional TX-100 lysis buffer. TAPP-1 recovery 
was then measured as before, by immunoblotting the SDS eluates of the lipid-
Neuravidin complexes. The data confirmed the observations from Figure 3.5A that 
maximum TAPP-1 recovery was already attained by 10nmol lipid/unit of lysate. 
However, Figure 3.5B and the associated quantitation in Figure 3.5C highlights 
that TAPP-1 recovery is dependent on the relative concentration at which the lipid 
is presented, with a maximally effective concentration achieved between ~25-
50μM biotinylated-PtdIns(3,4)P2. This concentration dependent but relatively 
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mass independent characteristic of Neutravidin biotinylated-PtdIns(3,4,)P2 lysate 
recovery of TAPP-1 makes the process particularly attractive for scale up.  
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Figure 3.5  Optimising the affinity purification of TAPP-1 using 
immobilised lipid. 
 Panels A and B show the influence of lipid mass and concentration  respectively 
on the recovery of TAPP-1 protein from TX-100 membrane extracts of 1321N1 
cells pre-treated with bpV(phen) for 30 mins and permeabilised with digitonin. 
(A) Neutravidin-coupled to increasing amounts of biotinylated-PtdIns(3,4)P2 (as 
indicated) was used to deplete cell extracts for 60mins at 4°C (lower panel) with 
the recovery of TAPP-1 (upper blot), following LDS elution of the Neutravidin 
biotinylated-PtdIns(3,4)P2 complex, measured by immunoblots. Samples 
labelled blank are uncoupled to biotinylated-PtdIns(3,4)P2. (B) Altered amounts 
of lipid and volumes of lysates were used to generate various concentrations, as 
indicated, showing the concentration dependent recovery of TAPP-1 to the 
Neutravidin biotinylated-PtdIns(3,4)P2 complex. Control (upper panel) 
represents uncoupled Neutravidin and TAPP-1 control (lower panel) is positive 
control for TAPP-1 from lysate. A and B are representative of similar data 
obtained from two further experiments. (C) Quantification of the upper panel 
from B illustrating the biotinylated PtdIns(3,4)P2 concentration dependent 
depletion (μM) of cell extracts as a percentage of total TAPP-1 recovered 
following Triton X-100 extraction of bpV(phen) treated, digitonin permeabilised 
cells. 
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Figure 3.5 
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  The utility of this immobilised lipid precipitation step is further demonstrated 
by Figure 3.6. TX-100 extracts of 1321N1 cells, permeabilised with digitonin and 
following treatment as indicated were subject to a maximally effective amount and 
concentration of biotinylated-PtdIns(3,4)P2 coupled to Neutravidin. The presence 
of TAPP-1 in the final SDS elution from the lipid matrix, as well as fractions 
sampled from the extracts both prior to and after depletion, were quantified by 
immunoblotting. Following PI 3-kinase-dependent membrane recruitment of 
TAPP-1, ~75% could be depleted from the resulting TX-100 extract by the lipid 
matrix, a value which could be further enhanced with subsequent, additional 
depletions (data not shown). Approximately 25% of the total cellular TAPP-1 
could then be efficiently recovered by SDS elution of the matrix despite extensive 
washing to remove background proteins. These data highlight the capacity of this 
approach to recover TAPP-1 and, potentially to recover similarly responsive 
proteins into an enriched fraction of limited complexity and, in contrast to 
Ins(1,3,4)P3 eluates, into a small volume. 
 
  Similarly generated affinity precipitated samples were further analysed by 
silver stained SDS-PAGE for candidate bands enriched in a PI 3-kinase dependent 
manner. Figure 3.7 shows an example SDS elution from an immobilised lipid 
depletion of 1321N1 TX-100 extracts, treated as indicated, and analysed by SDS-
PAGE. Multiple, wortmannin sensitive bands are immediately apparent following 
washing and SDS elution of the lipid matrix. Two of the most heavily enriched of 
these bands, present in duplicate bpV(phen) stimulated samples at 70kDa and 
105kDa, are indicated within Figure 3.7. Although this immobilised lipid 
precipitation is lacking in the initially intended Ins(1,3,4)P3 selective elution, and 
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undoubtedly includes contaminating membrane and organelle proteins, the 
presence of multiple PI 3-kinase-dependently enriched bands suggest that this 
protocol is sufficient to isolate potentially novel PtdIns(3,4)P2 or 3-PI interacting 
partners. 
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Figure 3.6  The affinity precipitation of TAPP-1. 
 
  
 The cellular recruitment and affinity capture approaches, in combination, 
allow efficient recovery and concentration of TAPP-1. TX-100 soluble fractions 
generated from control (CON) and bpV(phen) (STIM) (100μM, 30mins) 
treated, digitonin permeabilised 1321N1 cells were sampled before (Pre) and 
after (Post) depletion by a maximally effective concentration (25μM) of 
immobilised PtdIns(3,4)P2 prior to recovery by LDS elution of the complex 
(PD). The lower panels are representative immunoblots of TAPP-1 recovery in 
each fraction. The results indicate the proportion of TAPP-1 recovered, as a 
percentage of the total TAPP-1 recruited to cell membranes. The lower panels 
show example blots which contribute to the quantification. Values represent 
the mean ± S.D of three experiments. 
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Figure 3.7  Affinity capture with immobilised PtdIns(3,4)P2 reveals PI 
3-kinase responsive proteins. 
 
 
 1321N1 astrocytoma cells were pre-treated for 30mins with 0.1% (v/v) DMSO 
alone or DMSO plus 1μM wortmannin (W) followed by treatment with (STIM) or 
without (CON) 100μM bpV(phen) for 30 mins. Unbound cytosolic proteins were 
eluted by digitonin permeabilisation prior to TX-100 solubilisation of residual 
membrane fraction. Extracts were depleted by Neutravidin biotinylated-
PtdIns(3,4)P2 prior to LDS elution from the complex and analysis by SDS-PAGE 
and silver staining. The arrows indicate bands (105kDa and 70kDa) recruited in a 
PI 3-kinase-dependent manner. The results are representative of similar data 
obtained in several further experiments. 
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  Consistently enriched bands, such as those indicated at 70kDa and 105kDa 
within Figure 3.7 were processed for identity by MS, the results of which will be 
addressed in Chapter 4. Further identities, albeit from less enriched bands, proved 
too complex to confidently identify candidate proteins by MS, similar to the 
Ins(1,3,4)P3 eluates previously. However, the capacity of this approach to provide 
a third affinity purification step and to precipitate large sample volumes should, in 
conjunction with the advantages offered by the Ins(1,3,4)P3 elution step, yield 
samples of sufficient protein concentration and limited background, so as to 
achieve multiple candidate identities. 
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3.3  Discussion. 
  As a consequence of the central role that PtdIns(3,4,5)P3 plays in normal and 
aberrant cell signalling, much attention has been focussed on the downstream 
effectors regulated and recruited by it. In contrast, little attention has been directed 
towards PtdIns(3,4)P2, due in part to the lack of an established independent 
function attributed to this lipid. Recent studies are however beginning to implicate 
PtdIns(3,4)P2 with varied roles; from its requirement for complete PKB activation 
to neurodegeneration. Furthermore, SHIP2, the enzyme predominantly thought 
responsible for its synthesis, has been implicated in type II diabetes and proposed 
as a viable therapeutic target. 
 
  This study attempts to redress the imbalance of previous wide ranging 
protein-lipid binding screens by focussing on identifying novel PtdIns(3,4)P2 
effector proteins. This Chapter is concerned with the optimisation of three affinity 
steps which are intended for integration into a combined three tier approach which 
benefits from the advantages of multiple affinity purifications. 
 
  Previous studies to identify novel lipid interacting proteins have 
predominantly used immobilised lipid depletions from cell lysates/extracts with a 
variety of synthetic lipids [89,98,174,186,187], an affinity approach similarly 
developed for PtdIns(3,4)P2 in 3.2.3. However, these approaches in isolation 
present a number of caveats. Foremost is the identification of candidate proteins 
by their ability to bind non-physiologically presented lipids in a single affinity 
step, providing little basis on which to distinguish authentic candidates from 
contaminating proteins. Furthermore, the quantity of background proteins is 
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undoubtedly increased by the application of a complex, un-purified lysate directly 
to the matrix. Additionally, studies have often used indiscriminate lysis of whole 
cells or tissues with mixed cell extracts [89,98,174]. Whilst the latter readily lends 
itself to large scale sample generation, the increasing need to understand cell type 
specific PI 3-kinase expression and signalling networks requires the use of 
homogeneous cell populations [189-192]. Equally, lysis of whole cells with little 
regard to compartmentalisation can complicate the subsequent fractionation, 
analysis and interpretation. Moreover, through mass spectrometric analysis, 
existing studies are often data rich but the affinity and selectivity of resulting 
candidate binding proteins in vitro, or their in vivo functional relevance, are rarely 
tested. In developing the protocols described in this Chapter, for generation of a 
three-tier affinity purification, this study aims to improve the likelihood of 
identifying PtdIns(3,4)P2 specific binding proteins and minimise the proportion of 
non-specific binding proteins present during analysis. 
 
  The foundation of this approach utilises the previously observed effect of the 
PTP inhibitor, bpV(phen) to switch the output of class IA PI 3-kinases from 
PtdIns(3,4,5)P3 to PtdIns(3,4)P2. This allows a primary step of enrichment based 
on the recruitment of binding proteins, alongside TAPP-1, to dramatically elevated 
concentrations of PtdIns(3,4)P2, presented in the physicochemical context of an 
authentic membrane bilayer. Membrane features, such as lipid composition, 
curvature and additional protein components are notoriously difficult to replicate 
in vitro but can be crucial factors in the binding between lipids and proteins. An 
obvious advantage of utilising such dramatic increases in the cellular 
concentration of PtdIns(3,4)P2 is to encourage membrane recruitment and 
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retention, prior to recovery, of even relatively low affinity PtdIns(3,4)P2 binding 
proteins. However, it is possible that this approach will lead to the recruitment of 
proteins that are not physiologically regulated by PtdIns(3,4)P2 and/or that have 
much higher affinity for a similar physiological regulator, such as PtdIns(3,4,5)P3 
[193]. 
 
  This primary recruitment to the cell membrane of PtdIns(3,4)P2 interacting 
proteins was coupled to digitonin permeabilisation which allows selective 
targeting of the plasma membrane. Such an approach offers distinct advantages 
over other less discriminating detergents. Firstly, digitonin allows the removal of 
unbound cytosolic proteins, considerably reducing the complexity of subsequent 
samples. Secondly, the integrity of internal membranes is maintained, limiting the 
release of proteases and other enzymes which may destabilise protein-lipid and 
protein-protein interactions, allowing for retention of binding proteins at the 
membrane. The utility of this combined novel approach of membrane recruitment 
and crude cell fractionation was demonstrated by the ability to recruit and retain 
the majority of TAPP-1 to cell membranes in a PI 3-kinase dependent manner. 
 
  The optimisation of a second affinity purification step, utilising Ins(1,3,4)P3, 
allowed recovery of TAPP-1 and presumably of other similarly recruited proteins, 
from membranes enriched in PtdIns(3,4)P2. For TAPP-1 at least, the selectivity of 
this approach was demonstrated by the lack of elution from identically treated 
membranes when incubated with Ins(1,4,5)P3. Whilst this selectivity is consistent 
with the reported characteristics of the C-terminal TAPP-1 PH domain, the 
requirement for Ins(1,3,4)P3 concentrations giving a molar excess of ~100-1000 
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fold that of the cellular PtdIns(3,4)P2 to yield ~60% elution, suggest additional 
interactions between TAPP-1 and the membrane, perhaps via membrane insertion. 
Alternatively, this may be due to localised PtdIns(3,4)P2 concentrations within 
regions of the cell membrane achieving concentrations similar to that of the 
competing Ins(1,3,4)P3. Regardless, any potential limitation in the recovery of 
TAPP-1 at this stage is significantly outweighed by the enrichment, relative to 
cytosolic proteins, gained at the previous step. Furthermore, TAPP-1 with its 
characteristically high affinity PH domain is likely to represent the higher affinity 
end of the spectrum and additional PtdIns(3,4)P2 interacting proteins could be 
expected to be more readily eluted with Ins(1,3,4)P3. This conclusion is supported 
by the recovery of numerous bands enriched in an Ins(1,3,4)P3 dependent manner 
from bpV(phen) treated and digitonin permeabilised 132N1 cells. 
 
  In order to take advantage of the novel aspects of the protocols described 
above, the optimisation of an immobilised lipid affinity step provided the ability to 
precipitate protein samples into small volumes. In this Chapter, the approach was 
optimised as a stand alone technique on TX-100 extracts of bpV(phen) treated, 
digitonin permeabilised 1321N1 cells. The integration to this, of the Ins(1,3,4)P3 
elution step will be addressed in Chapter 4. The determination that the capacity of 
the Neutravidin for the biotinylated-PtdIns(3,4)P2 was not limiting, made the 
approach particularly attractive for large scale sample preparation. Indeed, 
assuming that the concentration can be maintained at the maximally effective ~25-
50μM value, by limiting sample volume, then even large scale experiments should 
only require sparing use of biotinylated-PtdIns(3,4)P2. To put this binding capacity 
into context, if the 5nmol lipid used in Figure 3.5A is capable, conservatively, of a 
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lipid-candidate protein interaction ratio of 10:1, then 5nmol PtdIns(3,4)P2 interacts 
with 0.5nmol of candidate proteins. If these candidate proteins are then assumed to 
be represented by a homogeneous population of 75kDa in size, then 0.5nmol 
relates to 37.5μg of candidate protein. Even if these candidate PtdIns(3,4)P2 
binding proteins were present in lysates in the range 1:10,000-100,000 of the total 
cellular proteins, 5nmol lipid would still be sufficient to deplete 0.375 -3.75g of 
cellular protein. This feature will limit the volume of Neutravidin required to bind 
sufficient lipid for lysate depletion and similarly the volume of elution buffer 
needed to efficiently elute from the matrix, even for large scale experiments. Thus, 
the protein concentration of final samples and consequently the protein quantity 
processed for MS identification can be maximised. 
 
  Despite such apparent capacity for binding, TAPP-1 recovery from the lipid-
matrix depletions appears to be limited to ~25-30% of total cellular TAPP-1. In 
contrast, the data indicate that ~75% of TAPP-1 can be depleted by first pass 
immobilised lipid depletions from lysates. This disparity in the retained/depleted 
TAPP-1 was shown to be as a consequence of the extensive washing used to 
minimise the non-specific protein binding to the matrix. However, when coupled 
to the already enriched Ins(1,3,4)P3 fraction - considerably reduced in complexity 
from the lysates presented to the lipid-matrix in this Chapter - such extensive 
washing could be dispensed with, if necessary, in order to achieve greater 
recovery of TAPP-1 and other candidate proteins. 
 
 This Chapter establishes the first essential phases in isolation of potential 
PtdIns(3,4)P2 binding proteins by optimising each step of a three tier affinity 
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purification. However, each step is clearly capable individually of identifying 
numerous PI 3-kinase responsive candidates which co-purify with TAPP-1. This is 
perhaps, most elegantly demonstrated by the isolation of two bands of sufficient 
purity and protein content to be identifiable by MS, a feature dealt with in Chapter 
4. 
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Mass Spectrometric Analysis and the Application of SILAC. 
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4.1 Introduction.  
  In the previous Chapter data were presented which demonstrate that separate 
and combined affinity steps can be used to concentrate TAPP-1 into an enriched 
fraction. The protocols were optimised individually under the assumption that 
additional, as yet unknown PtdIns(3,4)P2 binding proteins would be co-purified. 
This Chapter develops this concept; firstly, by identifying two such candidate 
proteins using peptide mass fingerprinting. Secondly, the Chapter describes the 
integration of the individual enrichment approaches into a superior, three-tier 
affinity isolation scheme, expected to dramatically reduce non-specific protein 
carry through into the subsequent MS analysis. Thirdly, to address the inherently 
non-quantitative nature of MS analysis, the multi-step affinity purification is also 
coupled to SILAC or Stable Isotope Labelling Assisted Cell culture. The 
differential isotope labelling of cells achieved by this technique provides a ratio-
metric readout to distinguish authentically responsive components from co-
purifying background proteins. The results of this powerful combined approach 
identify a number of existing and candidate lipid binding proteins which represent 
the most complete set of potential PtdIns(3,4)P2 binding proteins reported to date. 
 
 4.1.1  An Introduction to Mass Spectrometry (MS). 
Prior to the application of mass spectrometry to protein identification, the 
existing technique relied upon was that of sequencing by Edman degradation 
[194,195]. This approach requires sequential chemical removal and identification 
by chromatography of individual amino acids starting from the amino terminus. 
The limitations of this approach include the extended time frame necessary to 
complete a sequencing project and the development of secondary metabolites 
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which interfere with and limit reactions to sequences of approximately 50 amino 
acids in length. Furthermore, the procedure fails entirely if the protein is 
acetylated or otherwise modified at its amino terminus. Mass spectrometry became 
widely applicable to protein identification upon the introduction of suitable means 
to ionize peptides [196-199]. This, coupled to the availability of sequence (and 
recently whole genome) databases, meant that for the first time samples did not 
need to be purified to homogeneity for identification [200-202]. Moreover, 
ionization allowed fragmentation and subsequent identification in seconds as 
opposed to hours and days for the Edman degradation technique. Lastly, mass 
fingerprinting techniques are capable of identities despite protein modifications. 
 
Mass spectrometers achieve identification of peptides by accurate 
measurement of mass to charge ratios (m/z) derived from the ionised sample. The 
measurement of m/z requires three basic components within a mass spectrometer; 
the ion source, a mass analyser and a detector [203,204]. Beyond these three 
components the growing list of variations, additions and resulting permutations 
can make MS platforms considerably more complex. Ion sources operate via two 
common methods of ionisation; presenting samples in the gas phase, either by 
sublimation of a crystalline matrix using laser pulses or rapid evaporation from a 
liquid sample. These are known as MALDI (matrix-assisted laser 
desorption/ionization) and ESI (electrospray ionization), respectively [197,198]. 
The detector component simply consists of a metal plate(s) which records the 
charge induced or current produced when positive ions pass by or are neutralised 
upon contact with a surface [205,206]. 
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The mass analysers available all share a common function, to isolate the 
peptides on the basis of their m/z value. Typically peptide ions are isolated by 
accelerating via charge repulsion, away from the ion source, through a vacuum. 
The path of each ion is then deflected as a consequence of an electromagnetic field 
applied across the vacuum. Obviously both factors are affected by the size and 
charge associated with the ion (m/z value) and the temporal features of the 
variable electromagnetic field determine those which can reach the detector.  The 
four basic types of mass analyser are; ion trap [207-209], time-of-flight (TOF) 
[210], Fourier transform ion cyclotron resonance (FTICR) [211,212] and 
quadrupole (Q) [208,213,214], and are selected on the basis of experimental 
requirement and cost. Multiples of these within a single instrument (i.e. 
quadrupole - time of flight [QTOF]) are referred to as tandem mass spectrometers 
(MS/MS) and they typically have a collision cell between the two analyser 
components [213,215]. This cell allows collision induced dissociation (CID) 
where the isolated precursor ion, measured in the first analyser, is sub-fractionated 
into product ions which are measured in the second analyser [216]. This process 
contributes considerably to the probability of identification of the precursor ion as 
well as providing primary sequence data.  
 
Traditional three dimensional ion traps, whilst sensitive, robust and relatively 
inexpensive have a limited capacity for mass accuracy due to charged ions being 
stored at a point-like centre of the trap [203]. The increased charge density 
associated with this centre then distorts their, and those of subsequent ions, 
localisation. The development of “two dimensional” or linear ion traps 
considerably increased the capacity for ion storage and consequently increased 
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resolution and mass accuracy [207,209]. Furthermore, coupling such an ion trap 
in-line with an orbitrap analyser, developed by Alexander Makarov, further 
improves resolution, sensitivity and accuracy [217,218]. The orbitrap design 
consists of a barrel shaped trap with an inner spindle offering considerably more 
potential for ion distribution. High mass accuracy is intrinsic to an orbitrap due to 
the capacity for ions of identical m/z ratios to be isolated by synchronous rotation 
around the central spindle (Figure 4.1). Furthermore, these orbiting rings of m/z 
values have an axial motion along the central spindle, the oscillation frequencies 
of which are inversely proportional to the square root of their m/z ratios [217].  
 
The development of the commercially available orbitrap platform was 
completed with the additional front end application of a C-trap (essentially a 
“curved” linear ion trap) to the existing design (Figure 4.1). The primary function 
of this was to match the curvature of the orbitrap entrance, squeezing ions into a 
condensed cloud for efficient injection. An additional benefit however, was to 
provide a second ion trap for storage prior to injection [219-221]. This C-trap 
allowed ions of lock mass, otherwise known as background airborne ions, to be 
injected directly, providing an internal control for real time calibration [220,222]. 
Furthermore, the not inconsiderable contamination of low yield protein samples by 
airborne keratins derived from human skin is a particular problem for MS 
analyses. This can be limited to an extent within an orbitrap by filtering out known 
identities of lock mass contaminants. The culmination of this novel design of the 
orbitrap is to achieve accuracy of m/z ratios in the parts per billion range – a 
significant increase on that previously available [219,222,223].  
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Figure 4.1  The schematic layout of an LTQ Orbitrap XL. 
 
  
 
 
 
The upper image shows a schematic representation of an LTQ Orbitrap XL 
including the ion source, linear ion trap, C-trap and Orbitrap. The lower images 
detail a cross section of the orbitrap and how following injection, ions orbit the 
central spindle. Images reproduced from  [224-226]. 
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4.1.2  The Application of SILAC and the Associated Software for 
Analysis. 
An established shortcoming of traditional MS analyses, despite the 
unparalleled sensitivity for protein identification, is its non-quantitative nature; a 
caveat pertinent to this and similar studies. An elegant solution to the requirement 
for comparative quantitation between two cell populations was provided by 
SILAC. This approach employs the differential metabolic labelling of control- and 
test-cell populations, for example with normal (12C) and heavy (13C) isotope 
substituted amino acids respectively. The specific amino acids labelled with stable 
isotopes can be selected to suit the intended means of enzymatic digestion for MS 
analysis. Typically for tryptic digestions, lysine and arginine are used – as trypsin 
cleaves peptides C-terminal to both - ensuring that each peptide fragment retains 
at least one, but usually two, substituted amino acids. The isotopes are added to 
the medium and allowed to be incorporated into cellular proteins via turnover 
[125,126] and can be assumed to be fully and equally incorporated within the 
proteome (>99% proteome coverage) after 7 cell doublings [227,228]. There 
appear to be no adverse effects or altered cellular growth rates as a result of 
incorporation of one isotope over another. The advantage to metabolically 
labelling two separate populations of cells for MS analysis is that although 
functionally the proteins remain identical, their peptide fragments are 
distinguishable due to a shift in mass [229]. By identifying two identical patterns 
of product ions or peptides differing only by the shift associated with the increased 
mass of a heavy isotope, the relative contribution of each can be quantified by the 
comparison of peak intensities. In this way the notoriously non-quantitative single-
sample analysis traditionally achieved by MS can be quantified [203,204,229]. 
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From the perspective of this study a significant advantage of this is that SILAC 
allows signal and noise to be distinguished as a consequence of the ratio between 
normal (12C) and heavy (13C) isotope labelled proteins. Furthermore, SILAC has a 
distinct advantage over MS-compatible chemical labelling techniques such as 
isobaric tagging which, unlike SILAC, are often incomplete and modify peptides, 
reducing the compatibility between observed and expected m/z ratios [229]. 
 
Traditionally the analysis of complex MS data was highly esoteric and mining 
of vast data sets by existing methods was laborious. The development of the 
quantitative software “MaxQuant”, made the advantages of SILAC more 
accessible to non-specialists [223,230,231]. Furthermore, it had the added effect of 
maximising the data output and accuracy achieved, essentially by taking 
advantage of greater data resolution, when compared to existing software. This 
increase in accuracy was possible due to the nature of the analysis, where 
MaxQuant fits Gaussian distribution peaks to the three most central raw data 
points for each observed m/z ratio (Figure 4.2). Each of these 2D Gaussian 
distribution peak determinations are then further assembled on the z plane - the 
liquid chromatography (LC) column retention times. The generation of such 3D 
profiles or centroids, allow many m/z values to contribute towards identification 
and mean values are weighted according to their intensities. The result of this is to 
smooth outlying data points due to the increased intensity of the most prevalent 
ions [223,230]. This feature increases the accuracy of observed m/z values, 
offering greater data resolution and allowing partially overlapping data points to 
be confidently assigned separate m/z values. Moreover, observed values for ions 
can also be matched with more confidence to the equivalent peaks derived from 
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the heavy/light isotope. Such pairing of data points provides another advantage of 
SILAC labelling, in that the duplicate isotope patterns acts as a potent noise filter 
for eliminating false positives [223,230]. Further still, in some experimental 
designs the application of two isotopic variations, for instance (12C), (13C) and 
(14N), (15N) where heavy isotopes could be limited to specific amino acids such as 
(15N) to lysine and (13C) to arginine allows for pooling or binning of data sets at 
the analysis stage. The result of the latter is to speed up processing and increase 
the number of identities assigned due to the “handle” or confirmed amino acid(s) 
each peptide possesses prior to mining databases such as MASCOT. 
 
This elegant process of metabolic labelling offered by SILAC and the resulting 
quantitation achieved by analysis with the MaxQuant software complements our 
approach to identify novel PtdIns(3,4)P2 binding proteins. The ability to 
differently label control and test cell populations allows candidate proteins 
isolated in a PI 3-kinase dependent manner to be readily distinguishable from the 
background, non-specific proteins. 
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Figure 4.2  How MaxQuant achieves increased accuracy and 
resolution for m/z values (Figure reproduced with permission from 
[223]). 
(A) A two dimensional (2D) peak derived from multiple fragment ion m/z 
values. Shown is an example of a 2D peak whose intensity drops to zero on 
both sides. The determined centroid mass (green line) is calculated as a fit of a 
Gaussian distribution to the three central raw data points. 
 (B) The resolution of overlapping 2D peaks. Where peaks overlap they are 
broken up (red lines) at points of local intensity minima of the Gaussian 
distribution peaks. 
(C) Assembling 3D peak hills. The m/z values are assembled in the z-plane 
(indicated as t); the m/z retention time. Peaks whose centroid m/z positions are 
sufficiently close are connected. 
(D and E) An example 3D peak connecting multiple centroid m/z values. 
Shown is an example of a 3D peak eluting over 1.5min with colour coded 
intensity, increasing from yellow to green, in the mass-retention time plane. 
Forty nine centroids (central red line) are connected to form a 3D peak. Note, 
weakest intensity is related to apparent mass deviations. 
(F) Multiple 3D peaks forming isotope patterns. Eleven 3D peaks can 
clearly be seen contributing to two isotope patterns although masses of upper 
and lower patterns are near identical. The resolution of these pairs is possible 
due to the intensity profiles incorporated by the 3D peaks. 
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Figure 4.2 
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4.2  Results. 
4.2.1 The Identification of PARIS-1 and SWAP-70 as Candidate 3-PI 
Binding Proteins.  
The results presented in the preceding Chapter established that single step 
affinity purifications of TAPP-1 could be achieved (Figure 3.1 and 3.7). Although 
a primary purpose of this Chapter was to improve upon this purification of TAPP-
1, it should be re-emphasised that single affinity purification was already 
sufficient to show several candidate bands visible above background on staining of 
SDS-PAGE gels (Figure 3.7). Many such bands however, were too low in 
abundance to enable identification by MS. Whilst attempts to isolate these bands 
by pooling multiple samples was thwarted by their variable occurrence between 
experiments or their low ratio of enrichment, two bands at 70kDa and 105kDa 
could be reproducibly obtained and in sufficient quantity to facilitate 
identification. Thus, the bands at 70kDa and 105kDa were isolated and processed 
for identification by MS.  
 
Figure 4.3 shows the prominent protein identities associated with the 105kDa 
band following analysis with the identification program MASCOT, on data 
generated by LC MS/MS (ESI in a LTQ Orbitrap XL). Figure 4.3A details the ten 
most significant protein identities for the 105kDa band. Only six of these matched 
correctly to proteins present within the human proteome. However, the non-human 
protein identities were consistent with reagents used for sample isolation and 
processing such as trypsin and avidin. Of the remaining six potential protein 
contributors to the 105kDa band, four are keratins, known and common 
contaminants of mass spectrometry samples due to their ease of ionisation and 
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abundance in laboratory environments. The remaining two candidates were then 
assessed on the basis of their molecular weight and known cellular localisation. 
The 92kDa HNRNPU (heterogeneous nuclear ribo-nuclear protein U) could not be 
dismissed purely by its improbable presence in a band excised at ~105kDa. 
However, in combination with its reported nuclear localisation, bearing in mind 
the primary step of cytosolic fractionation by digitonin, this identity could be 
discounted as less feasible and/or non-specific. The only remaining credible 
candidate therefore, was the PH domain containing, 105kDa cytosolic protein, 
PARIS-1 (prostate antigen recognised and identified by SEREX 1 [232]), 
identified with a high MASCOT Protein Score of 1035 (published protein 
identities start some 20-50 fold below this value).  
 
Figure 4.3B lists the 98 peptide queries which were identified and their 
individual Ion Scores which contributed to the total Protein Score of 1035 for the 
identification of PARIS-1 (TBC1D2) [232], detailed in Figure 4.3A. The 
multiplicity of some peptides (additional query numbers listed in blue following 
peptide sequence), the Ion Score and Expect values indicate the confidence with 
which PARIS-1 was identified. The Ion Score and Expect values were determined 
by MASCOT and are based on the probability that an observed match between 
experimentally derived data and the database records are a random event [233]. 
The Ion Score is determined by the significance threshold selected for peptide 
inclusion (i.e. P=0.05 or 0.01) and the number of candidate peptides within the 
database which fall within the mass tolerance window of the experimentally 
isolated precursor ion [234]. Essentially however, irrespective of the threshold 
selected, significance can be thought of the extent to which the protein/ion score 
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differs from that of background scores. Alternatively, the Expect value can be 
used as a marker of the confidence of the Ion Score, with, typically, values <0.1 
representing a confident match. 
 
 Figure 4.3C shows the protein coverage that the 98 successfully matched 
peptides achieved within PARIS-1. Sequence coverage demonstrates that of the 
105kDa PARIS-1, 47% of the protein was identified by one or more peptides with, 
in places, considerable redundancy in unique peptide identities contributing to the 
high certainty of identification (multiple query numbers for individual peptides in 
Figure 4.3B). 
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Figure 4.3  Mass spectrometric analysis of the protein constituents of the 
105kDa band. 
(A) The ten most significant identities derived from excised band at 105kDa. 
Tryptic digestions of this band were analysed on an LTQ Orbitrap XL and the ten 
most significant identities as determined by MASCOT with their associated 
scores (database search parameters as indicated) are shown. Following 
exclusion of known contaminants PARIS-1 is identified as the constituent 
protein responsible for the increased intensity of this band in response to PI 3-
kinase activation. 
(B) Peptide matches to PARIS-1. 
The individual peptides matched by MASCOT, their associated observed and 
expected mass values (Observed and Mr [expt]) and the resulting MASCOT 
scores are detailed for PARIS-1 (identity No 5 – TBC1D2). The results are 
representative of one sample from a duplicate with similar results obtained on 
one further occasion. 
(C) PARIS-1 sequence coverage. 
The 47% sequence coverage of PARIS-1 achieved by the peptides identified in 
(B) are shown in red. 
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Figure 4.3A 
Mascot Search Results 
Database               : Sprot 20100425 (516603 sequences; 181919312 residues) 
Timestamp              : 26 Apr 2010 at 13:00:39 GMT 
Fixed modifications    : Carbamidomethyl (C) 
Variable modifications : Dioxidation (M),Oxidation (M),Phospho (ST),Phospho (Y) 
Peptide Mass Tolerance : ± 20 ppm 
Fragment Mass Tolerance: ± 0.8 Da 
Max Missed Cleavages   : 2 
Number of queries      : 3217 
1.     sp|P04264|K2C1_HUMAN       Mass: 66170            Score: 1528              Queries matched: 81      
                             Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 
2.     sp|A5A6M6|K2C1_PANTR       Mass: 65621            Score: 1419              Queries matched: 72      
                             Keratin, type II cytoskeletal 1 OS=Pan troglodytes GN=KRT1 
3.     sp|Q00839|HNRPU_HUMAN      Mass: 91269            Score: 1310              Queries matched: 112      
                             Heterogeneous nuclear ribonucleoprotein U OS=Homo sapiens GN=HNRNPU 
4.     sp|P35527|K1C9_HUMAN       Mass: 62255            Score: 1046              Queries matched: 51      
                             Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 
5.     sp|Q9BYX2|TBD2A_HUMAN      Mass: 104953           Score: 1035              Queries matched: 98      
                             TBC1 domain family member 2A OS=Homo sapiens GN=TBC1D2 
6.     sp|P13645|K1C10_HUMAN      Mass: 59020            Score: 684               Queries matched: 29        
                             Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 
7.     sp|P02701|AVID_CHICK       Mass: 16872            Score: 632               Queries matched: 30      
                             Avidin OS=Gallus gallus GN=AVD 
8.     sp|Q14532|K1H2_HUMAN       Mass: 51769            Score: 583               Queries matched: 40      
                             Keratin, type I cuticular Ha2 OS=Homo sapiens GN=KRT32 
9.     sp|Q6EIZ0|K1C10_CANFA      Mass: 57847            Score: 502               Queries matched: 21        
                             Keratin, type I cytoskeletal 10 OS=Canis familiaris GN=KRT10 
10.    sp|P00761|TRYP_PIG         Mass: 25078            Score: 432               Queries matched: 49      
                             Trypsin OS=Sus scrofa 
 122
Figure 4.3B 
5.    sp|Q9BYX2|TBD2A_HUMAN    Mass: 104953   Score: 1035   Queries matched: 98   emPAI: 1.27 
  TBC1 domain family member 2A OS=Homo sapiens GN=TBC1D2 PE=1 SV=2 
      Query  Observed  Mr(expt)  Mr(calc)   ppm  Miss Score Expect Rank  Peptide 
 570  393.727256  785.439960  785.439529  0.55 0  12  30 3   R.QIAELGR.R 
 666  408.732457  815.450362  815.450089  0.33 0  42  0.038 1   K.IQALESR.S 665 
 685  412.250269  822.485986  822.486435  -0.55 0  12  11 4   R.WLVHLR.V 
 856  441.218620  880.422688  880.422501  0.21 0  24  2.3 2   K.CAYLQAR.N 
 975  461.734685  921.454818  921.455597  -0.85 0  30  0.58 3   R.DFLSQQGK.I 974 
 1052  494.258299  986.502046  986.503235  -1.21 0  44  0.026 1   K.ALEAAQQEK.R 1051 
 1076  500.774343  999.534134  999.534882  -0.75 0  31  0.35 1   R.QIELDLNR.T 1075 
 1087  508.279777  1014.545002  1014.545761  -0.75 1  24  2.3 3   R.ERLEAELR.E 
 1129  522.799776  1043.585000  1043.586258  -1.21 0  48  0.0079 1   R.VLQDLLSEK.L 1128 
 1201  542.791203  1083.567854  1083.567245  0.56 0  54  0.0017 1   R.ESLAHTASLR.E 1202 
 1228  546.308040  1090.601528  1090.602249  -0.66 0  26  1.5 1   K.PSLTISFAQK.A 
 1297  565.301358  1128.588164  1128.588699  -0.47 1  47  0.01 1   R.RVEALEQER.E 1296 1298 
 1401  611.303673  1220.592794  1220.592453  0.28 0  74  2.9e-05 1   K.ADAEEGIFEIK.T 1400 1402 
 1515  664.828554  1327.642556  1327.644852  -1.73 0  53  0.0047 1   R.VWDAFLYEGTK.Y 1514 
 1615  712.318868  1422.623184  1422.623825  -0.45 0  30  0.77 1   K.HFTCPTSSFPDK.L 
 1633  722.415713  1442.816874  1442.816666  0.14 0  99  4e-08 1   K.VAALEQQVLMLTK.E 1631 1632 
 1661  730.412061  1458.809570  1458.811584  -1.38 0  (65) 0.00011 1   K.VAALEQQVLMLTK.E 1662 
 1670  735.402961  1468.791370  1468.792557  -0.81 0  56  0.0012 1   R.WAALGDLVPSAELK.Q 1671 
 1720  755.406544  1508.798536  1508.798691  -0.10 0  64  0.00026 1   R.LQNGLEIYQYLR.F 1719 1721 
 1728  507.244243  1518.710901  1518.713638  -1.80 1  41  0.079 1   K.IEHLKDDMEAYR.T 1729 1730 1731 
 1912  819.827945  1637.641338  1637.636261  3.10 0  (15) 19 1   R.AVSEGCASEDEVEGEA.- 1914 
 1991  829.403980  1656.793408  1656.789627  2.28 0  42  0.075 1   R.QNNTFPFFSEGITR.N 1990 1992 1993 
 2012  832.422523  1662.830494  1662.826004  2.70 0  49  0.012 1   K.HLGTEIQNTMHNIR.G 2009 2010 2011 2013 2014 
 2112  571.656475  1711.947597  1711.948166  -0.33 1  29  0.43 1   R.SHHLLGLEAVDRPLR.E 2113 2114 2115 2116 2117 2118 
 2153  859.811160  1717.607768  1717.602585  3.02 0  15  11 1   R.AVSEGCASEDEVEGEA.- 
 2154  859.811160  1717.607768  1717.602585  3.02 0  (12) 23 5   R.AVSEGCASEDEVEGEA.- 
 2230  891.886092  1781.757632  1781.752640  2.80 0  9  1.2e+02 9   R.DPQVPPPEEESGDCAR.S 2231 
 2360  907.454503  1812.894454  1812.890732  2.05 1  36  0.27 1   K.RQNNTFPFFSEGITR.N 2361 
 2366  909.946349  1817.878146  1817.873032  2.81 0  42  0.073 1   R.TQNCFLNSEIHQVTK.I 2363 2364 2365 2367 
 2465  937.862008  1873.709464  1873.703690  3.08 1  19  7.7 1   R.RAVSEGCASEDEVEGEA.- 
 2503  960.457108  1918.899664  1918.894180  2.86 0  108  1.9e-08 1   R.LQEALGDEASECSELLR.Q 2504 2505 2506 
 2524  646.659905  1936.957887  1936.957764  0.06 0  39  0.15 1   R.VQHLHTPGCYQELLSR.G 2523 2525 
 2644  693.367556  2077.080840  2077.080322  0.25 2  44  0.033 1   R.ASSAYLAAAEDKDRLELVR.H 2645 2646 2647 
 2660  1047.539144  2093.063736  2093.057526  2.97 0  61  0.00069 1   R.EQQVQELQQHVQLLMDK.N 2657 2658 2659 2661 2662 
 2669  704.026053  2109.056331  2109.052444  1.84 0  (27) 1.9 1   R.EQQVQELQQHVQLLMDK.N 2668 2670 
 2794  1134.031757  2266.048962  2266.042343  2.92 0  72  9.6e-05 1   R.TAQDANPLDSIDLSSAVFDCK.A 
 2812  763.676523  2288.007741  2288.005386  1.03 0  11  1.1e+02 2   K.QAQGTGHEPPGEDSPQSGEPQR.E 
 2841  788.058559  2361.153849  2361.146179  3.25 1  29  1.8 1   K.VTQDFTHPPDQSPLRPDAANR.D 2842 2843 
 2961  878.429243  2632.265901  2632.261612  1.63 2  27  3 1   R.EEQPLASDASTPGREPEDSPKPAPK.P 2960 
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Figure 4.3C 
 
Mascot Search Results 
Match to: sp|Q9BYX2|TBD2A_HUMAN Score: 1035 
TBC1 domain family member 2A OS=Homo sapiens GN=TBC1D2 PE=1 SV=2 
Nominal mass (Mr): 104953; Calculated pI value: 6.05 
Taxonomy: Homo sapiens 
 
Fixed modifications: Carbamidomethyl (C) 
Variable modifications: Dioxidation (M),Oxidation (M),Phospho 
(ST),Phospho (Y) 
Cleavage by Trypsin/P: cuts C-term side of KR 
Sequence Coverage: 47% 
 
Matched peptides shown in Bold Red 
 
     1 MEGAGENAPE SSSSAPGSEE SARDPQVPPP EEESGDCARS LEAVPKKLCG  
    51 YLSKFGGKGP IRGWKSRWFF YDERKCQLYY SRTAQDANPL DSIDLSSAVF  
   101 DCKADAEEGI FEIKTPSRVI TLKAATKQAM LYWLQQLQMK RWEFHNSPPA  
   151 PPATPDAALA GNGPVLHLEL GQEEAELEEF LCPVKTPPGL VGVAAALQPF  
   201 PALQNISLKH LGTEIQNTMH NIRGNKQAQG TGHEPPGEDS PQSGEPQREE  
   251 QPLASDASTP GREPEDSPKP APKPSLTISF AQKAKRQNNT FPFFSEGITR  
   301 NRTAQEKVAA LEQQVLMLTK ELKSQKELVK ILHKALEAAQ QEKRASSAYL  
   351 AAAEDKDRLE LVRHKVRQIA ELGRRVEALE QERESLAHTA SLREQQVQEL  
   401 QQHVQLLMDK NHAKQQVICK LSEKVTQDFT HPPDQSPLRP DAANRDFLSQ  
   451 QGKIEHLKDD MEAYRTQNCF LNSEIHQVTK IWRKVAEKEK ALLTKCAYLQ  
   501 ARNCQVESKY LAGLRRLQEA LGDEASECSE LLRQLVQEAL QWEAGEASSD  
   551 SIELSPISKY DEYGFLTVPD YEVEDLKLLA KIQALESRSH HLLGLEAVDR  
   601 PLRERWAALG DLVPSAELKQ LLRAGVPREH RPRVWRWLVH LRVQHLHTPG  
   651 CYQELLSRGQ AREHPAARQI ELDLNRTFPN NKHFTCPTSS FPDKLRRVLL  
   701 AFSWQNPTIG YCQGLNRLAA IALLVLEEEE SAFWCLVAIV ETIMPADYYC  
   751 NTLTASQVDQ RVLQDLLSEK LPRLMAHLGQ HHVDLSLVTF NWFLVVFADS  
   801 LISNILLRVW DAFLYEGTKY NEKEILRLQN GLEIYQYLRF FTKTISNSRK  
   851 LMNIAFNDMN PFRMKQLRQL RMVHRERLEA ELRELEQLKA EYLERRASRR  
   901 RAVSEGCASE DEVEGEA 
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Similarly, Tables 4.1 and 4.2 present the MS data generated from the 70kDa 
band, where the samples were analysed using the less sensitive MALDI Q4700 
TOF/TOF due to the comparative abundance of the 70kDa band over the 105kDa 
band. Table 4.1 highlights the certainty by which SWAP-70 (switch associated 
protein-70) was identified as the prominent protein constituent within the 70kDa 
band. Non-specific background proteins achieved MASCOT protein scores of 20-
30 whilst SWAP-70 was the only candidate achieving a score markedly above 
this. The highly significant MASCOT score of 207 for SWAP-70 (70kDa, 
Accession number: IPI00307200) is in conjunction with a confidence interval of 
100% (confidence interval is similar to the Expect value but presented as 
percentage, C.I. % = [1-P]x100; where P represents significance i.e. a P value of 
0.05 equals C.I. of 95%). As expected for background proteins, all other identities 
were deemed non-significant, as represented by zero values for C.I. %. 
 
Table 4.2 shows the features of the ~25 contributing peptides successfully 
matched from the MS/MS peak list to SWAP-70. The amino acid sequence for 
each of these peptides is listed together with their position within SWAP-70 (start 
sequence and end sequence position of the peptide) and the accuracy with which 
the observed peptide m/z ratios were matched to the calculated masses of 
hypothetical peptides generated by tryptic digestion of SWAP-70. From these, and 
repeat analysis on separately produced samples, we could unequivocally conclude 
that SWAP-70 is the prominent protein identity associated with the 70kDa band 
enriched as a consequence of cellular PI 3-kinase activation in Figure 3.7. 
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Thus, the identification of two PH domain containing proteins, PARIS-1 and 
SWAP-70, of which the latter has an established interaction with 3-PIs, 
demonstrates proof of principle for the described protocol designed for isolating 
and enriching novel 3-PI interacting proteins via single affinity purifications.  
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Table 4.1. The ten most significant identities derived from the 
excised band at 70kDa.  
Following tryptic digestion, the sample derived from the band at 70kDa was 
analysed on an ABI MALDI Q4700 mass spectrometer. The ten most significant 
protein identities are shown with their accession number, molecular weight 
(Mw Wt.), protein score (as determined by MASCOT) and the confidence interval 
– a measure of the probability associated with the identity. SWAP-70 was 
identified with a confidence interval of 100%. A description of ion score 
significance values can be found at [234]. Precursor ion scores and their 
confidence interval are also included. Database search parameters are identical 
to those detailed in figure 13A. ND = not determined. The results are 
representative of one sample from a duplicate. Similarly conclusive data were 
obtained from analysis on LTQ Orbitrap XL on two further occasions. 
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Table 4.1 
 
Peptide-Peptide summary by spot – MALDI Q4700 
Database: IPI Human 
Sample ID Rank Protein Name   
Acc. 
Number   Mw Wt. 
Protein 
P.I. 
Protein 
Score C.I. % 
Total Ion 
Score 
Total Ion 
C.I.% 
                                        
071018_H01 1 Gene_Symbol=SWAP70 IPI00307200 69353.6 5.66 207 100 70 100 
071018_H01 2 Gene_Symbol=SWAP70 IPI00514279 17946.2 5.17 87 99.987 39 99.124 
071018_H01 3 Gene_Symbol=NIF3L1 IPI00451429 28668.5 8.55 34 0 ND ND 
071018_H01 4 Gene_Symbol=LOC339742 IPI00736604 53915.9 8.43 33 0 27 85.022 
071018_H01 5 Gene_Symbol=ZFYVE19 IPI00386862 52610.7 5.57 33 0 ND ND 
071018_H01 6 Gene_Symbol=LOC651987 IPI00747409 9276.6 9.84 31 0 ND ND 
071018_H01 7 Gene_Symbol=FLJ39660 IPI00783185 129535.9 6.58 29 0 14 0 
071018_H01 8 Gene_Symbol=SUHW4 IPI00792669 35113.8 8.68 28 0 ND ND 
071018_H01 9 Gene_Symbol=LOC727874 IPI00786905 20868 5.01 28 0 ND ND 
071018_H01 10 Gene_Symbol=ZFYVE19 IPI00386862 52610.7 5.57 26 0 ND ND 
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Table 4.2  The identified peptides contributing to the identity of 
SWAP-70. 
Listed are the peptides identified with the 70kDa band which are attributed to 
SWAP-70. Included for each peptide is the ion score, confidence interval, any 
modifications, expected masses (Calc. Mass), the observed masses (Observ. 
Mass) and the deviation between these values (±da). An alternative measure for 
the agreement between Observ Mass and Calc Mass values, taking into account 
fragment ion size is shown by ±ppm ([observed – exact]/exact x 1000000). Also 
detailed are the individual sequences attributed to each peptide and their 
relative position within SWAP-70. 
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Table 4.2 
 
Calc. Mass Obsrv. Mass ± da ± ppm Start Seq. 
End 
Seq. Sequence 
Ion 
Score C.I. % Modification 
876.4057 876.4142 0.0085 10 441 447 QDEETVR         
881.4363 881.4378 0.0015 2 387 393 FSTELER         
903.4894 903.507 0.0176 19 361 368 KLEEAASR         
916.4482 916.4505 0.0023 3 483 489 QELENQR         
972.5109 972.5142 0.0033 3 352 359 QQELEAVR         
1031.5746 1031.5751 0.0005 0 538 546 VAHHEGLIR         
1102.5375 1102.5377 0.0002 0 429 437 LQEALEDER         
1185.6587 1185.6587 0 0 377 386 LQTQVELQAR 17 0     
1185.6587 1185.6587 0 0 377 386 LQTQVELQAR         
1244.6117 1244.6116 -0.0001 0 330 339 QLAEQEELER         
1252.6168 1252.6179 0.0011 1 409 418 SSELEQYLQR 22 54.974     
1252.6168 1252.6179 0.0011 1 409 418 SSELEQYLQR         
1295.6664 1295.6719 0.0055 4 419 428 VRELEDMYLK         
1311.6614 1311.6749 0.0135 10 419 428 VRELEDMYLK     Oxidation (M)[7] 
1389.7261 1389.7285 0.0024 2 106 117 NPLLITEEDAFK         
1524.7441 1524.7451 0.001 1 81 92 VQDNFDKIEFNR 31 94.132     
1524.7441 1524.7451 0.001 1 81 92 VQDNFDKIEFNR         
1796.8715 1796.8566 -0.0149 -8 11 26 AIWHAFTALDQDHSGK         
1796.8715 1796.8566 -0.0149 -8 11 26 AIWHAFTALDQDHSGK         
1817.0068 1816.9893 -0.0175 -10 295 309 QEWIQAIHSTIHLLK         
1939.9508 1939.9741 0.0233 12 467 482 WHLEQQQAIQTTEAEK         
1945.1018 1945.0957 -0.0061 -3 294 309 KQEWIQAIHSTIHLLK         
2395.1677 2395.1492 -0.0185 -8 554 574 NPHLITNWGPAAFTEAELEER         
2395.1677 2395.1492 -0.0185 -8 554 574 NPHLITNWGPAAFTEAELEER         
2652.3052 2652.259 -0.0462 -17 554 576 NPHLITNWGPAAFTEAELEEREK         
2837.3813 2837.364 -0.0173 -6 467 489 WHLEQQQAIQTTEAEKQELENQR         
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4.2.2 Coupling a Three-Tier Affinity Purification Approach to SILAC 
Gives an Effective Screen for 3-PI Effector Proteins.  
  Although a single step affinity purification step had resulted in the successful 
identification of SWAP-70 and PARIS-1, and indicated clearly that other PI 3-
kinase responsive proteins were present in purified extracts, it was evident that to 
succeed in identifying a wider group, a modified strategy would be required. To 
this end, the value of merging three affinity purification steps to achieve greater 
enrichment of candidate proteins and reduce contaminants was assessed. The three 
tier affinity enrichment scheme comprised; (i) the cellular recruitment of proteins 
to PtdIns(3,4)P2 enriched membranes (Table 3.1), (ii) cell permeabilisation by 
digitonin (Figure 3.1) to allow Ins(1,3,4)P3 displacement of 3-PI bound candidates 
(Figures 3.2-3.4) and  (iii) immobilised PtdIns(3,4)P2 affinity purification (Figures 
3.5-3.7). The scheme was tested with a pilot, comparative analysis using this 
multi-step approach prior to attempting integration with SILAC.  
 
Figure 4.4 illustrates the results of this pilot experiment and shows the 
advantages offered by this combined affinity approach. Digitonin permeabilised 
1321N1 cells, pre-treated with bpV(phen) with and without wortmannin (control 
and test cell populations respectively), were eluted with Ins(1,3,4)P3 and finally 
depleted with immobilised PtdIns(3,4)P2, prior to SDS recovery from the lipid 
matrix. The subsequent SDS-PAGE staining pattern is presented in Figure 4.4 and 
the numerous bands enriched in a wortmannin dependent manner between control 
and test samples are highlighted by the associated densitometry. Figure 4.4 reveals 
>10 bands enriched in a wortmannin-dependent manner, emphasising the number 
and range of proteins that can be isolated by this combined approach. Also, 
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lending further credibility to those enriched bands is the agreement of intensity 
associated with background non-specific bands, again shown by the densitometry 
traces. These data extend the limited number of proteins previously isolated using 
Ins(1,3,4)P3 elution (Figure 3.4) and similarly for immobilised lipid precipitation 
alone (Figure 3.7). This pilot, three-tier purification scheme underlined the 
potential of integrating multiple affinity steps for identification of novel binding 
proteins and suggested that the application of SILAC would allow a quantitative 
proteomic analysis of numerous proteins enriched in a PI 3-kinase responsive 
manner. 
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Figure 4.4  A three-tier affinity purification approach reveals multiple 
co-purifying PI 3-kinase responsive proteins. 
 
 
 
Following pre-treatment with wortmannin (CON – blue) or vehicle alone (STIM 
– red) 1321N1 cells were treated with 100μM bpV(phen) for 30mins. Cells were 
then permeabilised by digitonin and residual membrane fractions eluted with 
100μM Ins(1,3,4)P3 prior to concentration of this eluate by anion exchange and 
affinity chromatography. The samples were analysed by SDS-PAGE and silver 
stained. Molecular weight markers are indicated on the right hand panel (kDa). 
The left panel highlights via a densitometric scan the PI 3-kinase responsive 
elements enriched in STIM (red trace) over CON (blue trace) sample. Similar data 
were obtained on at least 3 further occasions. 
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Having confirmed the utility of the approach with a pilot scale experiment 
(Figure 4.4), the experimental design was coupled to SILAC and scaled up 
considerably in order to maximise the protein content processed for MS 
identification. Figure 4.5 details how SILAC was integrated into the existing 
protocol for a three-step affinity purification. Following the differentiation of 
control- and test-cell populations by growth in appropriate SILAC medium, and 
stimulation as indicated, samples were successively affinity purified, as detailed 
previously.  
 
Furthermore, Figure 4.5 illustrates a feature provided by the application of 
SILAC – the immediate post-challenge merging of experimental workflows. As 
the sample of origin can be ascertained at the analysis stage courtesy of the 
metabolic labelling, there is no requirement to process samples independently. A 
considerable advantage to pooling control and test samples in this manner is to 
eliminate variability commonly introduced as a result of independent sample 
handling. A further advantage; in contrast to the preceding protocol which 
permeabilised cells in situ on tissue culture plates, requiring relatively large 
volumes of buffer; was that pooling samples presented an opportunity to 
dramatically reduce this volume of buffer per unit of cellular material processed. 
This was achieved by scraping all cellular material, regardless of sample origin 
into a single volume of digitonin permeabilisation buffer and extracting unbound 
cytosolic proteins by repeated cycles of centrifugation and re-suspension in fresh 
buffer. Crucially, this reduction in volume also decreased the amount of 
Ins(1,3,4)P3 required to achieve an effective concentration for protein elution from 
the cellular membranes (Figure 3.2). The limited use of Ins(1,3,4)P3 at this stage 
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coordinately reduced the amount of biotinylated-PtdIns(3,4)P2 required to achieve 
a ratio compatible with the effective affinity precipitation of TAPP-1 at the 
following step (data not shown). Moreover, a reduction in the biotinylated-
PtdIns(3,4)P2 proportionally lessened the Neutravidin required and hence the 
volume of SDS needed to efficiently elute from the matrix, thus increasing the 
relative amount of sample which could be loaded onto a single SDS-PAGE gel for 
MS analysis. 
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Figure 4.5  The protocol for incorporation of SILAC into the three-tier 
affinity purification approach. 
 
 
 
A stepwise process to label control cells (blue scheme, pre-treated with 
wortmannin) with “light” amino acids and stimulated cells (pink scheme, 
treated with vehicle) with “heavy” amino acids. Workflows were then combined 
following bpV(phen) treatment and subsequent purification as indicated. 
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4.2.3 The Reduction of Sample Complexity Achieved by Ion 
Exchange Chromatography. 
Having established the utility of the combined affinity purification approach 
and the method in which SILAC would be integrated into the existing scheme, an 
additional chromatography step was included between the Ins(1,3,4)P3 elution and 
the immobilised lipid precipitation (Figure 4.5). The purpose of including 
anion/cation exchange chromatography (and residual flow through fractions), as 
indicated, was to reduce sample complexity, reduce carry over into later affinity 
purifications of potentially competing concentrations of Ins(1,3,4)P3 and thereby 
enhance the outcome of SILAC analysis. This method of dividing samples 
according to their ion exchange characteristics allowed greater depth of MS 
analysis into the final tryptic digestions without sacrificing overall sample content. 
 
Figure 4.6 demonstrates the purpose of including additional chromatography 
steps to reduce sample complexity by showing the elution profile of TAPP-1 from 
one such ion exchange column in comparison to the total protein elution. Extracts 
from 1321N1 cells, pre-treated with bpV(phen) with and without wortmannin and 
permeabilised with digitonin were recovered by TX-100 and applied to an anion 
exchange column. Prior to recovery with increasing concentrations of NaCl, as 
indicated, columns were washed extensively (a minimum of 10x bed volume). The 
total protein content of the NaCl eluates is reflected by colloidal coomassie 
staining of samples on SDS-PAGE gels and the TAPP-1 elution profile was 
measured by immunoblotting. Figure 4.6 indicates that TAPP-1 was quantitatively 
recovered into a specific fraction (100-200mM NaCl). This elution profile of 
TAPP-1 is in contrast to that of the general protein profile and suggests that the 
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application of an additional chromatography step can result in a final sample 
significantly enriched in TAPP-1 with respect to background proteins. Although 
Figure 4.6 shows a limited NaCl elution profile of TAPP-1 from a single ion 
exchange column, it is intended to demonstrate the principle of reducing sample 
complexity according to varying ion exchange elution/binding characteristics. The 
full scale SILAC protocol used higher NaCl concentrations, to recover as wide a 
range of proteins from the column as possible and yet reduce sample complexity 
by sub-dividing samples by their retention, or not, on both anion and cation 
exchange columns. These data suggest that ion exchange chromatography will 
provide an effective way to sub-divide sample complexity, subsequently providing 
greater depth of analysis achieved by the parallel processing of sample 
fractionated through one or more ion exchange steps.  
 
As alluded to previously, an additional benefit of including ion exchange 
chromatography steps was to limit the amount of the Ins(1,3,4)P3 carried through 
from the preceding step into subsequent fractions for lipid depletion (data not 
shown). Although earlier experiments had suggested that a ten fold excess of 
Ins(1,3,4)P3 over PtdIns(3,4)P2 had only limited effect on TAPP-1 recovery from 
TX-100 lysates (data not shown), the possibility that any as yet unidentified 
PtdIns(3,4)P2 binding protein might be similarly unaffected could not be assumed. 
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Figure 4.6  The elution profile of TAPP-1 in comparison to bulk, 
background proteins from an ion exchange column. 
 
 
Control (C) and stimulated (S) samples were prepared by pre-treatment with 
wortmannin or vehicle alone respectively before treatment with 100μM 
bpV(phen) for 30mins. Cytosol removal by digitonin permeabilisation was 
followed by TX-100 extraction of the resulting membrane fraction and samples 
were applied to an anion exchange (Q-sepharose) column. 100mM incremental 
NaCl washes as indicated were collected and analysed by both colloidal 
coomassie staining for protein content (upper panel) and immuno-blotting, 
specifically for TAPP-1 (lower panel). Similar data for protein elution obtained 
on at least 3 further occasions. 
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4.2.4 SILAC Analysis I. 
Having optimised each step required for a SILAC labelled three-tier affinity 
purification, sub-fractionated by ion exchange chromatography, as set out in the 
scheme shown in Figure 4.5, an initial attempt was made to quantitatively identify 
candidate 3-PI interacting proteins, enriched in a PI 3-kinase dependent manner. 
The experiment yielding the results illustrated in Figures 4.7 and 4.8 were derived 
from 24 x 15cm2 dishes of confluent 1321N1 cells split between the two SILAC 
conditions (cultured as detailed in Materials and Methods, and treated as indicated 
in Figure 4.5). Calculations suggested that this should generate 400-800mg of total 
cell protein for subsequent processing. Following post challenge merging of the 
control and test samples and the ensuing cytosol elution by repeated 
suspension/centrifugation in digitonin buffer the residual membrane bound 
fraction was eluted with 200μM Ins(1,3,4)P3. This value was chosen in order to 
maximise the elution of Ins(1,3,4)P3-sensitive proteins, whilst ensuring that even 
total carry through into any one ion exchange eluate-fraction would not adversely 
affect subsequent immobilised lipid depletions. Thus, 200μM Ins(1,3,4)P3 
(500nmol in 2.5ml) did not exceed the maximally determined concentration ratio 
of 10:1 [Ins(1,3,4)P3 to biotin-PtdIns(3,4)P2], previously observed to have a 
negligible effect on TAPP-1 recovery from cell extracts enriched in the former.  
 
This initial SILAC experiment utilised both anion and cation (henceforth 
referred to as AQ and CS respectively) exchange chromatography steps, with the 
Ins(1,3,4)P3 eluate successively flowed first through AQ and then CS columns. 
The column flow through and subsequent washes, however, were not retained for 
experimental processing. Both AQ and CS columns were then eluted with 350mM 
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NaCl, recovering the fractions for depletion by the Neutravidin biotinlylated-
PtdIns(3,4)P2 complex (50nmol/20μM lipid). This somewhat conservative starting 
point for NaCl eluate concentration was selected on the basis of the binding 
characteristics of TAPP-1. Whilst undoubtedly limiting the total protein recovery 
from the columns, this allowed TAPP-1 to be quantitatively recovered and yet 
maintained buffer conditions for affinity precipitation of TAPP-1 that were 
compatible with those optimised previously. Although increasing NaCl 
concentrations would have recovered a broader spectrum of proteins, it was 
considered that these conditions might also adversely influence subsequent 
protein-lipid binding. Thus, since these factors cannot be tested for potential 
unknown proteins it seemed prudent, to at first, validate the approach with 
conditions established for TAPP-1.  
 
Figure 4.7 specifically detail the ~650 protein identities established from the 
MS analysis of the AQ exchange eluate for the SILAC I experiment. The data are 
presented showing the relative enrichment of heavy to normal (or “light”) isotope 
labelled peptides contributing to a given proteins identity along the y-axis, with 
randomly assigned identification numbers on the x-axis. A ratio >1 indicates 
enrichment as a consequence of PI 3-kinase dependent recruitment to cell 
membranes. Identified proteins of particular interest or those with established lipid 
binding characteristics are indicated, such as PKB/Akt, TAPP-1 and SWAP-70. 
For inclusion into the data set represented by Figure 4.7, each protein required 
identification of at least two peptides. In order to eliminate any potential skew 
introduced, for example, by unequal control and stimulated cell populations, these 
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ratios are adjusted so as to achieve a normal distribution, with the median value 
designated as 1.  
 
Table 4.3 details the features of a limited subset of the most heavily enriched 
candidate proteins identified within the AQ eluate, illustrated in Figure 4.7. 
Amongst these are a number of established or proposed lipid binding proteins, 
including TAPP-1, SWAP-70 and all three isoforms of PKB, highlighted in 
yellow. For each identity, Table 4.3 shows the relative ratio of enrichment (heavy 
v.s light peptides), the posterior error probability (P.E.P, the probability of wrong 
assignment of peptide spectra) and the number of peptides associated with the 
particular identities. For inclusion into Table 4.3, each protein identity required ≥2 
unique peptides. However, complete data sets for all protein identities (~650), 
regardless of the ratio of enrichment and number of peptides, can be found in 
Supplementary Table 1. The capability of the SILAC software to distinguish non-
specific, background proteins from those genuinely enriched is further provided by 
the prevalence of keratins, common contaminants in MS analyses, identified with 
the lowest ratio of heavy to light peptides (Supplementary Table 1, enrichment 
<0.1-0.01). 
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Figure 4.7  SILAC I – Anion exchange eluate. 
After three tiers of purification following pooling of control and test sample, the 
anion exchange eluate reveals ~650 proteins identified with at least one unique 
peptide. These proteins are represented as an arbitrary identification number 
on the x-axis plotted against the enrichment ratio of heavy:light peptides. A 
blue line marks the normalised distribution value of 1 and a red line the 
arbitrary enrichment value of 1.5 – isolating ~5% of the most heavily enriched 
proteins. Proteins of interest or those with established lipid binding 
characteristics are indicated. Prominent peaks derived from single peptide 
identities are, however, ignored. 
 
 
 
 
 
 
 
 
 
 143
Figure 4.7 
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Table 4.3  SILAC I – The candidate list of potential PtdIns(3,4)P2 
binding proteins from the anion exchange fraction. 
A detailed list is shown of the most heavily enriched candidate proteins 
following quantification of MS data from a SILAC labelled, triple purified anion 
exchange column eluate. Proteins required at least two unique peptides for 
inclusion. For each protein, shown is the arbitrary I.D. number assigned as 
indicated in figure 17, the number of peptides identified, the molecular weight, 
the ratio of enrichment and the P.E.P. value (an indication of the certainty of 
identity as P.E.P.   0). Those proteins of interest or with established lipid binding 
characteristics are highlighted in yellow and CLIC1; a target selected for further 
analysis in Chapter 5, is indicated in red. 
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Table 4.3 
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Figure 4.8 reveals the ~275 identities assigned to the CS eluate from the 
SILAC I experiment. As previously, the data are presented with ratio of isotopic 
enrichment against arbitrary peptide number. Proteins of interest or with 
established lipid binding characteristics, identified with more than one unique 
peptide are indicated. Table 4.4 lists the P.E.P., ratio of enrichment and peptide 
number associated with only those proteins which achieved a ratio of ≥1.5 and, 
highlighted in yellow, are those marked in Figure 4.8. Similar data for all of the 
identified proteins is available in Supplementary Table 3. It is, however, 
noticeable that significantly more proteins emerged from the AQ column than the 
CS column. This may be a consequence of the experimental design where the 
Ins(1,3,4)P3 eluate passed first through the former and then the later. Alternatively, 
a precedent does exist where a previous study observed a considerable 
predominance of potential PtdIns(3,4,5)P3-responsive proteins in an anion- as 
opposed to a cation-fraction [98]. Similarly, amongst the data set presented here, 
established lipid binding proteins are almost exclusively identified within the AQ 
(anion) exchange fraction. 
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Figure 4.8  SILAC I – Cation exchange eluate.  
The proteins identified in the corresponding cation exchange eluate from the 
sample derived for Figure 4.7. The bar chart shows the ~250 proteins identified 
with at least one unique peptide. These proteins are also presented with an 
arbitrary identification number on the x-axis plotted against the ratio of 
enrichment of heavy:light peptides. Blue and red lines are as previously 
described. Proteins of interest or those with established lipid binding 
characteristics are indicated, whilst those with only a single peptide identity are 
ignored. 
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Figure 4.8 
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Table 4.4  SILAC I – The candidate list of PtdIns(3,4)P2 binding 
proteins from the cation exchange fraction. 
 
A detailed list is shown of those proteins identified with a ratio of enrichment 
greater than 1.5 following quantification of MS data of the SILAC labelled, triple 
purified cation exchange eluate. Proteins required at least one unique peptide 
for inclusion. The results are presented as described in the legend to Table 4.3. 
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Regardless of the chromatographic fractions in which they are found, the 
identification amongst the list of most heavily enriched proteins of PKB/Akt and 
of TAPP-1 is of particular importance. Their identification provides convincing 
proof of principle in the developed protocol to isolate, enrich and allow 
identification of 3-PI-responsive proteins. Moreover, each isoform of PKB/Akt 
was identified with multiple unique peptides and marked enrichment ratios 
ranging from 4-7, whilst the identification of TAPP-1 was more modest with an 
enrichment of 1.36 and 2 unique peptides. Pertinently, other proteins identified 
with a high ratio of enrichment within this data set include SWAP-70, vinculin 
and PRDX-1. Each of these have been reported as potential PtdIns(3,4)P2 binding 
proteins either as a consequence of their ability to associate with an immobilised 
lipid matrix or by their binding in protein-lipid overlay assays [89,98,174]. Also, 
within Tables 4.3 and 4.4 there are listed a number of further established or 
putative lipid binding proteins, with the proposed capacity to bind ligands 
including PtdIns(4,5)P2, PtdSer and inositol. These include, but are not limited to; 
profillin, talin, RASA3/GAP1 (IP4 binding protein), oxysterol binding protein, 
vigilin, epsin, and several annexins. 
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4.2.5 SILAC Analysis II. 
Despite considerable success in identifying established lipid binding proteins 
such as PKB, TAPP-1 and SWAP-70, and novel candidates alike, the 
experimental protocol from SILAC I was revisited for two reasons. Firstly, to 
expand the repertoire of proteins recovered from the ion exchange columns by 
increasing the NaCl elution concentration from 350mM to 600mM. And secondly, 
to address the relatively meagre identification of TAPP-1 peptides, possibly a 
contributing factor to its relatively limited ratio of enrichment.  
 
Figure 4.9 illustrates the spectrum of proteins identified in the more 
comprehensive SILAC II experiment. This experiment incorporated 32 x 15cm2 
dishes of confluent 1321N1 cells, resulting in 600mg – 1.2g of total cell protein. 
Cell extracts were generated as described previously (Figures 4.5 - 4.8), but eluted 
from residual cell membranes with 100μM Ins(1,3,4)P3 (500nmol in 5ml). Beyond 
increasing the input of total cell protein, SILAC II addressed the deficits of SILAC 
I by increasing the NaCl concentration for column elution (from 350mM to 
600mM), with final adjustment to 150mM for efficient recovery by immobilised 
lipid. This resulted in a more comprehensive array of proteins being recovered 
from the chromatography columns (data not shown). Furthermore, in addition to 
the retention of the AQ and CS column eluates for analysis, this experiment also 
retained the combined flow-through fraction, from both columns for analysis 
(subsequently referred to as F0 fraction), in contrast to SILAC I. Conceivably 
however, the most pertinent alteration from SILAC I was to decrease the ratio of 
Ins(1,3,4)P3 to biotinylated-PtdIns(3,4)P2 (100nmol per affinity precipitation at 
25μM) used for membrane elution and affinity precipitation, respectively. This 
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should enhance the recovery of lower affinity PtdIns(3,4)P2 binding proteins, as 
well as those which have limited selectivity between the lipid and the soluble 
head-group, whose precipitation by immobilised lipid may have previously been 
adversely affected by the carry through of Ins(1,3,4)P3. 
 
Figures 4.9 illustrates the spectrum of proteins identified in this second, more 
comprehensive SILAC analysis of PtdIns(3,4)P2 interacting proteins. Column 
fractions QA, CS and F0 underwent separate immobilised lipid depletion steps but 
in the MaxQuant analysis the data sets were combined to maximise the number of 
protein identities ultimately obtained. The normalised data are presented with the 
heavy to light ratio of isotope-labelled peptides, identified within candidate 
proteins, on the y-axis and randomly assigned identification numbers on the x-
axis. Figure 4.9 reveals that ~1500 proteins were identified, each with a minimum 
of two peptides. A ratio of enrichment above the median value of 1.0, as before, 
reflects PI 3-kinase-dependent membrane recruitment. A subset of some of the 
most enriched candidate proteins are indicated (arrows A-Ω), selected on the basis 
of ratio of enrichment and number of peptides identified. 
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Figure 4.9  SILAC II – Three-tier affinity purification coupled to 
comprehensive ion exchange chromatography identifies multiple 3-
PI-responsive proteins.  
After labelling and purification the pooled samples yielded ~1500 protein 
identities each requiring a minimum of two unique peptides for inclusion at the 
analysis step. These proteins are presented with arbitrary identification 
numbers plotted against the corresponding heavy:light isotope ratio. Details of 
those indicated (A-Ω), with the most heavily enriched ratios or those with 
defined signalling roles, are provided in table 4.5. 
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Figure 4.9 
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The identities of the indicated proteins from Figure 4.9 (arrows A-Ω) are listed 
in Table 4.5 with additional details relating to each candidate protein. These 
details include the number of peptides identified for each protein, the P.E.P., and 
the presence of any established domain structure where this is not inherent in the 
protein’s name. Similar data for all other identified proteins not indicated within 
Figure 4.9 is available in Supplementary Table 3. Immediately apparent amongst 
the 32 candidates presented within Table 4.5 is the prominence of those proteins 
possessing domains with established lipid binding characteristics such as PH, 
ANTH, ENTH, FYVE, FERM and PX domains, consistent with their purification 
through multiple lipid/head-group-dependent steps. The identification of TAPP-1 
(arrow Y) as the most enriched protein, showing a ratio of enrichment of ~4, 
underlines the success of this modified, more comprehensive SILAC approach. 
Furthermore, the identification of all three isoforms of PKB (arrows F, G and K 
respectively) with significantly enriched ratios (between ~2-4) suggests that any 
proteins which co-purify with similarly enriched ratios represent plausible 
candidates for 3-PI-mediated membrane recruitment. Confirmation of the 
reproducibility of the approach was further provided by the identification; once 
again of SWAP-70 (arrow z), now identified as a candidate 3-PI interacting 
protein on three separate occasions. Significantly, the success of manipulating the 
variables discussed, to increase peptide recovery in the second SILAC experiment 
is highlighted in Table 4.5, most pertinently by SWAP-70, increasing peptide 
number by ~7 fold from SILAC I to achieve more than 200 peptides in this SILAC 
experiment; a sequence coverage of ~80%. 
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Table 4.5 SILAC II – The candidate list of putative PtdIns(3,4)P2 and 
other 3-PI effector proteins. 
The proteins described are those indicated in Figure 4.9 (A-Ω) whose ratio of 
enrichment discriminate them from background proteins. The complete data 
set can be found within Supplementary Table 3. Table headings are as 
described previously but in addition, included here are any relevant protein 
domains within each candidate other than those apparent from the proteins 
name. 
 
 
 
 
 
 
 
 
 
 
 157
Table 4.5 
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These data therefore represent the most comprehensive list of candidate 
PtdIns(3,4)P2 binding proteins identified to date. Furthermore, this approach is the 
first to include within its data sets so many established lipid binding proteins 
isolated under the same enrichment conditions. This predominance of known 3-PI 
interacting proteins lends credibility to the notion that other proteins identified by 
the screen, without previously recognised lipid binding capability, are genuine 
candidates for 3-PI mediated recruitment/regulation, either directly or indirectly. 
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4.3  Discussion. 
Whilst many informatics based, mining approaches or affinity 
chromatography studies have focussed their attention on identifying novel PI 
binding proteins [89,98,174,186,235], little effort has been directed specifically 
towards uncovering novel PtdIns(3,4)P2 effectors. This study aimed to redress this 
by taking a unique approach to enrich and isolate candidate PtdIns(3,4)P2 binding 
proteins. Using the methods described, proteins present at physiologically 
appropriate concentrations were recruited to authentic lipid bilayers and 
subsequently recovered by a combination of selective membrane permeabilisation 
and inositol phosphate effected elution followed by affinity precipitation. This 
approach alone represented a significant advance from the prior use of single step 
affinity purification of proteins from indiscriminate cell or tissue lysates 
[89,174,186,187,235,236]. Furthermore, the coupling of this refined approach to 
sample preparation to SILAC yielded the most sophisticated screen for PI binding 
proteins yet attempted. 
 
In common with previous screens, the preliminary attempts to identify 
novel PtdIns(3,4)P2 binding proteins with a single affinity purifications, described 
in Chapter 3, relied on traditional MS analysis. The difficulty encountered in 
identifying all but the most prominent proteins (SWAP-70 and PARIS-1), 
highlights a significant shortcoming of existing screens. Accepting that traditional 
MS approaches are inherently non-quantitative [203,204,229] then, despite 
complex proteomics and in many cases elegant chemistry, the selection of 
candidate bands, is essentially dependent on rudimentary visual selection 
according to differential SDS-PAGE gel staining patterns [237]. This process is 
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widely open to experimental bias, especially for cases of marginal enrichment and 
in highly complex samples where many proteins may contribute to a single band. 
Furthermore, the selection of stain is also critical, as the relative enrichment in test 
over control samples may be obscured by the linear response range of the chosen 
stain. For instance, a particular caveat with silver staining is that whilst it is 
particularly sensitive to sub-nano gram quantities of protein, within an order of 
magnitude it rapidly loses stain density/protein concentration linearity [237,238]. 
This allows two relatively abundant proteins differing by a factor of 5 fold 
between control and test samples, to appear equivalent. Conversely, in my hands 
at least, colloidal coomassie possess a much greater range of stain linearity from 
approximately 100ug (presumably only limited by the chromatography and 
capacity of the polyacrylamide gel matrix) down to 50ng [239,240]. However, 
despite this range the comparative lack of sensitivity renders it of little use in 
small scale experiments or those limited in size by the cost of reagents. 
 
The quantitative nature of SILAC, however, renders staining redundant as 
a means of comparative selection of potentially enriched bands. Moreover, 
removing the dependence on visual selection may reveal, in analysis, many 
enriched candidate proteins, otherwise obscured by staining patterns or sensitivity 
[241,242]. SILAC does however, benefit from protein staining as a means of 
visualising sample boundaries on polyacrylamide gels. Defining the sample 
boundaries in this manner minimises excess polyacrylamide excised for each gel 
band, increasing the efficiency of subsequent tryptic digestions and reducing 
sample preparation times, and volumes. Furthermore, slicing gel lanes into 
multiple bands according to protein staining allows division for roughly equal 
 161
protein distribution, maximising the depth of subsequent MS analysis. An 
additional caveat to requiring stain in any format is the chemical modifications 
made by these to peptides under certain conditions [237]. For instance, the 
colloidal coomassie stain used here contains methanol and acid, components that 
can cause methylation or esterification of carboxylic acids [243]. Undoubtedly, 
these modifications will adversely affect the identification of peptides, resulting in 
m/z values unmatched to the peptide database and possibly mismatches or a 
reduction in fragment identity scores. The use of recently available MS-
compatible, methanol-free stains would limit these problems. 
 
Another feature, pertinent to this study, which affects the number of 
peptides successfully matched to the observed m/z values in the SILAC analysis, 
is the use of particular isotopes, with the advantages of mixed isotopes recently 
becoming clear. The SILAC method employed here took the commonly used 
approach of substituting (13C) arginine and (13C) lysine into the “heavy” medium 
which results in a 6Da or 12Da shift in peptide masses if one or both isotopes are 
incorporated respectively. The drawback to this experimental design is that it is 
not possible to distinguish whether incorporation of lysine and/or arginine is 
responsible for the increased mass of peptides, confounding the software where 
m/z ratios are not unique. If however, (15N) arginine (4Da shift) and (13C) lysine 
(6Da shift) are used for labelling the “heavy” sample it is easy to imagine how 
data analysis is considerably easier with at least one or multiple residues 
immediately identifiable according to the recorded mass shift. By applying this 
dual labelling format the rapid, first pass binning of SILAC pairs into discrete data 
sets at the analysis stage should significantly increase the m/z values attributable 
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to peptides and subsequently increase the certainty associated with SILAC 
enrichment ratios. 
 
Irrespective of these minor issues associated with increasing peptide 
numbers, the existing strategy provided unequivocal identification of a multitude 
of proteins shown to be enriched in a PI 3-kinase-dependent manner. The 
identification of TAPP-1 as one of the most heavily enriched proteins within the 
second analysis reflects that not only are PI 3-kinase-responsive proteins 
recovered but they include those which selectively bind PtdIns(3,4)P2. The 
identification of all three isoforms of PKB/Akt which have been widely 
demonstrated to interact with both PtdIns(3,4)P2 and PtdIns(3,4,5)P3 also supports 
this conclusion. Furthermore, the pervasiveness of additional proteins also 
reported to interact with PtdIns(3,4)P2 such as SWAP-70, vinculin, OSBP and 
ARAP1, similarly emphasises this view [89,100,101,244]. The occurrence of 
these, together with the wealth of other proteins expressing established lipid 
binding domains such as PH, FYVE, ENTH, and FERM, lend further credibility to 
the view that other proteins listed with currently unreported lipid binding 
characteristics may be potential 3-PI binding/regulated elements.  
 
Whilst a distinct advantage of this screen over its predecessors is the 
quantitative, non-biased output achieved, it is clearly not a practical prospect to 
determine the potential for interaction with 3-PIs for each protein identified with 
an enriched ratio. Thus, there was next a need to focus on a few select candidates 
in more detail. In attempting to reflect the unbiased nature of the screen, whilst 
maximising the possibility of revealing novel and directly recruited/regulated 3-PI 
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interacting proteins, the selection criteria were prioritised as follows; the protein’s 
prominence within each SILAC MS identity list (high ratio and high number of 
peptides isolated), proteins with defined roles in PI 3-kinase-sensitive or related 
pathways, and those with structural/sequence similarities to established lipid 
binding domains. Determining the parameters for structural/sequence homology, 
the third selection criteria, will be dealt with in Chapter 5. However, to qualify for 
inclusion to a limited subset of proteins for cloning, expression and binding 
analysis, candidate proteins required at least two of these features. Proteins which 
fulfilled these criteria include, but are not limited to: EPSIN1, thought to bind 
PtdIns(4,5)P2 and regulate receptor mediated endocytosis; FERMT2, involved in 
connecting the the actin cytoskeleton to the extracellular matrix; PKM2, an 
enzyme which generates ATP from ADP and phosphoenolpyruvate; SOLO 
(ARHGEF40), a little known PH domain containing GEF which may act on Rho 
family of GTPases; FOXK2, a fork-head transcription factor; OSBPL11, a PH 
domain containing protein implicated in lipid transport; YES1, a proto-oncogenic 
protein-tyrosine kinase; ANKFY1, a FYVE domain containing membrane 
anchoring protein; PFN1, thought to mediate the polymerisation of actin and 
purported to be capable of PtdIns(4,5)P2 interaction; PXK, a PX domain 
containing serine/threonine kinase (possibly inactive) which may participate in the 
regulation of synaptic transmission; VCL, an actin binding protein involved in 
cell-cell and cell-matrix adhesion; EIF4G1, a component of the eIF4F complex 
which is involved in regulation of translation; and finally SWAP-70, CLIC1 and 
IQGAP1 (all of which are discussed more thoroughly below). Amongst this 
limited subset, SWAP-70, CLIC1 and IQGAP-1 were selected as primary 
candidates due to their structural features (Chapter 5); in addition to PARIS-1, 
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identified as a consequence of the earlier single affinity purification, and each is 
introduced specifically.  
 
SWAP-70 is a widely studied guanine nucleotide exchange factor (GEF) 
for Rac [245-247], containing a PH domain and has previously been isolated on 
the basis of immobilised 3-PI affinity chromatography [89]. Initially the 
relationship between the interaction of SWAP-70 and 3-PIs, for the activation of 
GEF activity was shown to be selective for PtdIns(3,4,5)P3. In contrast however, a 
subsequent article reported that binding of SWAP-70 can also be achieved by 
PtdIns(3,4)P2 [146]. Thus, SWAP-70 like PKB may bind both lipids, though not 
necessarily with the same functional consequences. As the purpose of this study is 
to identify novel PtdIns(3,4)P2 binding proteins, SWAP-70 will not be considered 
further although its isolation and identification provides good proof of principle 
for the enrichment by this screen of 3-PI interacting proteins beyond TAPP-1 and 
PKB. Therefore, it is a reasonable assumption, that the identification of the PH 
domain containing PARIS-1, enriched within the same samples might indeed 
represent a novel 3-PI interacting protein. PARIS-1 is a little studied Rab 
guanosine triphosphatase (GTP)-activating protein (GAP) whose reduced 
expression has been implicated as a marker for prostate cancer [248]. The 
association of PARIS-1 with, or the regulation of its activity by, 3-PI interaction 
has not previously been determined, despite PARIS-1 (TBC1D2A) and its 
homologue TBC1D2B being the only recognised TBC domain containing proteins 
(35+ in the human proteome) which also have a C-terminal PH domain. 
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CLIC1 (chloride intracellular channel 1) identified within SILAC I, is 
proposed to act as an intracellular chloride channel, although it expression and 
tissue distribution remains uncertain [249]. CLIC1 has been proposed to 
participate in the control of salt secretion/absorption, cell volume homeostasis, the 
regulation of membrane potentials, organellar acidification, apoptosis and the cell 
cycle [250-252]. The biochemical properties of CLIC1 are highly unusual for ion 
channels in that CLIC1 appears capable of existence as a soluble, monomeric, 
cytoplasmic protein or equally as an integral membrane dimer, a morphometric 
change which is proposed to be dependent on pH and/or oxidation [252-254]. The 
protein is similar, structurally, to the GST superfamily with the exception that all 
established GSTs are known to be dimeric [255,256]. However, ITC (isothermal 
calorimetry) data also indicate little or no binding of CLIC1 to glutathione (Kd 
≥10mM) [257]. Although CLIC1 does not possess an established lipid binding 
domain, in keeping with other GST superfamily proteins, it does possess a redox-
sensitive cysteine (Cys 24). This may suggest that CLIC1 can be regulated by 
reactive oxygen species (ROS), which may act to modulate CLIC1 morphology 
and/or cellular localisation. ROS have also been implicated in the regulation of PI 
3-kinase signalling via the oxidation-mediated inhibition of PTP family members 
such as PTEN and 4-phosphatases, a mechanism likely to favour PtdIns(3,4)P2 
accumulation [258,259]. Thus, a scenario could be conceived in which CLIC1 
could be recruited for insertion into particular membranes in a 3-PI dependent 
manner. The characteristics of CLIC1 are considered further in Chapter 5. 
 
Prominent amongst the candidates from the second SILAC experiment but 
also identified within the first (Supplementary Table 1) was the much studied 
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protein IQGAP1, identified with ~160 peptides, a P.E.P. value of zero and a ratio 
of enrichment of ~1.5. IQGAP1 is a large, 190kDa protein which is associated 
with many signalling pathways as a consequence of its numerous protein-protein 
interaction domains [260-264]. It has been suggested that IQGAP1 is responsible 
for regulating pathways required for cytoskeletal organisation such as adhesion 
and migration [261,263,265]. Moreover, IQGAP1 has been proposed as an 
oncogene [264,266] and presents an interesting candidate if it is indeed recruited 
and/or regulated by 3-PIs. Despite the presence of a GAP domain, IQGAP1 
appears to act paradoxically to increase the GTP loading of Rho family GTPases 
such as Cdc42 and Rac1 [267]. The possibility that this enzyme activity of 
IQGAP1 may be modified by 3-PI interaction, such as reverting to classical GAP 
activity, presents an intriguing hypothesis. Furthermore, in support of its inclusion 
for subsequent analysis, although it does not possess a recognised lipid binding 
domain, IQGAP1 has been observed associated with the leading edge of polarised 
cells, a characteristic shared by PI 3-kinase and PtdIns(3,4,5)P3 [263,268].  
 
The selection of these candidate proteins for further analysis is strongly 
supported by their similar co-purification under conditions shown to selectively 
enrich a number of known 3-PI effector proteins. Indeed, the prominence of 
IQGAP1 and CLIC1 within the SILAC lists, representing the most comprehensive 
and the only quantitative attempts to uncover PtdIns(3,4)P2 effector proteins, 
argues persuasively their potential role as PtdIns(3,4)P2-mediated effector 
proteins. This is not, however, to suggest that these lists are all inclusive or that an 
enriched ratio represents proof of lipid binding selectivity or even of direct lipid-
protein interaction. Certainly, the absence of other reported PtdIns(3,4)P2 binding 
 167
proteins such as lamellipodin and DAPP-1 is of significance [99,269]. This may 
be explained by their lack of expression in our system or their failure to 
ionise/yield unique peptides in MS analysis. Equally however, the absence of 
DAPP-1 and lamellipodin may be explained by other experimental factors such as 
the Ins(1,3,4)P3/biotinylated-PtdIns(3,4)P2 concentration ratios or NaCl column 
elution concentration either of which might limit the recovery or enrichment of 
these proteins. Furthermore, despite the optimisation of each step for the recovery 
of TAPP-1, the determining factor for an enriched SILAC ratio is the activation of 
PI 3-kinase, which under the conditions described, favours the selective but not 
exclusive accumulation of PtdIns(3,4)P2. Thus, proteins with a preference other 
than for PtdIns(3,4)P2 can be expected to emerge from this approach. A specific 
example of this may be the increase in PtdIns(3)P following bpV(phen) treatment 
and the subsequent isolation of EEA1 (Table 4.5), a known PtdIns(3)P binding 
protein [270]. 
 
Moreover, the presence of a protein with a positive ratio of enrichment 
does not necessarily indicate direct binding to 3-PI, as recruitment and enrichment 
may be a consequence of interaction with a 3-PI-responsive adaptor protein. It is 
however, worth noting the absence of PTPL1 and MUPP-1 from these lists, both 
considered established partners for the scaffold protein TAPP-1 [124,170]. This 
may be due to factors previously considered such as expression or inability to 
ionise, equally however; their lack of identification may be due to losses of weak 
protein-protein interactions through the multi-step affinity purification. 
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In conclusion this Chapter extends previous studies focussing on 3-PI binding 
partners and presents the first quantitative analysis of proteins capable of binding 
lipids within an intracellular environment. Furthermore, this represents the most 
comprehensive study of proteins capable of interacting with PtdIns(3,4)P2. The 
utility of this approach is exemplified by the definitive identification of established 
PtdIns(3,4)P2 interacting proteins such as TAPP-1, PKB/Akt, SWAP-70, and 
ARAP1. A number of novel candidate proteins whose enrichment is a 
consequence of PI 3-kinase activation are identified and determination of the 
binding characteristics of a limited subset including PARIS-1, CLIC1 and 
IQGAP1 will be addressed Chapter 5. 
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Chapter 5. 
 
 
 
 
 
The Validation of Candidate 3-PI Effector Proteins. 
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5.1 Introduction. 
The previous Chapters have described a screen for 3-PI binding proteins 
and the candidates emerging from it. This Chapter will focus on a subset of these 
proteins selected on the basis of three primary criteria, (i) the protein’s enrichment 
ratio and the number of peptides identified (ii) the potential association of 
candidates with PI 3-kinase signalling pathways and (iii) the potential structural 
and/or sequence homology of candidates to established lipid binding domains. 
This last criterion is further developed; firstly by illustrating how a limited number 
of candidates from the subset, highlighted previously, might fulfil this feature. 
Later, the lipid binding characteristics of those deemed to fulfil this criterion as 
well as other candidates from the wider subset of ~20+ candidate proteins are 
examined. The data presented reveal a novel 3-PI interacting PH domain in one 
candidate protein and propose a new lipid binding motif in another. 
 
5.1.1 Established Lipid Binding Domains (LBDs). 
In order to address the possibility that some of the identified candidate 
proteins, may possess a novel motif for lipid binding, the general features 
conferring lipid binding capability on several established LBDs are considered. 
Some examples of the currently accepted LBDs include PH, PX, FYVE, ENTH, 
FERM, ANTH/CALM, TUBBY, C1/2, PHD, BEACH, GRAM, BAR, Gla and 
Annexin. These domains can be broadly divided into two distinct classes; those 
capable of high selectivity and/or affinity, and those exhibiting low affinity with 
little or no specificity [25]. In the latter instance binding tends to be as a 
consequence of general, physical membrane properties of the membrane such as 
charge, amphiphilicity and/or curvature [271]. This study aims to identify novel, 
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selective PtdIns(3,4)P2 interacting partners and will ignore this latter category of 
non-specific binding domains but focus on examples of the former, notably 
FYVE, PX and PH domains. Whilst this analysis of the properties of LBDs is not 
exhaustive, it is intended to demonstrate that spatial presentation of a minimum 
number of specific residues, rather than the domain superstructure, is crucial to 
lipid binding selectivity and affinity. 
 
5.1.1.1  The FYVE Domain. 
FYVE domains (named for Fab1p, YOTB, Vac1 and EEA1 [272,273]) are 
~60-70 amino acids in size and expressed in 26 human proteins [25]. They are 
almost exclusively involved in binding to PtdIns3P, prevalent in early endosomes 
[270]. Consequently, the majority of FYVE domain proteins are involved in 
endocytic trafficking, endosomal membrane fusion, vesicular transport and 
vacuolar sorting [274]. 
 
FYVE domains have several long loops at the N-terminus, two short double 
stranded antiparallel β sheets and a C-terminal α helix. An exception to this 
structure is the homodimeric EEA1, which possesses two additional α helices, one 
at the N-terminus and one connecting the β3-β4 strands (Figure 5.1) [275]. All 
FYVE domains are, however, distinguished by three highly conserved sequences, 
WxxD, RR/KHHCR and RVC. The conserved basic motif (RR/KHHCR) forms a 
relatively shallow but highly basic binding site for PtdIns3P which is stabilised by 
two Zn2+ ions [120].  
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Figure 5.1 Structural features of phospholipid specific binding 
domains (reproduced with permission from [25]). 
 The C1 domain of protein kinase Cδ (PKCδ) was solved in complex with 
phorbol-1,3-acetate (PDB: 1PTR [276]). The binding pocket, two stabilising Zn2+ 
ions and the hydrophobic loop thought to penetrate the lipid bilayer 
(represented by the shaded blue bar) are labelled. An EEA1 FYVE (Fab1, YOTB, 
Vac1, EEA1) domain dimer is shown, bound to Ins(1,3)P2 (PDBsum; 1JOC [277]) 
with structural Zn2+ ions marked. The central two molecules show two 
pleckstrin homology (PH) domains, one from phospholipase Cδ1 (PLCδ1, upper 
panel, PDBsum: 1MAI [278]) and the other from ARHGAP9 (lower panel, 
PDBsum: 2P0D [279]), both bound to Ins(1,3,4)P3 but showing standard and 
non-standard binding respectively. Similarly the two PX domains shown are 
from p40phox (upper panel, PDB; 1H6H [280]) and p47phox (lower panel, PDBsum: 
1O7K [281]) bound to PtdIns3P, the latter with reported selectivity towards 
PtdIns(3,4)P2 and additionally presenting a secondary binding site for anionic 
lipids [282]. Indicated yellow side chains are those likely to penetrate the 
membrane. 
 
 
 
 
 
 
 
 173
Figure 5.1 
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Figure 5.2 highlights the residues from the RR/KHHCR and RVC motifs in 
EEA1 which form critical hydrogen bonds to the 1- (diester phosphate) and 3-
phosphate of PtdIns3P. Also shown are the hydrogen bonds from the second 
histidine and the WxxD motif which tightly bind the hydroxyl groups of the 
inositol moiety at the 4-, 5- and 6- positions, creating high ligand selectivity [119]. 
An additional characteristic of the FYVE domain is the membrane insertion loop 
(MIL). This protrusion of hydrophobic residues allows the domain to significantly 
penetrate the lipid bilayer [120,270,283] (Figure 5.1). Adjacent to the MIL, at the 
level of the lipid headgroups are basic polar residues capable of non-specific 
electrostatic interactions with PtdSer, PtdOH or PtdIns [26]. In fact it is the strong 
positive potential around the MIL and binding pocket which facilitate initial 
membrane docking [119,270].  
 
These three types of interaction dramatically increase the binding affinity of 
FYVE domains towards target rich membranes compared with short-chain 
PtdIns3P [26,275,284]. The secondary electrostatic and hydrophobic interactions 
[284,285] allow the FYVE domains to achieve low nM affinities despite the 
limited number of phosphate groups for primary, specific recognition [119]. 
Furthermore, the ability of FYVE domains to dimerise (i.e. homodimer formed by 
EEA1) maintains membrane interaction still further by increased avidity 
[275,286]. Lastly, FYVE domain-membrane association has been demonstrated to 
be pH dependent. It has been shown that the neighbouring histidines within the 
RR/KHHCR motif confer greater affinity when positively charged and drive 
membrane release upon deprotonation, sometimes referred to as the histidine 
switch [287]. 
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Figure 5.2 Critical interactions conferring ligand selectivity within 
established LBDs (The Figure is amended from [119]).  
The charged residues which, via hydrogen bonds, confer selectivity towards 
their respective ligands within the indicated binding pockets are illustrated. 
Examples from left to right are EEA1 FYVE domain (PDB; 1JOC [277]), p40phox PX 
domain (PDB; 1H6H [280]) and Grp1 PH domain PDB: 1FGY [288]. In each 
instance the inositol ring is highlighted in blue. 
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Figure 5.2 
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5.1.1.2 The PX Domain. 
The PX domain of ~130 amino acids is present in 35 human proteins [25] 
and named following its identification in two proteins from the NADPH oxidase 
complex (phagocyte oxidase [PhoX]), p40phox and p47phox [289] but is most 
common in sorting nexins (SNX). PX domains are generally selective for 
PtdIns3P [290,291]. A notable exception is the PX domain of p47phox, which is 
selective for PtdIns(3,4)P2 and in addition, is proposed to possess a secondary 
binding site for anionic lipids (Figure 5.1) [292-294]. Most PX domain containing 
proteins are involved in endosomal or protein sorting although other functions 
include cell signalling, and phagocytic defence [293]. 
 
PX domains are typically based on three N-terminal β-strands comprising a 
β-sheet, which is followed by a helical domain of three or four α-helices (Figure 
5.1) [295]. Two of these helices are linked by a polyproline loop which in 
conjunction with the β1-β2 loop forms the basic binding pocket. Additional 
interactions once again include a basic surround to the binding pocket for non-
specific, electrostatic interactions and a loop capable of membrane insertion [296]. 
 
The three motifs required for binding, and which commonly identify PX 
domains, are RRYx2Fx2Lx3L of the β3-α1 loop, Px2PxK of the MIL and RR/Kx2L 
of the α2 helix. Figure 5.2 shows the bonding which confers selectivity for 
PtdIns3P in the PX domain from p40phox with the 1- and 3-phosphate interacting 
with the RRYx2Fx2Lx3L motif. Additional 1-phosphate interaction is provided by 
the MIL Px2PxK motif and hydrogen bonding of the 4- and 5-hydroxyls by 
RR/Kx2L [119,270]. 
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5.1.1.3 The PH domain. 
PH domains were first observed in Pleckstrin (Pleckstrin Homology) and 
later the PH domain of PLCδ1 was the first motif to show specific recognition of a 
phosphoinositide, in this case, PtdIns(4,5)P2 [297-300]. PH domains have now 
been shown to be the most widely expressed domain capable of lipid interaction, 
occurring within 258 human proteins [25]. With the solitary exception of the PX 
domain from p47phox, PtdIns(3,4)P2 and/or PtdIns(3,4,5)P3 appear to be uniquely 
recognised by a subset of PH domains. Examples of such include Btk and Grp-1 
which show selectivity for PtdIns(3,4,5)P3 and, PDK1 and PKB which show dual 
selectivity for PtdIns(3,4,5)P3 and PtdIns(3,4)P2 [83-85,87,134,301-304]. 
 
PH domains are ~125 amino acids in length and characteristically have little 
sequence similarity but possess a highly conserved secondary structure. Each 
contains two opposing β-sheets comprised of three and four strands, and capped at 
one end by an α-helix, often termed a “β-barrel” (Figure 5.1) [119]. The loops 
connecting the β-sheets at the open end create a deep binding pocket with ligand 
specificity determined by the basic residues in these loops. The inositide binding 
site within this sequence is almost always the β1-β2 and β3-β4 loop within the 
domain, the former most critical for binding and characterised by a conserved 
Kxn(K/R)xR motif [305-307]. 
 
Many PH domains are weak and promiscuous binding domains, however 10-
20% exhibit high selectivity with affinities ranging from low nM to low μM 
[305,306]. This is exemplified by a genome wide study of yeast PH domains 
where, of the 33 cloned and expressed, 26 showed little or no PI binding and only 
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one demonstrated high specificity and affinity [308]. An example of a high affinity 
PH domain is provided by Grp-1 and the interactions involved in stabilising the 
inositol headgroup of PtdIns(3,4,5)P3 are shown in Figure 5.2.  
 
In contrast to the other LBDs described here which achieve binding via 
multiple interactions, PH domains rely primarily on head-group recognition 
[119,178,306,309]. The lack of significance of secondary binding features may 
explain the relatively low proportion of high affinity PH domains [305,306,308]. 
Equally this lack of secondary membrane interactions may explain how PH 
domains often show little selectivity between soluble and membrane bound 
ligands. The PH domain of PLC-δ1 is an exemplary case as this binds more 
strongly to Ins(1,4,5)P3 than PtdIns(4,5)P2, generating a negative feedback loop 
upon synthesis of Ins(1,4,5)P3 following PLC-δ1 activation [310,311]. 
 
5.1.1.4 Structural Motifs Present Key Residues. 
The established binding motifs listed above share little sequence or structural 
homology to each other but yet achieve, in many instances, highly selective and 
high affinity binding. In each case the strength and specificity of ligand binding 
are determined by a combination of three types of interaction, (i) head-group 
recognition by basic residues, (ii) membrane insertion of hydrophobic residues and 
(iii) additional electrostatic interactions. These features are essentially determined 
by the special presentation of only a dozen, or less, residues.  
 
The importance of such a minority of residues within domains up to ~150 
amino acids in size is perhaps most elegantly demonstrated by the mutation of a 
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critical arginine residue within the binding pocket of PH domains, which abolishes 
lipid binding capability [134,145]. Furthermore, the functional effect of another 
mutation can be seen in the E17K mutation within the PKB/Akt1 PH domain, 
apparently contributing to tumour development. This amino acid substitution by a 
single nucleotide polymorphism shifts the selectivity of the PH domain in favour 
of PtdIns(4,5)P2 whose higher resting cellular concentration results in the 
constitutive membrane localisation and activation of PKB [312,313]. Moreover, 
an alanine to glycine mutation in the variable loop (β1-β2) region of the C-
terminal TAPP-1 PH domain removes the normal occlusion of the 5-position and 
increases selectivity towards PtdIns(3,4,5)P3. Correspondingly in DAPP-1, the 
reverse substitution increases affinity for PtdIns(3,4)P2 [314]. Indeed, the crystal 
structure of the PKB/Akt PH domain reveals that the 5-phosphate sits in an 
aqueous environment, not influencing binding, perhaps explaining the apparent 
lack of preference demonstrated by PKB/Akt between PtdIns(3,4)P2 and 
PtdIns(3,4,5)P3 [315].  
 
These studies highlight that mutational analysis and crystal structure 
comparisons can determine residues which confer selectivity within established 
LBDs. Nevertheless, the natural variation in sequence, within PH domains at least, 
means that these observations rarely translate into a predictive tool for ligand 
selectivity [102]. Conversely, they do support the hypothesis that the majority of 
the sequence contributing to the structure of a PH domain is purely scaffold, 
merely presenting key residues in a suitable manner, to create a binding pocket.  
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PH domains, however, are identified by bioinformatics tools according to 
their structural homology to the β-barrel scaffold, and not according to a minimum 
number of key residues or their lipid binding characteristics. Despite only a 
minority of these PH domains, identified by their scaffold, presenting key residues 
in the correct spatial orientation to yield high affinity lipid binding capability; a 
notion that PH domains are generic lipid binding modules persists. This perception 
is compounded further by the inherently biased approach of bioinformatics studies 
which often report selectivity/affinity of putative LBD proteins by using unreliable 
or incomplete binding assays. Conversely, affinity based screens which identify 
candidates by non-quantitative MS, by necessity, tend to focus on those proteins 
containing domains of proven ability to bind lipids. The predisposition of these 
approaches toward existing LBDs suggest that it may be plausible, within an 
unbiased approach, to identify domains which present the required residues for 
lipid binding but utilise a different scaffold; akin to the variation in scaffolds for 
known LBDs. The possibility that two candidate proteins (CLIC1 and IQGAP1) 
amongst the wider subset of 20+ proteins that fulfilled the previously described 
criteria, may present residues conferring lipid binding capability, without 
homology to the scaffold of established LBDs will be considered. 
 
5.1.2 The Determination of Lipid Binding Selectivity. 
The unbiased, ratio-metric identification of proteins by SILAC coupled to a 
three-tier affinity purification yielded a multitude of candidate 3-PI binding 
proteins (Chapter 4). It was, however, beyond the scope of this study to 
characterise the lipid binding capability of each. A limited subset of the most 
heavily enriched proteins was therefore selected, on the basis of association with 
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PI 3-kinase-dependent pathways and/or the possession of motifs which share 
general properties with other LBD. Whilst it was the intention that definitive 
experiments to determine lipid binding would be carried out by monitoring 
cellular recruitment/activity, preliminary in vitro binding studies were used 
initially, to qualify any lipid binding characteristics of the expressed recombinant 
proteins and thus minimise time-consuming in vivo analysis of all selected 
candidates.  
 
In selecting an in vitro approach for determining the lipid binding selectivity 
of expressed candidate proteins the caveats associated with working with lipids 
were considered. The principal problem and arguably the source of much 
conflicting data is the method of lipid presentation to the target protein. Accepting 
that it is not possible to reliably replicate authentic lipid bilayers with all of their 
associated physicochemical features such as, lipid composition (PtdIns, PtdSer, 
PtdOH, PtdCho, cholesterol etc.), membrane curvature, protein constituents and 
ionic environment, in vitro assays tend to employ one of two approaches. These 
involve either the use of immobilised lipid/protein approaches or of vesicle based 
assays. Broadly the former can be relatively inexpensive, requiring minimum 
input of reagents and allows high throughput, although very often lipid 
presentation is unknown. The latter has a tendency to require significantly more 
reagents, both lipid and analyte, and demands significant optimisation but can 
provide a more realistic lipid presentation [316-318]. 
 
Isothermal titration calorimetry (ITC) is commonly used to assess binding to 
lipid vesicles. Whilst this approach is considered one of the most accurate and the 
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lipid presentation more closely mimics physiological membranes, it requires 
significant development [318]. Also the approach is not conducive to high 
throughput with each reaction only allowing direct comparison to a control cell, 
with one ligand. Thus, when coupled to the comparatively large reaction chamber, 
this approach is very profligate with both lipids and candidate proteins [318]. An 
alternative approach to ITC for determining binding to vesicles is by using a 
vesicle sedimentation assay. This essentially sediments, via centrifugation, 
vesicles of increased density from a protein-lipid mix. Following centrifugation, 
the proportion of the protein which partitions into the vesicle pellet is determined 
by protein assays. A significant caveat of this approach is the inclusion of any 
precipitated protein within the vesicle pellet. To overcome this, sucrose gradients 
can be used but this introduces additional problems with protein determination of 
dilute fractions within a gradient [318]. Both of these approaches, however, also 
suffer from the stability of the generated vesicles which notoriously have short 
lifetimes, leading to inconsistencies between batches [317]. 
 
Two of the more commonly used immobilised lipid/protein approaches include 
protein-lipid overlay assays (fat blotting) and surface plasmon resonance (SPR). 
These approaches, more amenable to higher throughput, are both used within this 
study to determine the lipid binding selectivity of the candidate proteins identified 
in Chapter 4. The advantages and disadvantages of each technique will be 
introduced below. 
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5.1.2.1 Protein Lipid Overlay Assay. 
One of the most widely used assays to determine lipid binding selectivity is 
the protein-lipid overlay assay or fat blot [316]. This technique involves drying 
varying amounts of potential lipid ligands onto nitrocellulose membranes before 
incubation with a solution of the protein of interest. In the case of the typical GST 
tagged target, protein quantitation is provided by indirect measurement of 
chemiluminescence following anti-GST immunoblotting. Alternatively, the assay 
can be reversed by immobilising the protein and detecting binding to radio-
labelled short chain lipid/head-group but with the intrinsic disadvantages of 
handling radioactive reagents [318]. 
 
The protein-lipid overlay assay is attractive for three reasons, firstly it 
demands little optimisation, with commercial equivalents (PIP strips – Echelon) 
also available. Secondly, it is considerably cheaper than alternative approaches, 
which either extensively use synthetic lipids or require access to expensive 
equipment. Finally, despite its relative simplicity it remains very sensitive to even 
very low affinity binding. However, the approach epitomises the problems 
associated with lipid presentation. The unknown nature of how the lipid molecules 
physically orientate themselves on the nitrocellulose makes determination of the 
effective concentration available for binding difficult to determine. Moreover, the 
varying aqueous solubility of phosphorylated PI derivatives (PtdIns(3,4,5)P3 > 
PtdIns(3,4)P2 / PtdIns(3,5)P2 / PtdIns(4,5)P2 > PtdIns(3)P / PtdIns(4)P / 
PtdIns(5)P) means that following extensive washing, lipid spots of equal starting 
masses can differ significantly [318]. Thus, since monophosphorylated 
phosphoinositides tend to be less hydrophilic and are retained better by the 
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hydrophobic membrane, they often demonstrate disproportionately high protein 
interaction. Furthermore, in my experience at least, approximate affinities derived 
for commonly used probes to their respective ligands appear considerably greater 
than literature values achieved via more sophisticated techniques, implying protein 
denaturation onto the nitrocellulose membrane. These caveats may explain why 
many examples of fat blot-derived binding are reported in the literature but yet, 
these remain unconfirmed by other techniques. 
 
5.1.2.2 Surface Plasmon Resonance. 
Surface plasmon resonance (SPR) is based around an optical sensor which 
measures the changing refractive index of a solution [319]. One application of this 
sensitive technique takes advantage of immobilising tagged lipid onto a surface 
(chip) to measure mass dependent analyte- or protein-binding, reported as 
response units or RU. Another variation allows layering lipid vesicles onto 
hydrophobic chips, prior to measuring analyte binding but this requires greater 
optimisation than the immobilisation approach. The SPR platform allows 
automation and the real time measurements of analyte association and 
dissociation. This measurement of real time interactions is of significant advantage 
in measuring low affinity binding between ligand and analyte. In contrast, other 
approaches which require separation of bound and free ligand/analyte are 
adversely affected by high dissociation rates, making them inappropriate for 
measurement of all but the highest affinity interactions. Furthermore, the 
quantitative nature of the SPR platform allows measurement of ligand association 
and retention between assays, eliminating the varying lipid solubility issues 
associated with fat blots. This study utilises the pseudo-irreversible immobilisation 
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of biotinylated lipid with streptavidin chips resulting in negligible loss of tethered 
lipid to solutions, even over extended periods of washing [320]. Moreover, this 
biotin-avidin presentation of lipid, identically used for the third affinity 
purification step of the three-tier scheme, provided a proven means of lipid 
presentation to the candidate proteins. 
 
Another advantage to this technique is the option, on some platforms such as 
the Biacore 3000, to use the built in micro-fluidics system, to test protein binding 
to several different lipids, in real time, simultaneously [318]. Crucially this 
includes a blank reference cell allowing subtraction of non-specific binding. Also, 
due to the requirement for binding to be within 300nm of the SPR chip surface, 
flow cell volumes are extremely small (≤100nl) allowing sparing use of reagents 
[319]. Disadvantages of the technique include the requirement for expensive 
equipment and disposable reagents, depending on the experimental format. Also 
the assay is not as high throughput as fat blots although it is more reproducible. 
 
5.1.3 Cellular Translocation Studies. 
Following the identification of numerous, candidate 3-PI interacting protein 
from the three-tier affinity-coupled SILAC screens; a limited subset was selected 
on the basis of association with PI 3-kinase dependent signalling pathways and/or 
possession of features consistent with other, established LBDs. However, these 
criteria still yielded 20+ proteins of interest (Table 5.1) which are unlikely to all 
show direct lipid binding. The application of in vitro binding assays, discussed 
previously and exemplified later in this Chapter with the primary candidates 
identified in Chapter 4.3 (PARIS-1, CLIC1 and IQGAP1), is intended to 
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determine those with direct lipid binding potential prior to undertaking cellular 
translocation studies. Although preliminary data is discussed for these in vivo 
binding assays, more comprehensive analysis was limited by the time constraints 
of this study. 
 
However, where in vitro binding studies indicated lipid binding capability, 
one of two approaches was used to ascertain the physiological relevance of such 
lipid binding. Preliminary in vivo approaches included digitonin permeabilisation 
of 1321N1 astrocytoma cells to allow the localisation of candidate proteins to be 
tracked by immunoblotting cytosolic and membrane fractions as described for 
TAPP-1 in Chapter 3. Alternatively, EGFP constructs of the candidate binding 
domain were expressed in mammalian cell lines and their localisation under both 
unstimulated and a variety of stimulated conditions was determined by 
microscopy. 
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 5.2 Results 
  The possibility that a limited number of the candidates identified in Chapter 4 
possessed novel or established structural motifs capable of lipid interaction was 
investigated. Where spatial presentation of key residues, as determined by 
comparative analysis of established LBDs, could be ascertained; candidate 
proteins were cloned and expressed, along with other candidates from the wider 
subset of the most heavily enriched proteins. The lipid binding selectivity of each 
was then determined by in vitro assays. Proteins which demonstrated in vitro lipid 
binding, from either the wider subset or the limited number which showed features 
similar to LBD, were analysed further by preliminary in vivo studies, where time 
allowed. 
 
5.2.1 The Viability of Candidate Proteins: In Silico Data. 
5.2.1.1 Sequence Alignment of Candidate Proteins to Established LBDs. 
The sequence of candidate proteins that emerged from the screen described 
previously was compared with that of PH domains of known lipid binding 
selectivity for 3-PIs. Any similarity of candidate proteins to these PH domains, 
currently the only identified domain consistently capable of PtdIns(3,4)P2 and 
PtdIns(3,4,5)P3 interaction, could propose a potential binding mechanism. 
However, the lack of sequence alignment to PH domains does not necessarily 
preclude lipid binding, as discussed in 5.1.1.3. 
 
The sequences of each of the limited subset of candidate proteins identified 
by SILAC analysis (Chapter 4), were obtained from the Ensembl database 
(October 2009) and imported into the ClustalW alignment software, alongside the 
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sequences for domains whose 3-PI binding selectivity is well established 
[202,321]. Figure 5.3A thus shows a comparative sequence alignment of the 
KxGxn(K/R)xR motifs (highlighted in red) from the β1-β2 loops of the PH 
domains of TAPP1 (C-terminal), TAPP2 (C-terminal), PKB, Grp-1, DAPP1, 
Centaurin-α, and SWAP-70, shown to possess high affinity 3-PI binding, to that of 
the PH domain of the candidate protein, PARIS-1. This comparison is useful as, in 
many PH domains, it is the KxGxn(K/R)xR motif which is responsible for 
forming the majority of phosphate interactions within the binding pocket. The 
critical nature of these residues within a domain otherwise known for sequence 
variability is shown by the high level of conservation between these and other PH 
domains. From Figure 5.3A it can be clearly seen that the PARIS-1 PH domain 
shows remarkable homology to TAPP-1, Grp-1, PKB and SWAP-70 within this 
KxGxn(K/R)xR motif. Interestingly, when comparing PARIS-1 to the sequences 
of TAPP-1, DAPP-1, and Grp-1, and in particular the alanine/glycine residue 
(second amino acid of the β1-β2 variable loop, immediately following the 
conserved glycine), PARIS-1 shows closest homology to DAPP-1 and Grp-1. This 
alanine residue within TAPP-1 occludes the 5-position of inositol ring, hindering 
binding of PtdIns(3,4,5)P3. Importantly, PARIS-1 has a glycine in this position 
which may indicate an ability to bind PtdIns(3,4,5)P3 and/or PtdIns(3,4)P2, similar 
to Grp-1 or DAPP-1, respectively.  
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Figure 5.3 The sequence alignment of the defining motif of PH 
domains to candidate proteins, PARIS-1 and CLIC1.  
(A) The alignment of PARIS-1 PH domain sequence to that of the defining 
KxGxn(K/R)xR motif of PH domains from the proteins indicated. All 
sequences were obtained from Ensembl and aligned using the ClustalW 
software [202,321]. Highly conserved residues implicated in the 
conformation of binding pockets/directly form interaction with 3-PIs are 
highlighted in red. TAPP1 and TAPP2C both relate to their respective C-
terminal PH domains. 
(B) The alignment of CLIC1 to similar PH domain sequences aligned 
 according to their β1-β2 sheet transition. Conserved residues, as 
 previously  indicated in figure 5.3A, are marked in red. The residues 
 which contribute to  the characteristic hydrophobic loop, which forms 
 between β1 and β2 sheets  within PH domains, is marked in blue. A 
 structurally similar loop is seen  within CLIC1 and these residues are 
 similarly indicated. 
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Figure 5.3A 
 
 
 
 
TAPP1                 GYCVKQGAV--MKNWKRRYFQLDEN--TIGYF- 28 
TAPP2C                GYCVKQGNV--RKSWKRRFFALDDF--TICYF- 28 
PKBα                  GWLHKRGEY--IKTWRPRYFLLKNDGTFIGYK- 30 
GRP1                  GWLLKLGGR--VKTWKRRWFILTDN--CLYYF- 28 
DAPP1                 GYLTKQGGL--VKTWKTRWFTLHRN--ELKYF- 28 
CENTAURINALPHA1C      GYMEKTGPK-QTEGFRKRWFTMDDR--RLMYF- 29 
SWAP                  GYMMKKGHR--RKNWTERWFVLKPN--IISYYV 29 
PARIS                 GYLSKFGGKGPIRGWKSRWFFYDERKCQLYYS- 32 
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Figure 5.3B 
 
 
 
 
 
 
DAPP1    ----GTKEGYLTKQGGLVKT---------------------------WKTRWFTL-------HRNELKYFKDQMS---- 37 
GRP1     ----PDREGWLLKLGGRVKT---------------------------WKRRWFIL-------TDNCLYYFEYTTD---- 37 
SWAP     ----VLKQGYMMKKGHRRKN---------------------------WTERWFVL-------KPNIISYYVSEDL---- 37 
TAPP1    ----VIKAGYCVKQGAVMKN---------------------------WKRRYFQL-------DENTIGYFKSELE---- 37 
TAPP2C   ----LIKSGYCVKQGNVRKS---------------------------WKRRFFAL-------DDFTICYFKCEQD---- 37 
DAGK     ----SIKEGQLLKQTSSFQR---------------------------WKKRYFKL--------RGRTLYYAKDSK---- 36 
FAPP1    ------MEGVLYKWTNYLTG---------------------------WQPRWFVL-------DNGILSYYDSQDDV--- 36 
PKBα     ----IVKEGWLHKRGEYIKT---------------------------WRPRYFLL-----KNDGTFIGYKERPQDVD-- 41 
CENTA1C  ----YLKEGYMEKTGPKQTEG--------------------------FRKRWFTM-------DDRRLMYFKDPL----- 37 
PARIS    ----KKLCGYLSKFGGKGPIRG-------------------------WKSRWFFY------DERKCQLYYSRTAQD--- 41 
CLIC1    MAEEQPQVELFVKAGSDGAKIGNCPFSQRLFMVLWLKGVTFNVTTVDTKRRTETVQKLCPGGQLPFLLYGTEVHTD--- 76 
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Figure 5.3B shows a similar sequence alignment for the same array of PH 
domain KxGxn(K/R)xR motifs against the N-terminus of the candidate protein 
CLIC1. According to the hidden Markov model of the bioinformatic tool SMART 
(simple modular architecture research tool [116,117]) CLIC1 does not possess a 
known domain of any kind. However, the alignment, laid out according to the β1 
and β2 sheet structures of the PH domains, demonstrates that CLIC1 possesses the 
characteristic lysine and glycine residues (KxG) conserved in the transition 
between the β1 strand and the variable β1-β2 loop within PH domains. Due to 
structural variation however, the β1-β2 loop of CLIC1 turns into an internal α-
helix and is unlikely to contribute to any ligand binding. Following the internal α-
helix, the secondary structure reverts to a β2 strand which doubles back to 
structurally position itself next to the KxG motif of the β1 strand, presenting the 
KRR motif. A spatially similar loop to that seen in the β1-β2 transition of PH 
domains is then seen in the β2-β3 loop of CLIC1 (residues highlighted in blue). 
This region shares characteristics with PH domain loops in that both are exposed 
and comprise primarily of hydrophobic and/or basic residues. These extended 
loops of hydrophobic and basic residues may contribute to non-specific membrane 
interactions or even constitute a MIL. Thus, CLIC1 may present residues in a 
spatially similar manner to PH domains but use an alternative scaffold, in place of 
the classical β-barrel seen for PH domains. 
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5.2.1.2 Structural Homology of Candidate Proteins to Established LBDs. 
To investigate this hypothesis of alternative scaffolds presenting conserved 
features required for lipid binding, the tertiary structure for fragments of both 
CLIC1 and another candidate protein with little sequence homology to PH 
domains, IQGAP1, was compared to that of the C-terminal TAPP-1 PH domain. 
 
Figure 5.4A shows the crystal structure of the C-terminal TAPP-1 PH 
domain, to develop the concept of spatial presentation of specific residues giving 
rise to a binding pocket. The structure of the C-terminal TAPP-1 PH domain was 
obtained from the Protein Data Bank (PDBsum: 1EAZ) and imported into PyMOL 
software for rendering [314,322,323]. Images were processed by removing the 
ordered citrate ligand that was crystallised within the binding pocket and are 
presented in both structural and space filling formats.  The ribbon structure of 
TAPP-1 illustrates the β-sheets, α-helices and loops which generate the 
superstructure of the PH domain (coloured yellow, red and green respectively). 
Furthermore, the relative positions of the conserved residues, previously indicated 
within Figure 5.3A, which contribute to the binding pocket, are highlighted within 
this structure in blue (GYCVKQGAVMKNWKRRYFQLDENTIGYF). The 
cartoon ribbon model and the space filling model show how the binding pocket 
could accommodate the headgroup of PtdIns(3,4)P2, positioned accordingly to 
allow occlusion of the 5-hydroxyl group by the alanine residues of the β1-β2 loop, 
described previously. The upper panel illustrates the extent to which the 
hydrophobic sequence of the β1-β2 loop (green) must penetrate the membrane to 
achieve headgroup positioning of PtdIns(3,4)P2 within this binding pocket. This 
structural presentation of the C-terminal PH domain of TAPP-1 provides a model 
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for comparing the specific features presented by alternative scaffolds within other 
candidate PtdIns(3,4)P2 binding proteins. 
 
Figure 5.4B similarly focuses on the 27kDa candidate, CLIC1, previously 
identified via SILAC labelled enrichment of potential PtdIns(3,4)P2 interacting 
proteins (Table 4.2). All the images are adapted from the crystal structure of a 
monomer (PDBsum: 1K0o [324]), several of which have been fitted speculatively 
with Ins(1,3,4)P3. Immediately apparent is the departure from the established PH 
domain structure shown previously for TAPP-1. The only structural homology is 
provided by a β-sheet consisting of four β-strands which is only half of the 
traditional β-sandwich seen for PH domain folds. CLIC1 however, also has 
additional α-helices inserted between these β-strands. Despite this lack of 
sequence and structural homology to established LBDs, the residues which are 
capable of conferring lipid binding within PH domains, previously indicated for 
TAPP-1, are presented in a remarkably similar spatial manner. Thus, highlighted 
in blue within Figure 5.4B are K, G, KRR and Y to allow comparison to the 
TAPP-1 PH domain. The magnified section of the upper panel details how, despite 
differences in secondary structure, CLIC1 similarly presents these amino acids. 
The residues are numbered accordingly from the N-terminus to the C-terminus, 
revealing that following the KxG motif (13-15) the structure turns inwardly into 
an α-helix which then returns to the binding pocket via the β2 strand, presenting 
the KRR motif (amino acids 49-51) and the hydrophobic loop in a manner similar 
to PH domains. It is worth noting the small α-helix within the β1-β2 loop, the 
conformation of which may remain removed from the binding pocket or fold over 
to generate greater substrate selectivity. The PH domain of Grp-1 is afforded 
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greater selectivity towards PtdIns(3,4,5)P3 as a consequence of additional 
interactions from a similarly inserted α-helix between the β6-β7 loops. 
Alternatively this feature may contribute to the role of CLIC1 as an ion channel – 
possibly required for function or membrane insertion. Regardless, these data 
indicate that despite significant deviation from the structure of the PH domain 
fold, CLIC1 presents residues deemed critical for lipid binding in a surprisingly 
similar spatial orientation. 
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Figure 5.4  A structural comparison of the C-terminal TAPP-1 PH domain to 
the proposed binding pocket of candidate proteins.  
(A) The crystal structure of the C-terminal PH domain of TAPP-1 (PDB: 1EAZ 
[314]) was modelled in PyMOL and fitted with Ins(1,3,4)P3 in the upper left 
ribbon and lower right space filling models [323]. The left panel ribbon models 
detail the residues, highlighted in blue which comprise the KxGxn(K/R)xR motif. 
The remaining residues are coloured according to the domains secondary 
structure; β-sheets (yellow), α-helices (red) and loops (green). The central space 
filling models give an indication to the binding pocket created by classical β-
barrel of a PH domain. The orientations of all models are indicated in the upper 
right corner. 
(B) The crystal structure of CLIC1 (PDB: 1k0o [257]) was modelled in PyMOL and 
fitted with Ins(1,3,4)P3. The upper left panel and the magnified portion highlight 
in blue, the spatial distribution of residues similarly shown in A which are 
known to be critical for lipid binding within PH domains. Secondary structures 
are coloured as described in A. The space filling models illustrate the potential 
binding pocket. The orientation of each model is indicated by the central panel. 
(C) The crystal structure of C-IQGAP1 (amino acids 1561-1657, PDB: 1X0H [325]) 
was modelled in PyMOL and fitted with PtdIns(1,3,4)P3. The left panel shows the 
ribbon structure in multiple orientations including a magnified section to 
highlight (in blue) the similar spatial distribution of basic residues which are 
crucial in conferring lipid binding capability within established lipid binding 
domains. The ribbon structures also detail a similar structural fold to the β-
sandwich seen for PH domains. The space filling models give an indication of 
the proposed binding pocket both with and without ligand. Secondary 
structures are coloured as previously described in A and orientation of each 
model is illustrated in the upper right panel. 
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Figure 5.4A 
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Figure 5.4B 
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Figure 5.4C 
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Figure 5.4C shows the structural arrangement and space filling model for a 
third candidate protein, IQGAP1, which yielded a positive ratio of enrichment 
from both SILAC studies (Table 4.4 and Supplementary Table 3). All images are 
adapted from a crystal structure available for the extreme C-terminus of IQGAP1 
(PDBsum: 1X0H) [325]. The upper panel of Figure 5.4C shows the tertiary 
structure of the region which relates to amino acids 1561-1657 of IQGAP (1657 
amino acids in total) and its space filling equivalent. Similarly to PH domains, the 
proposed binding pocket is a β-sandwich configuration formed by two opposing β-
sheets of three and four β-strands. The characteristic “barrel” structure of PH 
domains aptly describes the capping of one open end by an α-helix in a near 
parallel orientation to the β-sandwich. In contrast, this structure is capped at the 
base by two shorter α-helices with two further short α-helices forming one side of 
a “modified barrel”, one even contributing to the conformation of the proposed 
binding pocket. All four α-helices are equally spaced and are perpendicular in 
orientation to the β-sandwich. 
 
The central panel of Figure 5.4C shows an alternative “top down” view 
which highlights the potential binding pocket of IQGAP1, hypothetically fitted 
with PtdIns(3,4)P2. In each image, residues highlighted in blue are those which 
surround the proposed binding pocket and are responsible for conferring lipid 
binding capability in established LBDs. The lower inset image indicates these 
residues and demonstrates that the region is rich in lysine and arginine, both basic 
residues which are responsible for headgroup recognition by electrostatic 
interactions in all LBDs. These data propose a potentially novel LBD within 
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IQGAP1, presenting residues known to be critical for ligand binding in established 
LBDs by an alternative scaffold. 
 
These sequence and structural comparisons of fragments from PARIS-1 (PH 
domain), CLIC1 (N-terminal and whole protein respectively) and IQGAP1 (C-
terminal fragment) to PH domains of proven lipid binding compatibility, present a 
persuasive argument that presentation of crucial residues can be achieved by 
scaffolds which differ from that of established LBDs. This assumption was tested 
by determining the selectivity/affinity of these candidates, amongst others, by in 
vitro binding assays.  
 
5.2.2 Cloning and Expression of Candidate proteins. 
Each of the candidate proteins identified and selected on the basis of the 
criteria discussed previously were cloned and expressed as a GST tagged 
recombinant protein. The candidate proteins included: CLIC1, PARIS-1 PH 
domain, IQGAP1 (both N-terminal and C-terminal fragments), PFN, OSBPL11, 
YES1, CRT, KDEL, PKM2, RACK1, EIF4G1, FERMT2, FOXK2, ANKFY1 (N-
terminal fragment), EPSIN1, VCL, SPARC, SERPIN, SOLO (PH domain), 
Annexin A6, PICALM, FKBP9 and PXK. Unfortunately, not all of these could be 
expressed in sufficient quantity/purity to facilitate analysis.  
 
Briefly, the cloning strategy involved isolation of a PCR product and 
ligation into the TOPO II vector prior to sequence confirmation. The successfully 
sequenced constructs were then sub-cloned into pGex-6P-(X) vectors. If blunt 
ligation into TOPO II failed, an alternative strategy involving restriction digestion 
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of the PCR product and direct ligation into pGex-6P-(X) was used. All constructs 
were expressed within, and purified from, E.coli. The resulting GST-column 
purified fractions were analysed for expression level and homogeneity by SDS-
PAGE analysis. Where necessary an expression matrix using 10ml LB cultures 
with variable conditions was used to optimise parameters including effective 
temperature, isopropyl β-D-1-thiogalactopyranoside (IPTG) concentration and 
time-dependent expression. An example of such a matrix, illustrating that for 
expression of two constructs of the PARIS-1 PH domain is shown in Figure 5.5. 
For the PARIS-1 PH domain, two constructs were expressed to reduce the 
possibility of deleterious effects of incomplete or unfolded secondary structure to 
the affinity of the PH domain. The 1-150 construct terminated immediately at the 
end of the reported PH domain structure, the 1-200 construct continued passed the 
next established unit of secondary structure prior to termination. Figure 5.5 shows 
the varying expression of both of these constructs induced by increasing 
concentrations of IPTG at a single temperature over time as indicated. For the 
examples presented, in order to maximise the ratio of protein expression to 
background contaminant proteins, 2 hrs at 37°C and 200µM IPTG were selected 
as the optimum expression conditions for both the PARIS-1 PH domain GST 
constructs. Each candidate, similarly expressed, required at least the level of 
sample purity/homogeneity demonstrated by the conditions for PARIS-1 
expression (2 hrs at 37°C and 200µM IPTG) prior to being considered suitable for 
analysis of lipid binding by in vitro assays. 
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Figure 5.5  The expression of candidate proteins. 
 
Two GST-tagged constructs for PARIS-1 were generated comprising amino 
acids 1-150 and 1-200. The expression profile over 24 hrs at 37°C for both 
constructs is shown in response to varying concentrations of IPTG induced 
expression (0, 50, 100, 200, 400 and 800μM – right to left for each time point). 
Following expression in E. Coli, proteins were recovered from bacterial lysates 
on GST-sepharose with extensive washing and analysed by SDS-PAGE. The 
Figure shows colloidal coomassie stained gels to indicate protein bands. 
Variations on expression conditions were similarly carried out, if required, for 
other candidate proteins. 
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5.2.3 Binding Studies. 
5.2.3.1 Protein-Lipid Overlay Assay for Determining Binding 
Selectivity. 
Preliminary efforts to determine the lipid binding characteristics of 
candidate proteins and positive controls alike, focussed initially on the protein 
lipid overlay assay or fat blot. This experimental approach involved spotting serial 
dilutions of dipalmitoyl PtdIns and its phosphorylated analogues onto 
nitrocellulose membranes, blocking with fatty acid-free BSA and then probing 
with the target protein [316]. Subsequently, membranes were washed extensively 
and any remaining bound protein was recorded by immunoblotting, in these 
examples, with anti-GST antibody. Whilst data for all expressed constructs is not 
presented, the utility of the approach is exemplified by the analysis of the PARIS-
1 PH domain constructs, in comparison to the known lipid binding PH domains, 
TAPP-1 and Grp-1. 
 
Figure 5.6 shows lipid overlay assays demonstrating the established lipid 
binding selectivity of the PH domains of Grp-1 and TAPP-1 (C-terminal) for 
PtdIns(3,4,5)P3 and PtdIns(3,4)P2 respectively, in comparison with similar assays 
to test the lipid binding preferences of the GST-PH domain(s) of PARIS-1. The 
various PI analogues were spotted on the nitrocellulose as indicated, and from left 
to right in a two fold serial dilution in chloroform:methanol:water (1:2:0.8) from 
200 pmol to 3.1pmol. The highest affinity binding demonstrated for Grp-1 and 
TAPP-1 towards PtdIns(3,4,5)P3 and PtdIns(3,4)P2 respectively, agrees well with 
that reported previously [102,316]. It is noticeable, however that the PH domains 
of both Grp-1 and TAPP-1 show a higher than anticipated binding to PtdInsP 
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isomers. This may be accounted for by the recognised tendency of these lipids to 
adhere more persistently than higher phosphorylated PIs to nitrocellulose 
membranes, owing to their comparatively lower aqueous solubility [318].  
 
The data presented in Figure 5.6 for both PARIS-1 PH domain constructs 
indicate that its selectivity favours bis- or tris-phosphorylated PIs, particularly 
PtdIns(3,4,5)P3 and PtdIns(3,4)P2. Although both PARIS-1 constructs present a 
qualitatively similar lipid binding profile, the shorter construct (1-150 amino 
acids) seems to show greater affinity for all PI species. This may be as a 
consequence of the additional sequence beyond the established PH domain motif 
in the larger construct (1-200 amino acids) hindering ligand binding. These data 
reveal the previously unreported lipid binding capability of the PARIS-1 PH 
domain and warrant further investigation of in vivo selectivity and affinity. 
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 Figure 5.6 Lipid binding selectivities as demonstrated by protein-lipid 
overlay assays. 
 
 
 Nitrocellulose membrane were spotted from left to right with dipalmitoyl PIs 
diluted in 1:2:0.8; chloroform:methanol:water as indicated, to give lipid masses 
of 200, 100, 50, 25, 12.5, 6.3, 3.1 pmol. The membranes were then blocked with 
fatty acid free BSA prior to incubation with candidate/established lipid binding 
domains; Grp-1 PH-GST, TAPP-1 PH-GST (C-term), PARIS-1 PH(1-150)-GST and 
PARIS-1 PH(1-200)-GST and  analysed by immunoblotting. The results are 
representative of at least 3 other experiments. 
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Although the results obtained for Grp-1 and TAPP-1 highlight the utility of 
this technique qualitatively to determine the selectivity of high affinity binding 
proteins, attempts to derive more quantitative data for these and other candidate 
proteins yield unrealistic affinities. This is likely to be due to denaturation of 
proteins onto the nitrocellulose membranes once in proximity to the lipid. For 
example, straightforward binding kinetics would dictate that even a high affinity 
binding protein with affinity constant of 109 M-1 should have a half time of 
dissociation ranging from ~1 min -1 hr (30°C and 0°C respectively) [326]. The 
fact that any binding to lipid spotted membranes is reported at all by this method, 
especially following extensive washing, implies largely irreversible binding of the 
protein - presumably to the nitrocellulose - albeit involving initial lipid 
recruitment. 
 
5.2.3.2 Surface Plasmon Resonance (SPR). 
To be able better to assess the lipid binding characteristics of candidate 
proteins, it was evident that a more reliable assay would be required. The solution 
to this problem was provided by the application of SPR, in this study using the 
Biacore 3000 platform. Furthermore, the availability of streptavidin chips 
presented the possibility of immobilising biotinylated lipids in a manner very 
similar to the third step of the affinity purification used to isolate the candidate 
proteins originally. Thus, the presentation of the lipids, though not physiological, 
would at least be consistent and in a fashion proven to be capable of interacting 
with established binding proteins such as TAPP-1, PKB, centaurin-δ (ARAP1) and 
SWAP-70. 
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Figure 5.7 shows some specific examples of SPR sensorgrams for the 
established LBDs (Grp-1, TAPP-1 and PLC-δ PH domains), and for two 
candidates from the subset of proteins originally identified in Chapter 4, IQGAP-1 
(C-terminal fragment) and PARIS-1 PH domain (1-150). These were selected for 
more comprehensive analysis because of their structural homology to established 
LBDs as detailed in 5.2.1 and are presented as exemplary data for the SPR lipid 
binding assay. Panels A-C of Figure 5.7 shows the selectivity of the control 
proteins, Grp-1, TAPP-1 and PLC-δ. These control proteins, of established lipid 
binding capability, each show the expected selectivity towards PtdIns(3,4,5)P3, 
PtdIns(3,4)P2 and PtdIns(4,5)P2 respectively. Subsequent SPR analysis on serial 
dilutions of the TAPP-1 PH domain indicated that the unexpectedly high affinity 
observed towards PtdIns(3,4,5)P3 is not due to saturating concentrations of the 
protein but may genuinely reflect its selectivity under these circumstances (data 
not shown). This supports a previous study which suggested that the selectivity of 
TAPP-1 for PtdIns(3,4)P2 over PtdIns(3,4,5)P3 may not be as high as previously 
reported [327]. 
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Figure 5.7 SPR reveals PtdIns(3,4,5)P3-dependent binding by C-
IQGAP1 and PARIS-1 PH domain. 
 A-D and F. The phosphoinositide binding selectivity of C-IQGAP and PARIS-1 is 
qualitatively similar to Grp-1. GST-tagged constructs of Grp-1 (A), TAPP-1 (B), 
PLC-δ (C), PARIS-1 (D) and C-IQGAP1 (F) all at 50nM except PARIS-1 (1μM) were 
passed over streptavidin (SA) chips without lipids or pre-loaded with equal 
amounts of PtdIns(3,4)P2 (red), PtdIns(4,5)P2 (black) and PtdIns(3,4,5)P3 (green), 
asdetailed in Materials and Methods, and any interactions recorded as SPR 
response units. Experiments are representative of data from a range of 
concentrations and were observed on at least one further occasion. 
 E and G. The concentration dependent binding of IQGAP-1 and PARIS-1 to 
PtdIns(3,4,5)P3. The C-terminal construct of IQGAP1 and the PH domain of 
PARIS-1 (1-150) at the concentrations indicated were passed over SA chips pre-
loaded with PtdIns(3,4,5)P3 in concentrations as indicated. The protein 
concentrations were applied sequentially from low to high. The sensorgrams 
shown are representative of those obtained on at least two separate occasions. 
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Figure 5.7  
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Panels D and F of Figure 5.7 show the selectivity of the PARIS-1 PH 
domain and of a C-terminal construct of IQGAP1 (amino acids 718-1657, 
henceforth C-IQGAP1) respectively. Both candidate proteins show selectivity 
towards PtdIns(3,4,5)P3 in a manner qualitatively similar to that of Grp-1. 
Furthermore, panels E and G show the concentration-dependent binding of 
PARIS-1 and C-IQGAP to PtdIns(3,4,5)P3, an effect not observed for 
PtdIns(3,4)P2 or PtdIns(4,5)P2 (data not shown). Importantly however, the N-
terminal half of IQGAP-1 showed no binding to PtdIns(3,4,5)P3, and analysis of a 
mutant R18G PARIS-1 PH domain GST construct - with a critical arginine residue 
mutated to glycine - abolished the observed binding to PtdIns(3,4,5)P3 seen with 
the PARIS-1 PH domain (data not shown). Whilst these proteins require more 
definitive characterisation by in vivo analysis, the extrapolation of a half maximal 
response for C-IQGAP1 of ~50nM is consistent with a range of affinities 
presented by other 3-PI interacting proteins [178,318]. These data combined with 
the structural homology of PARIS-1 to established lipid binding PH domains and 
the spatial presentation of key residues within C-IQGAP1, argue that both 
candidate proteins represent authentic targets for either regulation or recruitment 
by 3-PIs, particularly PtdIns(3,4,5)P3. 
 
Similar SPR analyses for other recombinant GST-tagged candidate 
proteins from the subset selected previously, including CLIC1 and several 
additional control proteins of established lipid binding affinity, are qualitatively 
interpreted within Table 5.1. The range and magnitude of the interactions between 
candidate proteins and the presented lipid ligands, in conjunction with the lipid 
selectivity demonstrated by control proteins (Grp-1, TAPP-1, PLC-δ, lamellipodin 
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and PKB) presents a convincing argument that test protein interactions are genuine 
and not a consequence of non-specific interaction to the SPR chip surface. 
Interestingly, both lamellipodin and the PKB PH domain demonstrated selectivity 
for PtdIns(3,4,5)P3, instead of the literature reported selectivity of PtdIns(3,4)P2 
and dual PtdIns(3,4,5)P3/PtdIns(3,4)P2 respectively [85,87,99]. This may be a 
consequence of the extended time with which these recombinant proteins have 
been stored and/or undergone freeze-thaw cycles; a feature carefully avoided for 
all candidate proteins expressed solely for the purpose of this study.  
 
Table 5.1 also shows that CLIC1, in contrast to its initial identification 
through 3-PI mediated affinity purification and structural studies showing promise 
for lipid interaction, demonstrated little or no lipid binding capability. Whilst it is  
feasible that its initial enrichment was due to indirect 3-PI interaction, the 
possibility that expression as a tagged, recombinant protein prevented 
conformational changes required for CLIC1 binding, such as its dimerisation, 
remain. Equally, CLIC1 may depend on other physiological features of a bilayer 
for lipid binding, a requirement compatible with its role as a transmembrane ion 
channel. These issues might be addressed by cellular experiments to determine the 
localisation of CLIC1 under a variety of conditions. 
 
  In order for inclusion within Table 5.1 of candidate proteins, qualitative 
assessment of lipid binding required analysis of at least five protein concentrations 
across two orders of magnitude and incorporating at least one concentration 
duplicate (ie 3nM, 10nM, 30nM, 100nM, 100nM, 300nM). Those proteins whose 
lipid binding selectivity is recorded as not determined (ND) within Table 5.1 
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represent proteins for which the data is too limited to meet this requirement or 
where the expressed protein was deemed of insufficient quantity or purity. These 
data, although not conclusive, provide proof of principle that present within the 
candidates identified via the SILAC labelled triple-affinity screen are a number of 
genuine lipid interacting proteins.  
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Table 5.1 SPR reveals novel 3-PI binding proteins. The binding of candidate 
and positive control proteins was assessed qualitatively on the basis of SPR 
analysis. Interactions with PtdIns(3,4)P2, PtdIns(4,5)P2 and PtdIns(3,4,5)P3 are 
indicated as follows: no interaction “-“, limited interaction “+”, concentration 
(analyte) dependent interaction “++”, interaction comparable to Grp1/TAPP-
1/PLC-δ “+++”. (PARIS-1 R18G PH represents a R18G mutation which eliminates 
binding). Typically lipid binding was determined over at least five protein 
concentrations (ranging from 0.1nM to 1μM) across two orders of magnitude 
and incorporated at least one concentration duplicate. Those recorded as not 
determined (ND) represent proteins whose purity or concentration was 
deemed insufficient to permit adequate analysis but which were nevertheless 
cloned and expressed for this purpose. 
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Table 5.1 
PROTEIN \ 
LIPID PtdIns(3,4,5)P3 PtdIns(4,5)P2 PtdIns(3,4)P2 
Grp-1 PH +++ - - 
TAPP-1 PH ++ + +++ 
PLC-δ PH + +++ - 
CLIC1 - - - 
PARIS-1 PH ++ - + 
PARIS-1 R18G PH - - - 
C-IQGAP1 +++ - - 
N-IQGAP1 - - + 
PFN + + + 
OSBPL11 - + + 
YES1 - - - 
CRT - - - 
KDEL - - + 
LAMELLIPODIN ++ - - 
PKB ++ - - 
PKM2 - - - 
RACK1 - - - 
EIF4G1 - - - 
FERMT2 ND ND ND 
FOXK2 ND ND ND 
ANKFY1 ND ND ND 
EPSIN1 ND ND ND 
VCL ND ND ND 
SPARC ND ND ND 
SERPIN ND ND ND 
SOLO ND ND ND 
ANNEXIN A6 ND ND ND 
PICALM ND ND ND 
FBBP9 ND ND ND 
PXK ND ND ND 
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 5.2.4 Cellular Translocation studies. 
 Having identified candidate proteins which demonstrated a 3-PI mediated 
interaction by in vitro analysis; the cellular lipid binding characteristics of 
candidate proteins were investigated, where time allowed. Preliminary 
experiments focussed on tracking the localisation of candidate proteins following 
bpV(phen) treatment of 1321N1 cells, digitonin permeabilisation and Ins(1,3,4)P3 
elution, with membrane fractions subsequently recovered by TX-100. Samples 
from each fraction were then immunoblotted with antibodies against the candidate 
protein. Examples of these immunoblots for tracking the cellular location 
including PARIS-1, CLIC1 and TAPP-1 are shown in Figure 5.8. Whilst untreated 
control samples confirmed that each of these proteins was predominantly cytosolic 
(data not shown), treatment with bpV(phen) resulted in the recovery of a 
proportion of each in the final membrane fraction, consistent with their initial 
enrichment and identification in Chapter 4. Indeed, similarly to TAPP-1, 
preliminary experiments showed that CLIC1 could then be in part recovered from 
membranes by elution with Ins(1,3,4)P3. However, efforts to repeat these data for 
CLIC1 were confounded by the inability to record its localisation in any fraction, 
other than cytosol. Despite this, the initial identification of CLIC1 with an 
enriched SILAC ratio, the preliminary data within Figure 5.8 and the structural 
model proposing a potentially appropriate binding pocket, all indicate that further 
work to examine the potential binding characteristics and/or conditions of CLIC1 
is warranted.  
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 Figure 5.8  The cellular translocation of candidate proteins.  
 
 
 
 Cell fractions from bpV(phen) treated 1321N1 cells were permeabilised with 
consecutive 10 min digitonin washes (D1 and D2) followed by wash buffer for 
30min at 4°C ±50μM Ins(1,3,4)P3 elution (W±IP3) and finally residual membrane 
fractions (M) were recovered by TX-100. Fractions were then analysed by SDS-
PAGE and immunoblotted for TAPP-1, PARIS-1 and CLIC1. Lanes marked X 
represent marker lanes. Experiments are representative of an n=1 for CLIC1 but 
PARIS1 and TAPP-1 data are representative of data obtained on at least two 
further occasions. 
 
 
 
 
 
 219
In contrast, PARIS-1 reproducibly demonstrated membrane translocation, to a 
limited extent, following treatment with bpV(phen). However, Ins(1,3,4)P3 elution 
from these bpV(phen) treated, digitonin permeabilised membranes, as reflected in 
Figure 5.8 appeared to recover little or no PARIS-1. Despite this lack of  
Ins(1,3,4)P3 elution the membrane translocation shown in Figure 5.8, coupled to 
the initial wortmannin dependent MS identification (Figure 4.3) is consistent with 
a 3-PI mediated interaction. Indeed, the demonstrated selectivity of PARIS-1 for 
PtdIns(3,4,5)P3 by the in vitro lipid binding assays would suggest it may be 
prudent to repeat these translocation experiments. Ideally, these would use both; a 
ligand known to stimulate an increase in PtdIns(3,4,5)P3 concentrations, such as 
PDGF/EGF; and an Ins(1,3,4,5)P4 elute with which to recover PARIS-1 from the 
stimulated, permeabilised cells. In an attempt to address this requirement, an 
EGFP PARIS-1 PH domain fusion protein (amino acids 1-150 construct) was 
expressed in HeLa cells, to allow comparison between the effects of PDGF and 
bpV(phen) treatment on the translocation of this construct. Unfortunately, the 
subsequent analysis by immunofluorescence microscopy revealed a predominantly 
cytosolic localisation, regardless of stimuli (data not shown). These data may, 
however, be compromised by the level of over-expression of the construct, 
masking the ~10-20% of PARIS-1 driven to membrane following bpV(phen) 
treatment as reported by the biochemical data, such as that in Figure 5.8.  
 
Similar, immunoblotting experiments to those described within Figure 5.8 but 
measuring the localisation of IQGAP1 in 1321N1 cells found that ~50% was 
membrane bound under basal conditions and this was not increased by bpV(phen) 
treatment (data not shown). The ability of an Ins(1,3,4)P3 elution step to diminish 
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this proportion of IQGAP1 retained on the membrane remains untested, however, 
data presented for the in vitro selectivity (Figure 5.7) would suggest that, similarly 
to PARIS-1, this would be better undertaken with PDGF/EGF stimulation, and 
elution with Ins(1,3,4,5)P4. 
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5.3 Discussion. 
Whilst bioinformatics and affinity chromatography approaches have been 
successfully used previously to identify 3-PI effector proteins [89,98,102,174], 
both approaches have their drawbacks. Bioinformatics approaches have a bias 
derived from their reliance on established LBD structures to predict new, similar 
LBD. Affinity chromatography approaches, often rely on domain features 
previously identified by bioinformatics, to select proteins of interest from a large 
data set, thereby eliminating the possibility of identifying novel LBDs. This study 
aims to take advantage of one of the significant features of SILAC labelling – that 
of unbiased identification on the basis of quantitative enrichment – in an attempt 
to identify novel PtdIns(3,4)P2 and other 3-PI interacting proteins, irrespective of 
modular domains. Furthermore, this chapter questions the perceived dependence 
on a limited number of binding domains for protein-lipid interaction and presents 
a sensitive, automated assay by which to reliably characterise the lipid binding 
selectivity of the many candidate proteins emerging from the SILAC based screen. 
 
Despite the focus they receive, PH domains or even the structural features 
which define them do not have a monopoly on lipid binding. One defining feature 
of PH domains is their conserved secondary structure of the familiar β-sandwich 
comprising seven β-strands in a “barrel” formation. This scaffold is seen in many 
similar motifs belonging to the larger PTB/PH family of proteins include the PTB, 
PDZ and FERM domains, capable of interacting with a wide range of ligands 
[120]. The evolutionary persistence of this structure presents a compelling 
argument that it is merely an amenable scaffold for creating a ligand binding 
pocket and that the superstructure of the domain provides little indication of ligand 
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specificity. Equally, the existence of other structural motifs which share little or no 
homology but are capable of interaction with identical ligands supports the 
hypothesis that domains are merely a structural scaffold within which to present 
key residues. This is best exemplified by the FYVE and PX domains whose 
sequence and structure are distinct from each other but examples of which 
recognise an identical ligand, PtdIns3P, with high selectivity [25,119-121]. 
 
 Perhaps however, the most pertinent demonstration that requirement of a 
conserved structural scaffold is not required for preferential lipid binding is 
provided by the significant number of proteins capable of highly selective lipid 
recognition, that possess no obviously conserved domain homology. Examples of 
these include; class I PI 3-kinases, capable of selective recognition of 
PtdIns(4,5)P2 [328-330]; PTEN, proposed to have a PtdIns(4,5)P2 binding site, but 
also capable of specifically recognising its substrate, PtdIns(3,4,5)P3 [331-334]; 
the Ins(1,4,5)P3 receptor, for selective recognition of Ins(1,4,5)P3 [27,32]; and 
Ins(1,4,5)P3 3-kinase, equally capable of substrate recognition for the synthesis of 
Ins(1,3,4,5)P4 [35]. That this large number of proteins is capable of recognising 
PIs or their corresponding inositol phosphate head-group in the absence of a 
recognised LBD implies that the list of binding domains may not yet be complete, 
or that conserved structures are not always required. This view in conjunction with 
the evidence that PtdIns(3,4)P2 may act as an independent lipid signal, prompts the 
need for further, unbiased studies such as this to seek additional, potential 3-PI 
effector proteins. 
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Having identified candidate 3-PI interacting proteins through a multi-tiered 
affinity purification approach, the lipid binding capability of these candidates was 
then assessed primarily by an SPR based assay. The significant advantage that this 
approach offers is measurement of real time association/dissociation of ligand-
analyte complexes; particularly relevant when analysing low affinity binding. 
Whilst this is by no means the first application of SPR technology to addressing 
the lipid binding capability of candidate proteins, most other studies utilising SPR 
do so by layering lipid vesicles onto hydrophobic chips [317,318]. Whilst this, 
undoubtedly presents the lipid in a more appropriate physiological form, the 
avidin-biotin presentation used within this study is consistent with the initial 
method of candidate purification. Furthermore, the effectiveness of this manner of 
lipid presentation is validated by the identity of numerous proteins from the 
SILAC screens with established lipid binding capability, such as TAPP-1, PKB, 
SWAP-70, ARAP1 and EEA1. In addition, this immobilised lipid approach 
benefits from greater reproducibility due to the more simplistic nature of the 
ligand presentation. Lastly, the shorter chain, water soluble biotinylated-lipids are 
more amenable to buffered long term storage than the equivalent longer chain 
lipids used for vesicle generation. 
 
One limitation, however, of the current SPR assay format is the need to 
extrapolate kinetic data based on approximations of the protein concentration at 
which half maximal binding is achieved. Although this is accepted as a suitable 
means of determining lipid-protein interaction in SPR studies [309,318], there are 
several factors which undoubtedly complicate any kinetic data derived from this 
assay. Firstly, the extent to which the GST-fusion proteins used within these 
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studies dimerise, which could contribute to a low off-rate, remains unclear 
[318,335]. Secondly, the presentation of the biotinylated lipid on the streptavidin 
chip, although consistent with the method of isolation, presents pure ligand in 
contrast to the mixed nature of lipids in a cell membrane, possibly contributing to 
artificially low off-rates. Finally, a feature intrinsic of the technology is limitation 
by the effects of mass transport, which irrespective of the analyte’s affinity, limits 
the recorded on-rate to the flow rate and concentration by which the analyte can be 
delivered to the chip surface [319]. Regardless of these caveats, the SPR approach 
described in this study offers significant advantages over alternative in vitro 
approaches and presents a viable assay for determining lipid selectivity. This is 
demonstrated by the selectivity shown for domains of known lipid binding 
selectivity, including TAPP-1, Grp-1 and PLC-δ PH domains and candidate 
proteins of unknown selectivity alike. 
 
PARIS-1, one of the primary candidates isolated in a PI 3-kinase-
dependent manner, demonstrates a selective and concentration-dependent increase 
in the binding towards PtdIns(3,4,5)P3. Indeed, the capacity of PARIS-1 PH 
domain to bind lipid was further supported by data generated from fat blots. 
Significantly, the observed lipid binding of PARIS-1 PH was abolished following 
mutation of the crucial arginine residue within the binding pocket (R18G). These 
binding data are consistent with the sequence alignments of PARIS-1 PH domain, 
suggesting homology with that of DAPP-1 and Grp-1.   
 
In comparison to the analysis of the Grp-1 PH domain, however, PARIS-1 
recorded smaller SPR response units for equivalent protein concentrations. Whilst 
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the magnitude of these responses does represent the mass of analyte bound to the 
chip surface and is suggestive of a lower affinity binding interaction than Grp-1, 
care must be taken when making comparative statements regarding affinity. 
Although protein concentrations were determined for each expressed protein, the 
effective concentration of protein, such as that correctly folded, may be markedly 
less. Furthermore, a significant component of the protein concentration may be 
from contaminant proteins or breakdown as a consequence of storage, giving an 
artificially high concentration. Alternatively, PARIS-1 may genuinely be of lesser 
affinity, possess distinct kinetics or require post translational modification (PTM) 
for full binding capability. Nonetheless, the functional relevance of PARIS-1 
affinity is supported by both the initial purification of PARIS-1 from 3-PI enriched 
membranes and the, albeit limited, in vivo data which suggests that under certain 
conditions a proportion can be driven to cell membranes. Alternatively, the 
concept of PARIS-1 as a low affinity PtdIns(3,4,5)P3 binding protein does not 
diminish the significance of its interaction.  Whilst a low affinity, may not be 
sufficient to facilitate membrane recruitment in isolation, PtdIns(3,4,5)P3 
interaction may be required for regulation of enzymatic activity. Determining the 
effect of PtdIns(3,4,5)P3 binding on the RabGAP activity of PARIS-1 is a current 
priority of continuing work on this protein. 
 
A further primary candidate, identified with an enriched ratio in the initial 
SILAC experiment was CLIC1. In support of this PI 3-kinase-dependent 
enrichment, structural studies suggested that CLIC1 possesses a previously 
unrecognised motif presenting amino acids crucial for lipid binding in a 
remarkably similar spatial orientation to established LBDs. The role that CLIC1 
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seems to play as a ligand-responsive chloride channel capable of membrane 
insertion and the implication of its role in the oxidative damage associated with 
Alzheimer’s disease identifies it as an intriguing candidate protein 
[250,252,253,255]. It has been shown that following treatment of microglial cells 
with β-amyloid and subsequent NADPH oxidase activation, CLIC1 translocates to 
and inserts into the membrane allowing flux of chloride ions [252]. Furthermore a 
separate study indirectly proposed a mechanism of activation via PI 3-kinases by 
showing PKB activation following treatment with β-amyloid peptide [336]. These 
data could be taken to suggest that PI 3-kinase activation may recruit and/or 
activate the NADPH oxidase complex via the p47phox PX domain whose 
interaction with PtdIns(3,4)P2 is established [282]. CLIC1 may then require 
coincidence detection of ROS and PtdIns(3,4)P2 for membrane insertion and ion 
channel activation. However, in vitro lipid binding analysis by SPR did not uphold 
this hypothesis, with little or no interaction to PtdIns(4,5)P2, PtdIns(3,4)P2 or 
PtdIns(3,4,5)P3. Conversely, initial in vivo studies suggested bpV(phen)-dependent 
membrane recruitment and subsequent elution by Ins(1,3,4)P3, although this result 
could not be reproduced. The ability of CLIC1 to bind lipids under varying 
conditions such as pH; increasing concentrations of divalent cations, particularly 
Mg2+; and the presence of peroxide; which may more closely mimic conditions 
resulting in CLIC1 membrane insertion within glial cells, are features which can 
be readily addressed in the future. 
 
The final primary candidate selected from the limited subset from Chapter 
4 and highlighted within this Chapter, IQGAP-1 was similarly identified by an 
enriched SILAC ratio following 3-PI mediated membrane recruitment and 
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recovery. Structural studies revealed a C-terminal motif of unknown function that, 
despite fundamental differences to established LBD domains presented key 
residues for lipid binding in an analogous manner. Furthermore, in vitro lipid 
binding assays confirmed that an expressed C-terminal fragment of IQGAP1, of 
which the proposed motif is a component, demonstrated high selectivity and 
affinity towards PtdIns(3,4,5)P3 comparable to that observed for the Grp-1 PH 
domain. Sequence homology searches of the putative, C-terminal lipid binding 
motif within IQGAP1 shows conservation among the other family members, 
IQGAP2 and IQGAP3. An assessment of any potential lipid binding associated 
with these proteins may determine if the motif identified within IQGAP1 
represents a conserved novel lipid interacting domain or purely another example 
of a lipid recognition motif such as those described earlier for PTEN and the 
catalytic site of PI 3-kinases. Regardless, the interaction of IQGAP1 with 
PtdIns(3,4,5)P3 proposes a novel mechanism of activation or regulation of the 
multitude of signalling pathways in which IQGAP-1 participates. Contrary to the 
presence of a GAP domain, IQGAP1 appears to act to maintain the active GTP 
bound state of Rac1 and Cdc42 [264,266,337]. This raises the intriguing question 
as to the effects of PtdIns(3,4,5)P3 binding on the GAP activity of IQGAP1. 
Similarly to the hypothesis presented for PARIS-1, it may be that lipid binding is a 
mechanism for regulating IQGAP1 enzymatic activity, such as switching GAP 
activity on in the presence of PtdIns(3,4,5)P3. Lastly, it may be of significance that 
this protein also possesses a calcium regulated calmodulin domain presenting the 
possibility that endogenously IQGAP1 is not regulated by PtdIns(3,4,5)P3 but 
rather functions as a dual detector for calcium/Ins(1,3,4,5)P4. 
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In conclusion, this Chapter assesses the lipid binding selectivity of a subset 
of candidates identified following a SILAC-coupled three-step affinity purification 
approach, and in particular focuses on PARIS-1, CLIC1 and IQGAP1. Firstly, this 
Chapter establishes that each possesses features consistent with lipid binding 
capability, despite only one of their number, PARIS-1, containing a currently 
recognised LBD. The identification of PARIS-1 and IQGAP1 proposes two 
previously unreported PtdIns(3,4,5)P3 binding proteins and, in the case of 
IQGAP1, a  potentially novel lipid interacting domain. The characterisation of the 
affinity and the functional consequences of IQGAP1 and PARIS-1 interaction 
with PtdIns(3,4,5)P3 requires additional work. The possibility that both may have 
their GAP activity regulated by PtdIns(3,4,5)P3 binding is an intriguing and readily 
testable hypothesis, assuming that a suitable small G protein, similar to Rac1 for 
IQGAP1, can be identified for PARIS-1- as currently this is unreported.   
 
The identification of such a repertoire of established lipid binding protein from the 
three-tier affinity approach detailed in Chapter 4, including; AKT1, AKT2, AKT3, 
TAPP-1, SWAP-70, EEA1, OSBP, EPSIN1 and ARAP1 highlights the power and 
the utility of this approach. Importantly, the isolation of PARIS-1 and IQGAP1, 
and their identification as novel 3-PI interacting proteins strongly justifies the 
application of SILAC to a multi-step affinity purification technique to yield novel 
3-PI interacting proteins. 
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6.  General Discussion. 
6.1 Introduction 
 This thesis attempts to identify novel lipid interacting proteins with the aim 
of gaining a more comprehensive and clear view of PI 3-kinase signalling. Lipids 
have long been considered more than merely structural components of 
membranes, with their tightly regulated metabolism implicated in multifarious cell 
processes. Of particular significance are 3-phosphoinositides, due to the 
disproportionately important role they play in both normal and aberrant cell 
signalling pathways. Much focus has been directed at PtdIns(3,4,5)P3, the primary 
product of class I PI 3-kinase activation [38,327,338,339]. However, in contrast 
little attention has been directed at PtdIns(3,4)P2; a lipid whose synthesis from 
PtdIns(3,4,5)P3 is tightly regulated by the 5-phosphatases and of which SHIP2, 
proposed as a therapeutic target for type II diabetes, is prominent [41].    
 
Existing studies have had a tendency to focus on candidate lipid binding 
proteins expressing established LBDs [89,98,102,174]. This bias is either by 
design, as with bioinformatics screens, or applied indirectly as is the case with 
affinity purifications approaches, which often select from large data sets those 
candidates with domains of previously demonstrated lipid binding capability. This 
bias is undoubtedly a consequence of the combined shortcomings of single affinity 
precipitations and non-quantitative MS, which provide a very limited basis on 
which to discriminate authentically responsive proteins from non-specific, 
background binding proteins. This study aims to avoid these limitations and 
address the lack of attention received previously by PtdIns(3,4)P2, by optimising 
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an unbiased, multiple-affinity based methodology founded on the primary 
recruitment of PtdIns(3,4)P2 binding proteins in an authentic cellular environment. 
 
6.2  The Optimisation of Three Affinity Purification Steps for the 
 Identification of Novel 3-PI Interacting Proteins. 
 This approach utilises a unique, three-tier affinity purification approach in 
contrast to preceding studies which predominantly employ a single affinity step 
based on immobilised, synthetic lipid-coupled matrices to recover proteins from 
indiscriminate, mixed cell or tissue lysates. The first of the enrichment steps 
within this scheme takes advantage of the pharmacological inhibition of PTP-like 
phosphatases to constitutively activate class IA PI 3-kinases; increase the specific 
activity of the prominent 5-phosphatase, SHIP2; and inhibit the action of the 4-
phosphatases [41]. The effect of these concerted actions is to favour the dramatic, 
but not exclusive, accumulation of PtdIns(3,4)P2. The consequence of which is to 
allow recruitment to the membrane, of proteins capable of interacting with 
PtdIns(3,4)P2. Subsequently, the digitonin permeabilisation of cells is then used to 
allow retention of these recruited proteins but removal of the bulk of background 
cytosolic contaminants. Crucially, this primary purification step offers a 
significant advantage over existing screens as proteins are present at physiological 
concentrations and are recruited to genuine lipid bilayers with all the additional 
physicochemical features associated with authentic cell membranes. Many of 
these features, such as background lipid composition, membrane curvature, 
protein content and the ionic environment are all important contributors to 
effector-protein membrane association/affinity [25,119,318], but are notoriously 
difficult to replicate in vitro. The efficiency of this membrane recruitment and of 
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the subsequent, additional two affinity enrichment steps, including the isomer-
specific elution with a propitious concentration of the water-soluble head-group, 
Ins(1,3,4)P3, was developed by monitoring the recovery of the archetypal 
PtdIns(3,4)P2 binding protein TAPP-1, at each stage. Interestingly, the 
requirement for a 100-1000 excess mass of eluting Ins(1,3,4)P3 over that of the 
estimated cellular PtdIns(3,4)P2 to recover the majority of TAPP-1 may indicate 
the true selectivity of this protein for the lipid target presented in the context of a 
cellular membrane. The power of additional purification steps; both the 
Ins(1,3,4)P3 elution and the biotinylated-PtdIns(3,4)P2 precipitation was 
highlighted by the ultimate yield of multiple wortmannin-sensitive bands visible 
following SDS-PAGE analysis. 
 
6.3 A SILAC-Coupled, Multi-tier Affinity Purification Scheme. 
The integration of these individual strategies resulted in an approach more 
successful than each in isolation, revealing >10 protein bands either absent in 
control samples or significantly enriched in a PI 3-kinase-sensitive manner. Two 
of these enriched bands were isolated in sufficient quantity and purity, even in less 
refined samples, to be identifiable by MS. Their analysis revealed SWAP-70, an 
established 3-PI interacting protein [89,146], and the little studied, PH domain-
containing PARIS-1 [232]. Whilst traditional MS techniques had been adequate 
for the identification of these relatively abundant candidates, the identities of those 
protein bands of more limited enrichment or of lesser abundance remained 
enigmatic. This difficulty in assigning candidate band identity highlights a 
limitation associated with non-quatitative MS analysis of complex samples – 
which is that this often generates a large number of protein matches, each with low 
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confidence. In order to facilitate the identification of a broader spectrum of the 
proteins that could be isolated by the three-tier affinity purification scheme, the 
differential metabolic labelling offered by SILAC was incorporated into the 
protocol. The rationale for this was that the quantitative ratio-metric output 
afforded by SILAC would reveal genuinely PI 3-kinase-responsive candidates 
with higher confidence and better discriminate these from background, 
contaminating proteins. 
 
 Indeed, the combined SILAC multi-step affinity purification process allowed 
the unequivocal MS identification of a number of proteins, recovered as a 
consequence of primary cellular PI 3-kinase activation, that were distinguishable 
from a multitude of co-purifying background proteins by their enriched isotopic 
profile. The identification of TAPP-1 as one of the most heavily enriched proteins 
confirms that this multi-affinity purification format can reveal not only PI 3-
kinase-responsive proteins but also those which preferentially favour 
PtdIns(3,4)P2. Equally, the identification of other proteins within these samples 
including all three isoforms of PKB, ARAP1 (centaurin-δ) and SWAP-70, each 
demonstrated to be capable of binding PtdIns(3,4)P2 [85,87,89,100,146], further 
supports this view. The prominence of TAPP-1 and other known PtdIns(3,4)P2 
binding proteins within these lists therefore presents a compelling case that this 
experimental design can isolate novel candidates that possess similar 3-PI binding 
characteristics. The importance of the combined approach for purifying samples 
and distinguishing genuine 3-PI binding proteins is underlined by the observation 
that when the secondary affinity steps were omitted, markedly fewer established 
3-PI interacting proteins yielded enriched SILAC ratios (data not presented). 
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 This is not to assume that the lists of candidate proteins yielded from the 
three-tier affinity SILAC procedure represent the complete repertoire of 
PtdIns(3,4)P2 binding proteins. Indeed, two proteins notable by their absence are 
lamellipodin and DAPP-1, reported to possess PtdIns(3,4)P2 and dual 
PtdIns(3,4)P2/PtdIns(3,4,5)P3 selectivity, respectively [99,138]. Interestingly, 
analysis of lamellipodin by in vitro binding assays within this study, revealed an 
apparent selectivity for PtdIns(3,4,5)P3. However, the absence of DAPP-1 and 
lamellipodin from the SILAC lists also may be readily explained either by their 
lack of expression in our system or by their inability to ionise or yield sufficient 
and/or unique peptides during MS/MS analysis. Furthermore, it is a distinct 
possibility that the SILAC lists incorporate proteins reflecting enriched ratios due 
to their indirect recruitment to membranes, possibly through adaptor proteins such 
as TAPP-1. Lastly, since the primary factor for SILAC enrichment is the 
activation of PI 3-kinase rather than the increased cellular accumulation of 
PtdIns(3,4)P2 exclusively, enriched ratios for proteins with other 3-PI selectivities 
can be expected. This may explain the presence of EEA1 [25,340], ARAP1 [100] 
and SWAP-70 [89] within the SILAC lists, which are thought to interact 
preferentially with PtdIns3P and PtdIns(3,4,5)P3 respectively . 
 
6.4 The Validation of Candidate 3-PI Interacting Proteins. 
The utility of the screen to identify novel 3-PI interacting proteins was tested 
by selecting a subset of some of the most promising candidates from those 
identified. The selection was achieved on the basis of (i) an enriched SILAC ratio, 
achieved in conjunction with the contribution to a given protein identity of at least 
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2 unique peptides, (ii) the association with PI 3-kinase related pathways or, (iii) 
the presentation of features compatible with lipid binding capability, although not 
necessarily expressed as an established LBD. The latter condition was determined 
by establishing conserved characteristics across a range of LBDs including C1, 
C2, FYVE, PX, ENTH, FERM and PH. The application of these three criteria 
resulted in the selection of a limited subset of candidate proteins (~20) from 
amongst >1500 protein identities. Furthermore, the third criterion revealed three 
primary candidates from within the subset of ~20 proteins, PARIS-1, CLIC1 and 
IQGAP-1, which were selected particularly as the focus for further study.  
 
IQGAP1 and CLIC1 among these primary candidates appeared to possess 
domains of either uncharacterised or of unknown function, which exhibit 
remarkably similar characteristics to those crucial to binding pockets within 
established LBDs, yet exhibit little homology to the scaffold of these domains. 
IQGAP1 and CLIC1 therefore presented the opportunity to test the hypothesis that 
it is not the superstructure of the domain/motif which is significant, but rather the 
spatial presentation of key residues within this which determines the lipid 
selectivity/affinity. This notion is elegantly supported by the convergent evolution 
seen for PX and FYVE domain recognition of PtdIns3P. In addition, the PH 
domain-containing candidate PARIS-1, demonstrated sequence homology to PH 
domains of recognised 3-PI affinity and notably to that of Grp-1 and DAPP-1, 
particularly with respect to a glycine residue in the β1-β2 variable loop. In a 
analogous position, TAPP-1 has an alanine residue which occludes the 5-
phosphate of the inositol head-group, a feature which has been suggested to 
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explain the reported selectivity of TAPP-1 for PtdIns(3,4)P2 over PtdIns(3,4,5)P3 
[314].  
 
The lipid binding capability of the primary candidates PARIS-1, CLIC1 and 
IQGAP1, as well as those from the wider subset which fulfilled the requirements 
previously described were determined by an in vitro SPR based assay. The 
advantages of this assay include; real-time association/dissociation; automation; 
ease of handling, afforded by the use of short-chain lipids as ligands and perhaps 
crucially, highly reproducible data sets. These features should make this approach 
particularly attractive to non-specialist labs that often, by necessity, use the 
accessible but flawed fat blotting approach, and allow for more reliable 
conclusions on lipid binding/selectivity to be drawn. The utility of the SPR screen 
was demonstrated by the selectivities observed for Grp-1 , TAPP-1  and PLC-δ PH 
domains towards PtdIns(3,4,5)P3, PtdIns(3,4)P2 and PtdIns(4,5)P2 respectively, 
which are in accordance with those reported previously from multiple 
experimental approaches [102,193].  
 
The primary candidates PARIS-1 PH domain and C-IQGAP1 both bound 
selectively and concentration dependently to PtdIns(3,4,5)P3 but not to 
PtdIns(3,4)P2 or PtdIns(4,5)P2. Moreover, these lipid binding characteristics were 
not reproduced with a mutant  PARIS-1 PH domain or an N-terminal fragment of 
IQGAP1, neither of which showed measurable binding to PtdIns(3,4,5)P3. PARIS-
1 is a little studied, 105kDa Rab GAP purported to be differently expressed 
between normal and cancerous prostate cells [232], and possesses a PH domain of 
previously unreported affinity or selectivity. IQGAP1, however, is a widely 
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studied 190kDa protein which is implicated in a number of roles modulating 
cytoskeletal architecture but does not contain a recognised LBD 
[263,265,266,337]. 
 
The efficiency of this unbiased three-tier affinity purification approach to 
identify protein(s) capable of lipid binding, regardless of reported domain features, 
is highlighted by the identification of IQGAP1 as a 3-PI interacting protein 
without an established LBD. Furthermore, the features presented by the putative 
LBD of IQGAP1 are consistent with the view that the lipid interaction is a 
consequence of the spatial presentation of key amino acids, similarly achieved by 
PH domains, despite little structural homology. The possibility that this spatial 
presentation of amino acids within a structure could be exploited by an informatics 
based tool to determine the characteristics of similar “orphan” crystal structures, to 
yield further potentially novel lipid interacting motifs is an appealing idea.  
 
6.5 Future Work. 
The utility of this screen was confirmed by the identification of numerous 
established 3-PI interacting proteins including TAPP-1, PKB, ARAP1 and SWAP-
70. However, the identification within this screen of two novel 3-PI interacting 
proteins in PARIS-1 and IQGAP1 confirms the success of the approach in 
achieving its goal of identifying novel 3-PI interacting proteins. Moreover, the 
wider implication of their identification is that the candidate lists generated are 
likely to contain other, as yet, unrecognised proteins from PI 3-kinase signalling 
networks. Whilst immediate future work should centre on determining the 
functional consequences of lipid binding to both PARIS-1 and IQGAP1, more 
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long term future work should focus on characterising further candidates by 
applying the structural principles and anecdotal association to PI 3-kinase 
signalling networks, 
 
Whilst more comprehensive in vivo analysis is required to ascertain the 
functional significance of the PARIS-1 PH domain interaction with 
PtdIns(3,4,5)P3, preliminary in vivo data suggested that 3-PI-enriched membranes 
alone, may not be sufficient to result in marked translocation of PARIS-1 from the 
cytosol. This view is supported by the comparative SPR results which indicate that 
PARIS-1 PH domain may bind 3-PIs less strongly than other established target 
proteins such as Grp-1. However, the possibility that the PtdIns(3,4,5)P3 
selectivity demonstrated by the PARIS-1 PH domain contributes to regulation of 
its enzymatic activity remains, and is not without precedent. Both PKB and, 
perhaps more pertinently, SWAP-70 have been shown to increase their activity as 
a consequence of lipid binding [89,341]. The possibility that the Rab GAP activity 
of PARIS-1 is affected in the same manner as the PtdIns(3,4,5)P3-dependent Rac 
GEF activity of SWAP-70 is eminently testable, assuming that its appropriate Rab 
G-protein(s) can be identified. 
 
In contrast to PARIS-1, much is known about the proteins with which 
IQGAP1 interacts. It has numerous domains including a calponin homology 
domain, a WW domain, IQ repeats and the Ras GTPase-activating protein related 
domain (GRD) [266]. These have been shown to facilitate interaction and mediate 
inputs from a diverse group of proteins including actin, β-catenin, E-cadherin, 
ERK1/2, PKA, calmodulin, Cdc42 and Rac1 [261,263,265,266,337]. Indeed, 
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although the prominent molecular function remains unclear, IQGAP1 has been 
postulated as an oncogene due its involvement in the modulation of cell-cell 
attachments and actin polymerisation [264,266]. Decreased adhesion and 
increased motility, features also required for metastasis, have been reported 
following increased IQGAP1 expression or the translocation of endogenous 
IQGAP1 to cell-cell junctions [266]. Moreover, E-cadherin and calmodulin have 
been shown to compete for IQGAP1 binding and following deletion of a C-
terminal region of IQGAP1, which includes the putative LBD suggested by this 
study, an increase in the calmodulin bound proportion and reduction in the cell-
periphery, E-cadherin bound proportion of IQGAP1 has been observed [342]. This 
result is consistent with the notion that PtdIns(3,4,5)P3 is required for its 
translocation or interaction at sites of cell-cell contact. The apparent selective 
localisation of IQGAP1 at the leading edge of migrating cells [261], a 
characteristic common to PI 3-kinases and PtdIns(3,4,5)P3 further emphasises this 
point. It is perhaps, however, not such a surprise that the limited in vivo data 
generated indicated that acute stimulation of PI 3-kinases did not dramatically 
alter the cellular localisation of IQGAP1, a protein clearly so integral to formation 
of large cytoskeletal complexes. Alternatively, similarly to that suggested for 
PARIS-1, the affinity of IQGAP1 for PtdIns(3,4,5)P3 may not be sufficient for 
translocation, instead providing a mechanism for coincident activation or the 
differential regulation of its GRD and/or that of its associated protein interacting 
partners. Nonetheless, the involvement of IQGAP1 in several cellular processes in 
which PI 3-kinase exerts an effect, the analogous localisation profiles to 
PtdIns(3,4,5)P3 and the binding presented in this study, implies a close integration 
of these components. Lastly, the sequence analysis of IQGAP family members, 
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IQGAP2 and IQGAP3 confirms that both possess homologous C-terminal regions 
to that of the proposed LBD of IQGAP1. The analysis of the lipid binding 
capability of these isozymes would determine if the motif present within IQGAP1 
indeed represents an example of a conserved, novel LBD. 
 
As alluded to earlier, longer term work should focus on determining the lipid 
binding capability of additional candidates suggested by this screen. This could be 
achieved by selecting candidates in an entirely unbiased fashion or advised by 
structural features and/or involvement in PI 3-kinase-dependent signalling 
pathways. An alternative strategy, however, would be select the most prominent 
candidates over the course of numerous, additional experimental repeats. This 
strategy of gaining repeated enrichment ratios for each protein, whilst profligate in 
expensive reagents would provide a statistical means by which to select potential 
candidates for lipid binding analysis. Furthermore, advised by this present study, 
the opportunity to repeat these SILAC based experiments would allow for subtle 
modification to the approach in order to maximise both the recovery of specific 
PtdIns(3,4)P2 binding proteins and, a more comprehensive set of chemically 
unmodified but isotopically labelled peptides. These modifications could be 
achieved by the complete elimination of Ins(1,3,4)P3 carry through from the 
second to the third affinity purification step by more rigorous intermediate 
chromatography, and the use of amino acid-specific isotope labels coupled to the 
use of more MS compatible stains respectively. 
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6.6  The Broad Implications of this Study for PtdIns(3,4)P2 as a Lipid 
Signal. 
 
To date, there have been few selective binding proteins suggested for 
PtdIns(3,4)P2, in stark contrast the number of molecular targets identified for 
PtdIns(3,4,5)P3. However, some of the latter are limited in their capability to 
distinguish between PtdIns(3,4,5)P3 and PtdIns(3,4)P2, and several examples of 
these occupy key signalling nodes, such as PKB and PDK1 [85-87,104,130]. Such 
observations coupled to the lack of distinct PtdIns(3,4)P2 effector proteins has 
contributed to the notion that these lipids fulfil a combined role. This screen, 
through primary PI 3-kinase activation and the manipulation of PTP-like 
phosphatases, attempted to identify novel PtdIns(3,4)P2 binding proteins and 
hence contribute understanding to its role as an independent signal. 
 
It is, however, apparent that both novel lipid interacting proteins identified 
by this screen, PARIS-1 and IQGAP-1, appear to be selective for PtdIns(3,4,5)P3. 
Although several other candidates did show minimal PtdIns(3,4)P2 binding, none 
showed high selectivity and affinity. Whilst the prospect remains that 
PtdIns(3,4)P2 does not possess independent signalling roles and is purely a 
metabolite of PtdIns(3,4,5)P3, there is now considerable evidence to the contrary. 
This evidence includes, principally, the existence of a mechanism for the 
independent synthesis of PtdIns(3,4)P2 [41] and the existence of an established 
selective binding protein, TAPP-1 [102]. It is feasible that features of this screen 
have inadvertently undermined the ability to isolate novel PtdIns(3,4)P2 binding 
proteins. Specifically, the presence of competing concentrations of Ins(1,3,4)P3, 
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introduced at the second affinity purification step, which may well interfere with 
the binding to the immobilised lipid precipitation. However, this feature seemed to 
have a negligible effect on the depletion of the model PtdIns(3,4)P2 binding 
protein, TAPP-1. A remaining possibility therefore, is that candidates may have 
simply been missed in the analysis or selection stage in the current SILAC lists 
and their selectivity is yet to be revealed by appropriate binding studies. In this 
case these candidates will benefit from the longer term further work described 
above and particularly, become evident following statistical analysis of multiple 
experiments. 
 
Perhaps, it may simply be an attribute of the output of class I PI 3-kinase 
signalling that few molecular targets possess extremes of selectivity (Grp-1 and 
TAPP-1) whilst most demonstrate overlapping selectivities (PKB, PDK1, SWAP-
70, DAPP-1 etc. etc.). This may mean that few specific PtdIns(3,4)P2 binding 
proteins exist but does not necessarily detract from the signalling role this lipid 
may play. For instance, a range of proteins each with overlapping, but discrete 
selectivities would allow a highly sensitive mechanism to respond to subtle 
fluctuations in the balance between cellular PtdIns(3,4)P2 and PtdIns(3,4,5)P3 
concentrations. Alternatively, the distribution of these 3-PI binding proteins may 
not be equal across a spectrum of lipid selectivities, ranging from those highly 
PtdIns(3,4)P2-specific at one end to those highly PtdIns(3,4,5)P3-specific at the 
another. In this scenario it may be possible to achieve activation of critical 
pathways, such as PKB/PDK1 with either ligand but further housekeeping or 
structural modifications through only one or the other. Speculatively, this may be 
demonstrated by examples isolated within this screen. For instance, PtdIns(3,4)P2 
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and PtdIns(3,4,5)P3 activate PKB, but PtdIns(3,4,5)P3-interacting Rho/Rab G-
protein regulators such as ARAP1, SWAP-70, PARIS-1 and IQGAP-1 may allude 
to a mechanism whereby PtdIns(3,4)P2 is a means to activate PKB without co-
incident alteration of Rho/Rab activity . 
 
6.7  Concluding Remarks. 
 In conclusion, this study describes the development of an unbiased screen for 
the identification of novel PtdIns(3,4)P2 and other 3-PI interacting proteins 
utilising a distinctive, multi-tier affinity-purification approach coupled to SILAC. 
This unique, quantitative approach results in the successful isolation of two novel 
lipid binding proteins. Firstly, PARIS-1, a little studied PH domain containing Rab 
GAP suggested as a marker for prostate cancer. Secondly, the much studied 
IQGAP1 implicated in a diverse range of cellular processes and proposed as an 
oncogene. Furthermore, the concentration-dependent binding of the C-terminal 
fragment of IQGAP1, analogous to that of Grp-1, is achieved without the 
expression of a recognised LBD. These data raise the exciting prospect that 
IQGAP1 exemplifies a novel, uncharacterised lipid binding motif. It is anticipated 
that the future characterisation of PARIS-1 and IQGAP1, as well as other 
candidates yet to be further investigated will both extend the current repertoire of 
3-PI effector proteins and contribute to the wider understanding of the PI 3-kinase 
signalling network. 
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